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The genus Chlamydia is the only genus in the family Chlamydiaceae and the order,
Chlamydiales. Much confusion has surrounded the classification of Chlamydiae,
which were originally classed as protozoa and then later, after their isolation in the
early 1930's (Bedson et al.) as viruses due to their small size. Unlike viruses,
however, Chlamydiae possess both types of nucleic acids, RNA and DNA, and
multiply by binary fission rather than self-assembly.
Chlamydiae are distinguished from other organisms by several criteria, most
significantly by their unique developmental lifecycle and the fact that due to their
inability to synthesise high-energy compounds such as ATP. they can only survive by
intracellular parasitism of host cells. In addition, Chlamydiae have been found to
have several genus specific antigens, including the lipopolysaccharide moiety of the
outer membrane which shows similarities to the outer membranes of Gram-negative
bacteria. However, unlike Gram-negative bacteria, Chlamydiae do not contain
detectable peptidoglycan.
The genus was originally separated into two species, namely Chlamydia trachomatis
and Chlamydia psittaci, as determined by morphological and chemical characteristics
in cell culture and by host specificities. Whilst C. trachomatis can be identified by
iodine positive staining of compact cell inclusions indicating the presence of
glycogen and by its sensitivity to sulphadiazine antibiotics, C. psittaci is
sulphadiazine resistant and produces diffuse cell inclusions which did not stain with
iodine. Species host specificities are also obvious. Whereas C. trachomatis was
exclusively a human pathogen, with the exception of one strain which infects mice
under experimental conditions (Mouse pneumonitis), C. psittaci strains infect only
animals (Table 1).
Until recently, all non-human isolates have been classed as C. psittaci strains giving
the species high variation in DNA homology, unlike C. trachomatis which shows
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considerable DNA relatedness within the species. Over the last seven years,
however, two new species have been accepted, both of which have arisen from
isolates originally classed as C. psittaci. The first new species, C. pneumoniae, is
now considered as a genuine human respiratory pathogen and not a zoonosis. Its
proposal was based on the unique ultrastructure of the infectious particle, as well as
DNA analysis and serology. C. pneumoniae showed 94% or greater DNA relatedness
within the species and only 10% or less with the other two species of Chlamydia.
Later, a second new species was proposed, C. pecorum, to incorporate all non-
abortion, non-conjunctival mammalian strains. Although it was morphologically
similar to C. psittaci, C. pecorum, like C. pneumoniae, could be distinguished by
DNA analysis and immunological assays.
Table 1.1. Characteristics of the four species of Chlamydia (Fukushi and Hirai,
1993).
Species
Characteristics C. pecorum C. psittaci C. pneumoniae C. trachomatis
Trachoma/LGV
Natural hosts Cattle,sheep Birds,
lower mammals
Humans Humans
Morphology of EB Round Round Pear-shaped Round
Morphology of inclusion Oval,dense Variable,dense Oval,dense Oval,vacuolar
Glycogen in inclusion No No No Yes
Folate biosynthesis No No No Yes
N°. of serovars 3 ? 1 12/3
Mol. % G+C ofDNA 39.3 39.6 40.3 39.8
DNA homology % to
C. pecorum 88-100 1-20 10 1-10
C. psittaci 14-95 1-8 1-33
C. pneumoniae 94-96 1-7
C. trachomatis 92
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Development of new powerful detection techniques focusing on DNA sequence
comparisons and the use of monoclonal antibodies in microimmunofluorescence
(MIF) have allowed more accurate typing of chlamydial isolates. In fact it has been
suggested that further species divisions within C. psittaci may be appropriate with the
continued application of gene analyses and the use of monoclonal antibodies to
identify common antigens. At present, C. trachomatis is known to have 15 serovars,
A, B, Ba, C, D, E, F, G, H, I, J, K, LI, L2, L3 which are divided between three
distinct biovars; the oculogenital biovar, the lymphogranuloma venereum (LGV)
biovar and the mouse pneumonitis biovar (MoPn). Serovars A to K belong to the
oculogenital biovar, whilst LI, L2 and L3 are members of the LGV biovar. Mouse
pneumonitis contains a single strain and therefore makes up only one biovar.
However recently, a new nonhuman chlamydial strain, SFPD, was isolated from
hamsters (Stills et al, 1991), and found to be closely related to C. trachomatis. This
new strain may belong to a rodent group which would also comprise the mouse
biovar. C. psittaci comprises 4 biovars; GPIC, the agent of guinea pig
conjunctivitis; avian strains; feline pneumonitis and abortifacient strains which
infect a diverse range ofmammals.
Diseases caused by Chlamydia
C. trachomatis, the larger species of the two human pathogens, infects primarily the
ocular and genital mucosal epithelium. Serovars A, B, Ba and C infect the eye,
whilst serovars D to K are responsible for infection of the genital mucosae. Although
C. trachomatis often produces asymptomatic infections, acute infections may occur
resulting in conjunctivitis, urethritis or pelvic inflammatory disease (PID). Chronic
infections are exemplified by chronic salpingitis, which results in infertility or
ectopic pregnancy due to blockage of the fallopian tubes. Progression of C.
trachomatis in the eye to a chronic inflammatory state, leads to the development of
trachoma. This is the major cause of preventable blindness in the world, with most
cases concentrated around developing countries in parts of Asia, Africa and South
America. Sexually transmitted C. trachomatis is responsible for epidemic disease in
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the United States of America and in Europe, causing an estimated 4.5 million
infections annually (Wyrick et al, 1993; Hook et al, 1994). C. trachomatis also
causes a systemic disease, lymphogranuloma venereum (LGV) by infection of the
inguinal or pelvic lymph nodes (Grayston and Wang, 1975). This is a far more
invasive sexually transmitted disease infecting both lymphoid and epithelial cells
(Schachter, 1990) and leading to considerable necrosis and formation of abscesses.
Infection by biovar LGV organisms stimulates granuloma formation in which
mononuclear phagocytes undergo transformation into epithelioid cells.
C. pneumoniae contains only one strain, previously known as TWAR. It is a human
pathogen causing a 'flu-like illness with a long-lasting dry cough. It has been shown
to be responsible for both endemic and epidemic pneumonia (Grayston et al. ,1986;
Kleemola et al., 1988; Saikku et al., 1985). At the peak of an epidemic it can
account for 45% of adult pneumonia cases (Leinonen et al., 1990). Typically, 5-7%
of adult respiratory infections can be attributed to C. pneumoniae (Marrie et al.,
1987; Grayston et al., 1990). Recently, the presence of antibodies against C.
pneumoniae has been associated with the occurrence of coronary heart disease (Kuo
et al., 1993; Saikku et al., 1988; Thorn et al., 1992), sarcoidosis ( Gronhagen-Riska
et al., 1988) and asthma (Hahn et al., 1991).
C. pecorum is an animal pathogen recently differentiated from C. psittaci strains by
DNA analyses and serology ( Fukushi and Hirai, 1992). It is known at present to
infect cattle, sheep and swine ( Fukushi and Hirai, 1992 and Kaltenboeck et al.,
1993), causing pneumonia, polyarthritis, encephalomyelitis and diarrhoea.
C. psittaci can be divided into mammalian and avian groups. The avian strains cause
a zoonotic human disease called psittacosis (from the Latin 'psittacine' - parrot)
(Harris, 1983 ; Grimes, 1987; Macfarlane and Macrae, 1983), which is manifested as
a mild 'flu-like infection or as a more serious atypical pneumonia requiring patient
hospitalisation (Shewan, 1980). Transmission of infection occurs by inhalation of
dried faecal dust which is contaminated with the organism. Mammalian hosts form a
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diverse group, including sheep, cattle, goats, cats, dogs, guinea pigs, muskrats and
koalas (Girjes et al., 1993). Mammalian isolates of C. psittaci cause guinea pig
inclusion conjunctivitis (GPIC) in experimentally infected animals (Rank and
Sanders, 1992), feline pneumonitis and ruminant abortions, in particular ovine
enzootic abortion (OEA). Not only is OEA a major cause of economic loss to the
sheep industry (Linklater, 1979), but it also has important ramifications as a zoonotic
disease causing systemic disease and abortion in pregnant women (Beer et al., 1982).
Confirmation of the association between C. psittaci and spontaneous abortion in
women was first documented in 1985 (Johnson et al., 1985) when a farmer's wife
who had been in contact with infected sheep during the 20th to 28th week of
pregnancy aborted in the 29th week following 4 days of fever, nausea, vomiting and
severe headaches. The causative agent, C. psittaci was isolated from the placenta and
foetus.
Abortifacient C. psittaci infection in sheep is characterised by a Chlamydia-induced
placentitis which results either in abortion in late pregnancy or in premature lambing
(Stamp et al., 1950; Storz, 1988). Infection and abortion can occur in the same
pregnancy (Blewett et al., 1982), or more usually naive animals are exposed to
chlamydiae-infected tissues in one season and subsequently abort in the next lambing
season. The intermittent period between infection and abortion still remains obscure,
with chlamydiae detectable only by methods which do not rely on cultivation of
chlamydiae in vitro (Papp et al., 1993). It appears that chlamydiae are mobilised
from their site of latency at some as yet undetermined stage of pregnancy (Wilsmore
et al., 1984; Huang et al., 1990) and are detectable in the placenta by culture at
approximately 60 days of gestation (dg). Infection becomes established primarily in
the placentome from where it gradually spreads forming visible lesions in the
intercotyledonary areas (Buxton et al., 1990; Papp et al., 1993). Although placental
infection occurs earlier, pathological changes are not apparent until the third trimester
of pregnancy (Buxton et al., 1990) and it is probably as a result of these changes to
the maternal-foetal junction that foetal death occurs. The extent of pathological
changes in the foetus varies between different species, with only minor effects
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apparent in lambs compared to more serious pathological changes in bovine foetal
tissue.
As a result of chlamydial abortion, dams develop considerable immunity to placental
infection and are generally resistant to further chlamydial abortions. It is possible,
however, that low levels of C. psittaci persist in immune animals and some evidence
suggests that chlamydiae may be excreted from the reproductive tract during
subsequent oestrus cycles (Papp et al., 1994), allowing transmission of chlamydiae
to other ewes during breeding. Whilst rams do become infected with C. psittaci,
causing epididymitis, periorchitis and poor quality semen (Storz et al., 1976;
Rodolakis and Bernard, 1977), there is no real evidence that sexual transmission
contributes to spread of infection to a significant degree (Linklater, 1996).
Lifecycle of Chlamydia
Chlamydiae have a unique biphasic lifecycle of which part must be completed within
eukaryotic cells. The cycle is best described by dividing it into several stages
according to the process(es) occurring at that time, namely: attachment to the host
cell; subsequent uptake; inhibition of phagolysosomal fusion; reorganisation of the
particle; multiplication and finally expulsion from the host cell. These stages will be
discussed individually following a brief overview.
Two distinct morphological structures exist representing the two major phases of the
lifecycle. These are the elementary body (EB) and the reticulate body (RB). Many
intermediate stages are passed through in the progression from one form to the other.
The EB is an extracellular, infectious form, which is metabolically inactive and
contains a highly condensed chromosome. Rigid disulphide linking of the outer
membrane holds the EB at a diameter of around 300 nm. This measurement
increases to approximately 800-1000 nm as the EB reorganises its outer membrane
structure, relaxing the condensed chromatin to form the metabolically active,
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vegetative RB. Division of the RB proceeds by binary fission and after several
rounds, some of the RBs begin a transformation back to the EB form. These events
occur within a host cell-membrane-bound vacuole and as more intermediate and
infectious forms appear, the size of the vacuole increases, pushing the host cell
cytoplasm to one side until eventually the vacuole bursts, releasing its contents into
the extracellular space. The mature EBs are free to infect further host cells and the
cycle continues.
i) Attachment
The attachment mechanisms by which chlamydiae gain entry into the host cell are
unknown. Since both chlamydial cell and host cell surfaces have acidic net charge,
receptor-mediated interaction between surfaces is needed for the attachment of
Chlamydia. It is likely that surface structures of the organism are involved in
adhesion to the host cell membrane and most likely are of proteinaceous nature,
given the loss in infectivity after heat-treatment of chlamydiae (Peeling and
Brunham, 1991). Notably heat-treatment affects attachment of trachoma biovar D
and not the LGV biovar, L2, indicating that different modes of attachment may be
available to chlamydiae. It has been speculated that the function of the major outer
membrane protein (MOMP), is that of an adhesin. Other functions of the MOMP
have since been investigated and these will be discussed later.
Viable chlamydiae are not required for attachment to host cells, since EB envelopes
can elicit not only attachment, but also endocytosis and inhibition of lysosomal
fusion (Eissenberg, 1983). Pre-formed components on the chlamydial outer
membrane are therefore presumably responsible for the major events in infection.
Treatment of host cells with trypsin and other proteases results in almost complete
loss of attachment of EBs, for as long as regeneration of receptors is inhibited (Byrne
et al., 1976). This information, together with that of Byrne and Moulder (1978),
Hatch et al. (1981) and Bose and Paul (1982) describing loss of EB attachment by
gentle heat treatment of the EBs, suggests that the chlamydial adhesin is most likely a
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protein. Evidence supporting a role for MOMP in the attachment process (Su et al.,
1988 and 1990; Caldwell and Perry, 1982; Lucero and Kuo, 1985), is strengthened by
the finding that cleavage of variable segment 2 (VS2) by trypsin-treatment results in
reduced attachment of EBs to HeLa cells (Su et al., 1988). Again, the inhibition is
serovar-specific, with loss of attachment of C. trachomatis serovar B but not L2.
More recently, Zhang and Stephens (1992) proposed a novel mechanism of
chlamydial attachment in which a glycosaminoglycan (GAG) bridge is formed
between receptors on both the chlamydial and host-cell surfaces. It is proposed that
chlamydiae are able to synthesise a molecular mimic of heparan sulphate and use this
to attach to host-cells via heparan sulphate receptors as seen with the pseudorabies
virus (Mettenleiter et al., 1990). This GAG-dependent mechanism of infection has
been proposed for both trachoma and LGV biovars (Zhang and Stephens, 1992; Chen
and Stephens, 1994), although only the former shows inhibition of attachment as well
as infectivity by a specific inhibitor, heparan sulphate. Eukaryotic cells have been
shown to endocytose free heparan sulphate by a receptor-mediated mechanism
(Barzu et al., 1985). Utilisation of such a mechanism which does not normally
result in phagolysosomal-fusion might explain the lack of fusion when the same
receptor is used by chlamydiae. The structure of the Chlamydia-synthesised GAG is
similar to that of other GAGs i.e. a linear polysaccharide chain consisting of
disaccharide repeats (Jackson et al., 1991). This is consistent with the sensitivity of
chlamydial attachment to periodate-treatment.
Furthermore, it was recently shown that the MOMP of chlamydiae is glycosylated
(Swanson and Kuo, 1991) and the glycan-moiety is involved in the attachment
process of C. trachomatis to HeLa cells (Swanson and Kuo, 1994). A second
glycoprotein of 32KD has also been implicated in chlamydial attachment (Swanson
and Kuo, 1994). Other proteins with this molecular mass include adhesins
(Hackstadt et al., 1996; Wenman and Meurer, 1986) and histone-like proteins
(Hackstadt et al., 1993), although the latter have a higher isoelectric focusing point
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(pi) compared to the 32KD glycoprotein. Other glycoproteins present in a range of
bacteria have been shown to act as adhesins (Sharon, 1984; Olden et al., 1985).
The process of chlamydial attachment therefore appears to be multifactorial and
probably depends not only on the chlamydial strain, but also on the specific host-cell
type.
ii) Entry
Similarly to attachment of chlamydiae to host-cells, uptake of chlamydiae is likely to
occur by more than one mechanism. Phagocytosis has been shown to occur
predominantly when chlamydiae are centrifuged onto host-cells (Reynolds and
Pearce,. 1991), a method of infection widely used in various laboratories.
Chlamydial (C. trachomatis, LI) ingestion can be impaired by the microfilament
inhibitor cytochalasin D and microtubule disrupters, vincristin and vinblastin, but not
by inhibitors of receptor mediated endocytosis (monodansyl cadaverine, amantadine)
(Ward and Murray, 1984) indicating a role for phagocytosis with centrifugation.
However, under static conditions, receptor-mediated endocytosis appears to be the
preferred mechanism of internalisation. The relevance of each of these processes to
the natural mode of infection is unknown, however it has been speculated that direct
cell-to cell transfer may be possible due to the force of expulsion of EBs from
infected cells.
Hodinka et al. (1988) showed that chlamydiae entry into host cells involves
microvilli, coated pits, coated vesicles and endosomes which are also characteristics
of receptor-mediated endocytosis entry mechanisms. Transmission electron
microscopy revealed that chlamydiae preferentially bind to pre-existing cell-surface
microvilli and travel down these structures to their base, where they enter the host
cell through specialised invaginated pits of the plasma membrane. Chlamydia appear
to be associated, however, with both uncoated and coated (clathrin) pits (Ward and
Murray, 1984; Hodinka and Wyrick, 1986; Wyrick et al., 1989). Upon
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internalisation, EBs are surrounded by membrane-bound vesicles which do not fuse
with host cell lysosomes (Friis, 1972; Eissenberg and Wyrick, 1981; Eissenberg et al,
1983).
iii) Inhibition of phagolysosomal fusion
Once internalised, chlamydiae reside within host-cell membrane-bound vacuoles.
These endosomes are able to avoid acidification and do not fuse with lysosomes
allowing the chlamydiae to complete their developmental cycle in a protected
intracellular environment. The mechanism by which chlamydiae are able to inhibit
phagolysosomal-fusion (PL-F) is unknown. However, Eissenberg et al. (1983)
demonstrated that EB envelopes were capable of inhibiting PL-F and intact
chlamydiae were not essential. Initially, binding to host cell microvilli may reduce
electrostatic repulsion between electro-negative membranes of the chlamydiae and
host, allowing more specific receptor-mediated attachment to occur. Eukaryotic cells
naturally utilise receptor-mediated endocytosis to ingest nutrients and regulatory
components (Goldstein et al, 1979; Silverstein et al, 1977) and only some of these
are destined to fuse with lysosomes. Thus, it is possible that chlamydiae utilise an
inherent endocytic mechanism which does not result in phagolysosomal-fusion.
Recently, Schramm et al. (1996) proposed that chlamydiae-filled endosomes were
able to avoid PL-F by retaining membrane characteristics of early endosomes. It has
been shown that only mature endosomes are able to fuse with lysosomes (Mullock et
al., 1989, Mullock et al., 1994), thus chlamydiae would be protected for as long as
the early endosome was prevented from developing further. Chlamydial components
are incorporated into both the inclusion (endosome) and host-cell membranes during
chlamydial development (Hackstadt et al., 1994) and it is possible that these may be
involved in maintaining the early characteristics of endosomal membranes. There is
evidence that a protein (Inc A) specifically synthesised by RBs is transported to the
inclusion membrane (Rockey et al., 1995). However, whilst Inc A is probably
involved in some aspect of inclusion membrane establishment, maintenance or
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functional modification, further work is required to determine its purpose
unequivocally.
iv) Metabolism
Chlamydiae are known as "energy parasites" requiring host-cell association to
survive and develop. Thus, the biosynthetic capacity of chlamydiae is much reduced
compared to bacteria in general. The loss of biosynthetic capacity may be an
explanation for the unusually small chlamydial genome, lxlO6 bp which is only a
quarter of the size of the Escherichia coli genome. Chlamydiae are therefore
restricted to an intracellular habitat and rely on the host cell for many of its nutrients
(amino acids, nucleotides, nucleotide-sugars and fatty acids) to construct
macromolecules (protein, DNA, RNA, lipids, LPS and murein) as well as to provide
ATP as an energy source. It has been demonstrated, however, that whilst chlamydiae
have evolved mechanisms to reduce energy-costs to themselves by obtaining
metabolic products from the medium, it appears that under certain circumstances of
nutrient deprivation, chlamydiae regain the ability to manufacture for example folates
in species which normally transport the thymidine nucleotide precursor from
exogenous sources. Such circumstances render the species involved, C. psittaci
(except strain 6BC) or C. pneumoniae unusually sensitive to sulphonamides, an
inhibitor of de novo folate biosythesis.
Transfer of cell-derived nutrients must essentially occur through three membranes;
the inclusion membrane, and the chlamydial inner (cytoplasmic) and outer
membranes. An alternative hypothesis suggests that chlamydial surface projections,
which appear to pass through the inclusion membrane, may allow direct transfer of
factors from the host-cell cytoplasm into the chlamydial inclusion. In addition to this
arrangement, the porin-like activity ofMOMP may behave as a non-specific nutrient
channel, allowing passive diffusion from the nutrient rich host cytoplasm to the
hypotonic environment of the chlamydial periplasm. Movement of components
across the chlamydial cytoplasmic membrane may involve specific carrier-mediated
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transport systems, which would explain the existence of a proton-motive force found
by Hatch et al. (1984).
Chlamydiae must, however, retain the ability to manufacture macromolecules unique
to bacteria and therefore are capable of limited protein, RNA and DNA synthesis
once supplied with the basic components and ATP. This has been demonstrated by
the inhibition of eukaryotic metabolism but not chlamydial growth, by cycloheximide
or emitine which are specific eukaryotic inhibitors. Genes encoding enzymes which
are involved in LPS synthesis have been identified. Other compounds not found in
host-cells, but present in chlamydiae are branched-chain fatty acids and
phosphatidylglcerol, necessary for fatty acid and lipid syntheses, respectively. Thus,
pathways involved in the syntheses of these compounds must also be retained by
chlamydiae. Species differences are again apparent in metabolic processes, C.
trachomatis can synthesise glycogen, whist C. psittaci can not. Tryptophan
requirements also appear to depend on individual strains.
v) Release
Todd and Caldwell (1985) described a mechanism of infectious EB release from host
cells by exocytosis, enabling the host cell to remain intact. In contrast, rupture of
degenerate infected cells showing vesiculation of the endoplasmic reticulum and loss
of ribosomes and microvilli (Todd et al, 1976) was suggested to be a more natural
scenario by Benes (1986) who observed explosive release of EBs from infected cells.
This was suggested as the mechanism of cell-to-cell transmission in vivo, in strains
which do not require centrifugation to assist infection in vitro.
Structure of the Cell Envelope
As discussed above, survival of chlamydiae depend upon successful attachment and
entry into host cells. The structure of the cell envelope is therefore of great
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importance, since it is this region of the organism which is involved in host cell to
bacterial cell contact. The following paragraphs describe the structure of the cell
envelope in some detail..
The envelopes of both EBs and RBs share some characteristics with those of Gram-
negative bacteria. Both possess an outer and an inner cytoplasmic membrane, each
of which contributes 3 layers to the overall cell envelope. At this point, however,
chlamydiae diverge from the typical Gram-negative morphology and no evidence of a
peptidoglycan layer has been found ( Caldwell et al., 1981; Manire and Tamura,
1967), nor has anyone been able to detect any N-acetyl muramic acid (Matsumoto,
1988; Barbour et al., 1982; Garrett et al., 1974) both of which are commonly found
in Gram-negative bacterial envelopes. Penicillin-binding proteins are, however,
present and render the chlamydiae susceptible to penicillin treatment (Barbour et al.,
1982).
Surface projections have been identified which associate with DNA fibrils radiating
from the nucleus and extend approximately 20 nm above the outer membrane
(Matsumoto, 1982). Each EB has approximately 22 projections, clustered in a
polarised fashion. Similarly, RBs have been shown to have varying numbers of
projections, ranging from approximately 45 at 10 hours after infection, to 20 at later
stages (20 hours) of development.
In addition, it is proposed that a lipopolysaccharide (LPS) moiety, sensitive to
periodate treatment (Barwell, 1952) nestles in the outer membrane and is exposed
towards the outer surface (Birkelund et al., 1988). The LPS is composed of lipid A
and a saccharide portion (Reitchel and Brade, 1992) which contains a trisaccharide of
3-deoxy-D-manno-octulosonic acid (Kdo) of the sequence aKdo(2->8)-
aKdo(2—>4)- aKdo (Brade et al., 1987; Hoist et al., 1993) and is therefore of the
rough type (R-LPS). Recently, an alternative form of LPS was isolated from
chlamydiae grown in yolk sacs of embryonated eggs (Lukacova et al., 1994). This
LPS was shown to share properties with those of LPS from enterobacterial wild-type
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strains (smooth form- S-LPS). Both types of LPS have a common 2,8-linkage,
unique to chlamydial LPS, whereas the 2,4-linkage is responsible for serological
cross-reactions between chlamydiae and other Gram-negative bacteria.
Proteins of the cell envelope
Chlamydial proteins contained in the cell envelope can be separated into two
fractions by sarkosyl (detergent) treatment (Filip et al., 1973; Caldwell et al., 1981).
Many proteins are soluble in sarkosyl, notably the 62 KD and 45 KD proteins. The
sarkosyl insoluble fraction consists primarily of proteins of 12-15, 40 (MOMP) and
60 KD (Hatch et al., 1984; Newhall, 1987; Sardinia et al., 1988). Both the 12-15
(OMP 3) and 60 (OMP 2) KD proteins are cysteine-rich lipoproteins (CRP) ( Allen et
al., 1990; Everett and Hatch, 1991; Everett et al., 1994) which are synthesised late
in the developmental cycle (Hatch et al., 1986; Kaul et al., 1990; Newhall, 1987;
Sardinia et al., 1988) and therefore are mainly found in EBs rather than RBs (Allen
et al., 1990; Batteiger et al., 1985). In contrast, the 40 KD protein which comprises
60% of the total outer membrane protein and is thus termed, the Major Outer
Membrane Protein (MOMP) is synthesised predominantly at midcycle, when RBs are
dividing. Extensive disulphide-bond cross-linking in EBs between MOMP, OMP 2
and OMP 3 provides both structural rigidity and osmotic resistance to the EBs (Hatch
et al., 1984; Hatch et al., 1986; Hackstadt et al., 1985) in much the same way as
typical Gram-negative bacterial peptidoglycan. RBs in comparison, are relatively
fragile structures. Different forms of MOMP have been found in RBs and EBs with
only monomeric MOMP existing in the metabolically active RB, whilst dimeric,
trimeric and oligomeric forms have been found in EBs (Newhall and Jones, 1983;
McCafferty et al., 1995; de Sa et al., 1995).
Other proteins of interest include the family of heat shock proteins (hsp60 and hsp70)
and several adhesins (31 KD and 18KD) also found on the outer membrane (table
below). The heat shock proteins are widely conserved amongst chlamydiae and in
particular the 57 KD and 75 KD proteins belonging to hsp60 and hsp70, respectively
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may be responsible for the hypersensitivity reaction associated with severe sequelae
of chlamydial infections (Brunham et al., 1985; Brunham et al., 1986; Brunham et
al., 1987; Cerrone et al., 1991). The gene encoding the 57 KD hsp has been shown
to have 48% homology to a human hsp (Morrison et al., 1990; Cerrone et al., 1991)
and therefore the immune response leading to the formation of scar tissue may
potentially be considered as an autoimmune reaction.
Major serologically defined antigens: (Brunham and Peeling, 1994).
Size (KD) Name Function/characteristic
75 DnaK heat shock protein
60 Gro EL heat shock protein
57 OMP 2 membrane protein
40 MOMP membrane protein
32 HctB histone
29 Mip peptidyl cis/trans isomerase
10 LPS Kdo transferase
MOMP as an antigen
In addition to being the major proteinaceous component of the chlamydial outer
membrane, MOMP i) is post-translationally glycosylated (Swanson and Kuo, 1994);
ii) plays an electrostatic role in adherence (Su et al., 1990); iii) may function as a
porin (Bavoil et al., 1984); iv) contains surface-exposed, trypsin-sensitive antigenic
epitopes (Baehr et al., 1988); and v) is a major candidate for chlamydial vaccine
development (Ward, 1992; Murdin et al., 1993).
MOMP contains a range of epitopes (Caldwell and Schachter, 1982; Zhang et al.,
1987) including species- (common to all serovars), sub-species- (common to several
serovars) and serotype- (unique to only one serovar) specific epitopes. The serovar
and subspecies MOMP determinants are immunodominant (Caldwell et al., 1987)
and are highly accessible on the surface of chlamydiae in their native form (Zhang et
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al., 1987). The exposed epitopes of MOMP have been mapped and shown to be
contained in three out of four variable domains (Baehr et al., 1988). In addition,
monoclonal antibodies against these surface exposed regions show neutralising
ability in vivo against chlamydial infection (Caldwell et al., 1987). Baehr et al.
(1987), proposed a scheme for the arrangement ofMOMP in the outer membrane and
identified primary areas of species, sub-species and serovar-specific epitopes (Table
1.2).




The immune response to chlamydial infection
Although different species display different host cell tropisms, the immune responses
triggered by chlamydial infections are notably similar. A general overview will be
described followed by a more specific discussion on cell-mediated and humoral
factors involved in controlling infection.
An initial acute phase reaction occurs upon invasion of the host by chlamydiae and
this is marked by the recruitment of polymorphonuclear leucocytes, mainly
neutrophils, to the site of infection. Subsequent sub-acute and chronic stages of
infection involve a switch to predominantly lymphocytes with additionally an influx
of plasma cells, eosinophils and macrophages (Monnickendam et al., 1980; Kuo,
1988; Buxton et al., 1990; Yang etal., 1994).
Animal models have been used to simulate chlamydial infections in order that the
immune response may be studied in more depth. Such models have shown the roles
of individual T cell subsets, cytokines and the involvement of humoural immunity in
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the host's response to infection. It is generally recognised that infection with
chlamydiae results in an initial Thl response (Kincy-Cain and Rank, 1995), which is
characterised by the secretion of interleukins 1, 2 and 8 (IL-1, IL-2, IL-8) and
interferon-gamma (IFN-y). IFN-y appears to play a pivotal role in bacterial clearance
in both C. trachomatis and C. psittaci (Williams et al., 1989; Zhong et al., 1989;
McCafferty et al., 1994) where it has a chlamydiostatic effect on infected cells. In
addition, Lyt-2+ (cytotoxic) T cells, produced in response to C. psittaci (Lammert,
1982) infection have been shown to be protective in mice (Buzoni-Gatel et al.,
1992). Evidence exists, however, for the activation of both cytotoxic and helper T
cells in the primary response to chlamydial infection (Stagg et al., 1993).
Despite the fact that CMI has been shown to be critical for the clearance of
chlamydial infection (Rank et al., 1985) and may even be capable of resolving
infection in the absence of antibody, passive transfer experiments have demonstrated
that antibodies against chlamydiae are also able to reduce chlamydial infection
(Buzoni-Gatel et al., 1990). In particular, antibodies mapping to linear peptides on
the surface exposed variable regions, VS1, 2 and 4, of C. trachomatis have been
shown to neutralise chlamydial infectivity in vitro (Zhong et al., 1989; Peterson et
al., 1991; Qu et al., 1993). Surface exposed regions of C. pneumoniae in
comparison, appear to be located on variable segments 1, 3 and 4 and may rely more
heavily on conformational structure for neutralising epitopes (Peterson et al., 1991).
In the latter case, contrasting evidence has been documented for the
immunodominance of MOMP. Whilst Campbell et al. (1990) found only weak
seroconversion in humans to the MOMP of C. pneumoniae, Peterson et al. (1996)
were able to select for either high or low MOMP-specific antibody titres in mice,
depending on the H-2 genotype of the mouse strain. The importance of the VSs in
chlamydial pathogenesis is unclear, although it is logical to assume that due to their
surface location and the diversity of VS sequences amongst chlamydial species, that




Cytokines have been extensively studied to elucidate their effects on chlamydial
infections. In particular, IFN-y appears to be a major factor in controlling chlamydial
development through its chlamydiostatic effects both in vitro (Rothermal et al.,
1983; Shemer and Sarov, 1985; Zhong et al., 1989; Rank et al., 1992) and in vivo
(Williams et al., 1988; Summersgill et al., 1995). IFN-y is an important
lymphokine produced by activated T-cells, which is able to induce microbicidal
activity in bacterially infected cells as well as increasing natural killer (NK) cell
activity in order to destroy infected cells (Nathan et al., 1983; Byrne et al., 1988;
Dijmans et al., 1989; Dijmans et al., 1990). Monoclonal antibodies against IFN-y
cause exacerbation of infection with C. psittaci in mice (McCafferty et al., 1994).
It is believed that one mode of action of IFN-y is to deplete tryptophan concentrations
in the cell (Taylor and Feng, 1991; Byrne et al., 1986; Carlin et al., 1987;
Pfefferkorn and Guyre, 1984; Rapoza et al., 1991). However, chlamydial strains
differ with respect to their tryptophan requirements (Allen and Pearce, 1983) and so
this may not be a universal mechanism of chlamydial restriction.
Other mechanisms modulated by IFNs include the generation of reactive oxygen
intermediates (Nathan et al., 1983), the production of nitrogen intermediates by
nitric oxide synthase (Green et al., 1990; Adams et al., 1990), as well as the
decyclisation of tryptophan by indoleamine 2,3-dioxygenase (IDO) (Byrne et al.,
1986; Pfefferkorn and Guyre, 1984). Furthermore, IDO activity has also been
detected after chlamydial infection of human macrophage cultures and found to
induce production of type I interferons (IFNa and IFN(3) (Paguirigon et al., 1994), as
well as modulate interleukin 1 (IL-1) production (Arenzana-Seisdedos et al., 1985;
Gerrard et al., 1987). IL-1 induction by chlamydiae in monocyte-derived
macrophages was also shown to occur by Paguirigon et al. (1994), Rothermal et al.
(1989) and Magee et al. (1992).
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IL-1 is produced not only by macrophages, but also under some circumstances by B-
cells, T-cells and fibroblasts (Akira et al., 1990) and may be involved in the
activation of T-cells and the induction of cytotoxic T-cell activity (Houssiau et al.,
1988 and 1989; Kunimoto et al., 1989; Mizutani et al., 1989). Carlin and Weller
(1995) demonstrated that IL-1 was able to enhance IFN-mediated inhibition of
chlamydial growth by increasing the amount of IDO activity induced by IFNs.
Furthermore, they identified IL-lp as the major contributor, with the activity of IL-
la only minor in comparison. IL-1 may also contribute to the inflammation and
fibrosis associated with trachoma and chlamydial tubal infertility (Rothermal et al.,
1989; Magee et al., 1992) because of its effects on the production of collagen
(Spielvogel et al., 1978) and collagenase (Dayer et al., 1986), as well as on
stimulation of fibroblast proliferation (Schmidt et al., 1982).
IL-6 appears to act synergistically with IL-1 in chlamydial infections (Magee et al.,
1992) and may be induced not only by IL-1, but also by TNF-a (either by itself or
with IFN-y), by IL-3, platelet-derived growth factor and GMCSF (Akira et al., 1990;
Van Snick, 1990). Importantly, it has been proposed that TNF-a , a potent mediator
of inflammation, is able to inhibit replication of C. trachomatis (Manor and Sarov,
1988; Shemer-Avni et al., 1988 and 1989) and of C. pneumoniae (Summersgill et
al., 1995). TNF-a production has been demonstrated in response to chlamydial
infection both in vitro (Williams et al., 1989) and in vivo (Williams et al., 1990),
although the mechanism of TNF-a production in the latter study was T-cell
independent, whilst host resistance against chlamydiae shows a major T-cell
dependency (Williams et al., 1981, 1982 and 1984). IFN-y may therefore be the
more important cytokine in controlling chlamydial infection (Byrne et al., 1987 and
1988; Williams et al., 1988).
ii) Humoral Immunity
Humoral immune responses are directed against the major surface exposed regions of
chlamydiae. Thus, since MOMP is considered to be the major immunodominant
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antigen, sera from C. trachomatis- and C. psittaci-infected individuals not
unexpectedly contain antibodies predominantly against epitopes on this protein
(Brunham et al., 1987). In addition, considerable seroconversion has been
identified against Omp 2, LPS and the two cytoplasmic heat shock proteins, DnaK
and GroEL (Brunham et al., 1987). In particular, sera from trachoma patients reacts
strongly with VS1 ofMOMP and less so against VS2 (Jones, et al. 1992). However,
since VS2 is the most sequence-variant region of MOMP (Yuan et al., 1990), this
would imply that immunoassays may not be able to detect the full complement of
VS2 epitopes which in turn indicates a high prevalence of conformational or
discontinuous epitopes on VS2. It should be noted however, that the MOMP of C.
pneumoniae does not appear to be immunodominant (Puolakkainen et al., 1993;
Yamamoto et al., 1992) unlike those of C. trachomatis and C. psittaci. In fact, the
species-specificity of C. pneumoniae appears to reside on a 35 KD peptide within the
76 KD protein. Antibodies prepared against this protein neutralise the infectivity of
C. pneumoniae in cell culture (Perez-Melgosa et al., 1994). In general, it is believed
that antibodies recognising serovar and subspecies- specific epitopes are protective,
whilst those directed against species-specific epitopes are not (Lucero and Kuo,
1985; Zhang et al., 1987).
Numerous in vitro analyses have identified species and serovar-specific MOMP-
specific monoclonal antibodies (MAbs) which are able to neutralise chlamydial
infectivity for cell monolayers (Caldwell and Perry, 1982; Caldwell and Schachter,
1982; Baehr et al., 1988; Lucero and Kuo, 1985; Zhang et al., 1987; Peterson et al.,
1988; Zhang et al., 1989; Toye et al., 1990; Peterson et al., 1991; Cheng et al.,
1992; Morrison et al., 1992; Su et al., 1990; Qu et al., 1993; Batteiger et al.,
1996). However, many variables can be used in performing in vitro serum
neutralisation assays (SNA) including the cell line, the use of centrifugation, the
diluent and the addition of complement (Peeling and Brunham, 1991; Peterson et al.,
1988; Su et al., 1991) all ofwhich may affect the outcome of the assay. Indeed such
divergent results were reported by different laboratories, that it was necessary to set
up a workshop to establish a universal protocol for SNA using C. trachomatis (Byrne
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et al., 1993). Furthermore, the similarity between in vitro and in vivo conditions is
unknown, so that a protective MAb in vitro may be non-protective in vivo. The
antibody isotype is also important in such cases, since neutralisation by IgG2b or
IgG3 antibodies, which are able to bind FcyRIII receptors, may be abrogated by using
cells which possess these specific receptors, such as macrophages (Ravetch and
Kinet, 1991).
Humoral immunity appears to be important in clearance of chlamydial infection,
since antibody produced by experimentally infected animals or naturally infected
humans can neutralise both C. trachomatis and C. psittaci infection in vitro and in
vivo (Howard, 1975; Megran et al., 1988; Nichols, 1973; Reeve and Graham, 1962;
Zhang et al., 1987; Buzoni-Gatel et al., 1990). Neutralisation was shown to depend
on bivalent IgG binding which caused either loss of EB attachment to host cells
possibly by reducing electrostatic attraction or by stearic hindrance of receptor-
binding areas, or inhibition of the porin function of MOMP after antibody-coated
chlamydiae were internalised (Caldwell and Perry, 1982; Peeling et al., 1984; Su et
al., 1990). None of these possibilities have yet been proved. That aggregation of
IgG molecules was not a cause of chlamydial neutralisation was shown by Su and
Caldwell (1991), who demonstrated that monovalent Fab fragments from two
neutralising MAbs were able to prevent chlamydial attachment to host cells.
Animal models of chlamydial infection
Animal models are not only useful tools for assessing the virulence of chlamydial
strains, but have also allowed greater examination of the immune response to
chlamydial infections. The high prevalence of both C. trachomatis-related ocular
disease and genital infections initiated the development of laboratory models to study
these important pathogens. In the first case, primates were used in conjunction with
human serovars of C. trachomatis (Fraser et al., 1975; Taylor et al., 1982) and the
resultant disease was found to be remarkably similar to human trachoma. The cost of
primate models is, however, limiting and consequently smaller laboratory animals
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were utilised. In such a model, the agent of guinea pig inclusion conjunctivitis
(GPIC), a C. psittaci strain, was used to simulate human inclusion conjunctivitis in
guinea pigs (Murray, 1964; Monnickendam et al., 1980). Not only was acute
conjunctivitis produced, but upon repeated infection, a trachoma-like disease was
illicited.
As with ocular infections, models based on primates (Patton et al., 1987; Moller et
al., 1980; Patton et al., 1983; Wolner-Hanssen et al., 1986; Jonson et al., 1980),
cats (Kana et al., 1985), Koalas (McColl et al., 1984), mice (Barron et al.,
1981; Tuffrey and Taylor-Robinson, 1981; Tuffrey et al., 1986; Ito et al., 1990) and
guinea pigs (Mount et al., 1973; Rank et al., 1979; Rank and Barron, 1983;
Batteiger et al., 1993) have been successfully used to study chlamydial genital
infections. Although the GPIC strain is a member of C. psittaci, it produces infection
in the genital tract of guinea pigs which is remarkably similar to human C.
trachomatis genital infection with respect to pathogenesis, pathology, immunity and
ability to be transmitted sexually (Patton and Rank, 1992; Rank and Sanders, 1992).
A major advantage of the guinea pig model is that GPIC is a natural pathogen of
guinea pigs and so the responses studied can be assumed to be the result of natural
host-parasite interactions. In addition, the reproductive system of female guinea pigs
is more similar to that of human females both histologically and physiologically, than
other rodents. An alternative model has also been developed to study chlamydial
genital infections and in this case, mice are infected with C. trachomatis, MoPn, the
agent of mouse pneumonitis (Barron et al., 1981 and 1984; Pal et al., 1993 and
1994). MoPn is much more virulent in mice than human strains of C. trachomatis
(Kuo and Chen, 1980), hence the preference for the MoPn strain in this particular
model. C. trachomatis has been associated with pneumonitis in infants (Beem and
Saxon, 1977; Tack et al., 1980). Consequently, a mouse model has been developed
which again uses the MoPn biovar of C. trachomatis (Kuo and Chen, 1980).
Whilst C. trachomatis infections have been extensively studied, interest in C. psittaci
has only escalated in the last 20 years after an increase in reported cases of ruminant
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abortion. Buzoni-Gatel and Rodolakis (1983) developed a mouse model in order to
explore the virulences of a number of isolates of C. psittaci. They defined virulence
as being the capacity of chlamydiae to cross mucosal barriers, to spread beyond
lymph nodes, to multiply in the reticuloendothelial system and to reach and colonise
target organs. Inoculation of non-pregnant mice via the footpad did not result in the
systemic spread of non-virulent (intestinal) strains, whilst virulent (abortifacient)
strains were able to progress beyond the lymph nodes and colonise the spleen. Not
only did this study highlight an attractive method for distinguishing abortifacient
from intestinal strains of C. psittaci, but it also demonstrated that infection by
abortifacient chlamydiae could be assessed by splenic colonisation.
In the same set of experiments, infection of pregnant mice with abortifacient
Chlamydia was also achieved, resulting in death of infant mice in utero. It was also
observed that intestinal strains were able to induce abortion, but only when extremely
large numbers were injected intraperitoneally into mice. Since C. psittaci strains
have been shown to preferentially inhabit macrophages (Wyrick and Brownridge,
1978), it was suggested that intraperitoneal injection allowed the chlamydiae the
opportunity to colonise peritoneal macrophages and thus be hidden from host-
immune surveillance and subsequently be disseminated to various organs by a
haematogenous route.
The mouse model was further used to characterise the immune response to C. psittaci
with respect to cell-mediated and humoral immunity (Buzoni-Gatel et al., 1987).
Both spleen and liver samples were analysed for viable chlamydiae by plaque assay
(Banks et al., 1970) and gave similar results to each other. Control mice were able
to completely resolve infection in some instances by day 8 after inoculation and so
samples were restricted to the period before this from day 4 to day 6 after
inoculation. McEwan and Foggie (1954) originally determined chlamydial infection
in mice by monitoring histopathological changes. Visual assessment of lesions,
particularly in the lung tissue were performed laboriously under the light microscope.
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Whilst Buzoni-Gatel et al., (1987) demonstrated an apparent involvement of both
cellular and humoral immunity in the defence against C. psittaci infection by passive
transfer of both spleen cells and immune mouse sera, McEwan and Foggie (1954)
had previously employed passive transfer of sheep serum to determine the immune
status of sheep after immunisation with various yolk sac vaccines. In the former
case, immune cells were able to lower infection levels in mouse organs by 3-5 log
plaque forming units (pfu), whereas immune sera only reduced infection by 1.5 log
pfu. Furthermore, transfer of immune cells led to rapid and total eradication of
infection, compared to a slower but significant reduction in chlamydiae titre with
transfer of immune sera. Cytotoxic T-cells have also been directly shown to control
C. psittaci infection, both in vitro (Fammert, 1982) and in vivo (Buzoni-Gatel et al.,
1992). In addition, transferred murine polyclonal and monoclonal antibodies were
able to lower levels of splenic colonisation by C. psittaci (Buzoni-Gatel et al., 1990),
however, characterisation of the antibodies in the latter study was not performed and
their specificities were unknown.
Mouse models have also been useful in investigating genetic factors which may
influence the susceptibilities of individuals to chlamydial infection (Byrne et al.,
1990; Fuentes et al., 1990; Tuffrey et al., 1992). Susceptibility to C. psittaci
infection was shown to depend both on the H-2 haplotype and on the genetic
background of the mouse strain (Buzoni-Gatel et al., 1994), whilst the antibody
response to the heat shock proteins hsp60 and hsp70 were shown to be H-2 restricted
in human chlamydial genital infection (Zhang, 1992). The availability of inbred
strains of mice is therefore a major advantage of mouse models of chlamydial
disease.
Vaccination against infection
The first commercial chlamydial vaccine was developed by McEwan and Foggie
(1952) in response to the identification of C. psittaci as the causative agent of ovine
enzootic abortion (OEA). Formalinised, yolk-sac grown material or infected ovine
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foetal membranes were originally used. However, this "watery" vaccine (Littlejohn,
Foggie and McEwan, 1952) was soon replaced with a more resilient adjuvanted
vaccine which abrogated the need to revaccinate ewes on a yearly basis (McEwan
and Foggie, 1954). The disease remained under control for approximately 20 years
by extensive use of the adjuvanted vaccine.
During the late 1970's however, vaccine efficacy began to breakdown (Linklater and
Dyson, 1979) and immunisation with adjuvanted vaccine or primary infection with
reference strain H574 was shown to have no protective effect against experimentally
infection of ewes with strain S26/3, isolated from an aborted ewe in a vaccinated
flock. Subsequent efforts to produce an efficacious vaccine have included the
development of an avirulent, live vaccine containing a temperature-sensitive mutant
strain of C. psittaci prepared by treatment with nitrosoguanidine (Rodolakis and
Bernard, 1984). The possibility of reversion of the mutant to a virulent form
however, is a major concern with this marketed vaccine.
Jones et al. (1995) recently reported good levels of protection in ewes using a semi-
purified, tissue-culture grown chlamydial vaccine. In this report, protection was
dependent on the vaccine dose administered and similar to the findings of McEwan
and Foggie (1954), on the nature of the adjuvant used. Limitations to the production
of such a vaccine commercially however, reside in the practical and economic
production of large quantities of antigen by tissue-culture.
It had been demonstrated that an outer membrane preparation of chlamydial EBs was
able to protect pregnant ewes against OEA (Tan et al., 1990). The main constituent
of the preparation was MOMP indicating an important immunoprotective role for
this particular protein in OEA. MOMP was therefore investigated for its ability to
prevent abortions when presented to ewes as a recombinant vaccine (Jones et al.,
1992). Initial studies involving expression of the MOMP sequence as a fusion
protein in E.coli (termed fMOMP) proved encouraging (Herring et al., 1992; Jones
et al., 1992). Construct pD5 contained all 367 amino acids of native MOMP plus 11
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additional amino acids derived from the vector and attached to the NH2 terminus. A
second construct, pC2 comprised only the last 228 amino acids of the Ci terminus
plus 8 residues at the NH2 end. Both recombinants were expressed as inclusion
bodies. Repetition of the study using freshly expressed constructs failed to produce
any protection against chlamydial infection in ewes. Analysis of the humoral
responses against each construct showed a marked lack of antibodies specific to VS2
and VS4 in the second experiment, although overall seroconversion was high. In
contrast, seroconversion to abortion resulted in antibodies which reacted with all 4
variable segments by immunoblotting (Herring et al., 1992).
Whilst expression of recombinant proteins by bacteria generally results in a
denatured conformation with the formation of insoluble inclusion bodies (Francis, in:
Vaccines for Veterinary Applications; Dascher et al., 1993), various chemical
treatments can be used to help the protein regain its native conformation.
Alternatively, the recombinant protein can be expressed so that it is automatically
translocated to the outer membrane of the vector, although problems of toxicity to the
vector may arise by accumulation of signal-peptides associated with transport of the
recombinant protein. Export of recombinant MOMP to the outer membrane ofE.coli
was achieved and the product designated mMOMP (Herring et al., in preparation).
The conformational integrity of the recombinant protein was unknown however. A
further adaptation of this construct was made by expression in a PET vector and the
product named MOMP19. The most recently produced recombinant construct of
MOMP in this project, has been named tMOMP (truncated MOMP) and although
expressed as an insoluble inclusion body like fMOMP, it was hoped that this
particular construct may be more natively refolded. At the initiation of the present
study, only fMOMP had been examined in pregnant ewes.
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Summary and Aims
Vaccination of sheep with inoculum grown in embryonated hen's eggs provided
effective protection against ovine enzootic abortion (OEA) for many years. The
reason for its loss in efficacy remains unclear, although changes in the dominant field
strain of C. psittaci may have been partially responsible. The high cost of inoculum
production and low economic returns, resulted in withdrawal of the OEA vaccine
from the veterinary products market. Subsequent analysis of reported sheep
abortions during the last twenty years, indicated an increasing prevalence of C.
psittaci in upland flocks and generated a new search for an efficacious vaccine.
The criteria for the modern OEA vaccine had altered from those associated with the
original egg grown vaccine. Production of large amounts of antigen were required
and at relatively low cost to the pharmaceutical industry. Neither egg grown nor
tissue culture produced antigen would be able to fulfil these requirements and so
alternative approaches to vaccine designs were considered. Amongst the various
proposals, an attractive idea was the presentation of chlamydial antigen as a
recombinant protein. Other vaccines had been produced as recombinant proteins by
expression in various bacterial systems, such as Escherichia coli, with great success.
Since it would be unnecessary to express a complete bacterial genome as a
recombinant protein and unlikely that the bacterial vector could survive such a feat,
only those parts of the immunising bacterium which are protective would be selected
for expression as a recombinant protein.
In the case of C. psittaci, it has been shown that the major outer membrane protein
(MOMP) is able to confer immunity on sheep and prevent abortion after
experimental exposure to the organism. Furthermore, studies on C. trachomatis have
indicated that protection may be provided by several epitopes located primarily in
regions of MOMP where variable amino acid sequences which give rise to different
serovars are found (variable segments 1-4). In C. psittaci, no such serovar
discrimination exists and whilst sequence variations occur in the variable segments,
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these are limited to species differences with C. trachomatis, C. pneumoniae and the
recently described C. pecorum. Thus a single MOMP sequence should be able to
provide universal protection against all abortifacient strains of C. psittaci. The basis
of the present study was therefore:
Hypothesis:- Humoral immunity plays a significant role in defence against
abortifacient C. psittaci infection and is directed against variable segment epitopes
located on the major outer membrane protein.
Aim:- To identify a protective recombinant protein which may be used as a
universal OEA vaccine and to define more clearly the relationship between immunity
and the humoral immune response of sheep to C. psittaci infection.
Approach:- 1) To develop an in vitro, or an animal model which could illustrate
protection against abortifacient C. psittaci infection.
2) To use the model to select recombinant proteins based on the MOMP sequence
and produced by expression in an E.coli vector, which are able to cause a reduction
in C. psittaci infection when formulated into a chlamydial vaccine.
3) To analyse the humoral response of individual sheep with respect to individual
variable segments, and to test the protective capacity of antibodies produced against







Female Blackface x Swaledale sheep aged between 4-5 years were used in annual
lambing experiments. All sheep were certified free from abortifacient C. psittaci
under the Premium Sheep Health Scheme (Scotland).
The sheep were treated with Heptovac P (HAH Ltd) before transportation to
Moredun Institute and wormed on arrival with anthelmintic. The ewes were isolated
from other sheep throughout the duration of the experiments. Before challenging
with live chlamydiae, the uninfected control group was separated from the rest of the
experimental animals.
Oestrus was synchronised in the ewes with ('Veramix', Upjohn Ltd.) and after one
full oestrus cycle the ewes were allowed to run with the tups.
2.1.2. Non-pregnant sheep
Greyface whether lambs aged 5 months old were used to produce serum for testing in
in vitro and murine models. All lambs tested negative for chlamydial antibodies
prior to exposure to C. psittaci as determined by immunoblotting of pre-
experimental sera. None of these animals came into contact with animals from any
other source whilst at Moredun.
2.1.3. Mice
Active immunisation: Strain CBA/ ADRA were used aged 3-4 weeks old at
primary vaccination. Blood samples taken from the lateral tail veins were tested for
antibodies to C. psittaci before the start of each experiment and found to be negative
by immunoblotting. Mice were assigned to groups by random allocation, with
restrictions on both age and sex.
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Passive immunisation: Strain CBA/ADRA and strain CBA/CaOLaHsd (Harlan
Olac Ltd.) were used aged 6-12 weeks old and between 15-20g in weight. Group
allocation and blood sampling were carried out as for active immunisation.
2.2. Cells
2.2.1. Growth of inoculum
L929 cells, mouse fibroblasts were used to grow inoculum from stocks of egg-grown
C. psittaci. L929 cells originated from normal areolar and adipose tissue from a 100
day old male C34/An mouse.
2.2.2. Titration of inoculum
BHK-21 cells , baby hamster kidney cells of fibroblastic origin were used to titrate
inoculum.
2.2.3. Serum neutralisation assay
McCoy cells of fibroblastic origin, were used in in vitro serum neutralisation assays.
2.3. Chlamydial Inoculum
Production:- Egg grown abortifacient C. psittaci, strain S26/3 (5 passages in eggs)
was used to infect L929 cells (mouse fibroblasts) in 225cm tissue culture flasks.
Complete RPMI was used as infection medium, containing antibiotics, 2% new born
calf serum (NBCS) and lpg/ml cycloheximide (Appendix 1). The inoculum was
passed 2-6 times, using a "hot" passage technique and stationary incubation in tissue
culture, before harvesting with glass beads and centrifuging at 12,000 rpm for 30 min
at 6°C. The pellet was resuspended in a small volume of cold PBS and homogenised
in a glass homogeniser to break up the clumps. After recentrifuging, the pellet was
washed again with cold PBS, recentrifuged and finally resuspended in CTM to 1/10
the original volume. The inoculum was aliquoted into Eppendorf tubes (1ml) before
being frozen at minus 70°C. Aliquots of chlamydial inoculum were titrated in BHK-
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21 cells. The procedure was repeated for other batches of inoculum, including strain
S95/3.
Titration:- McCoy cells were grown in RPMI maintenance medium (Appendix 1)
for three days at 37°C, 5% CO2 in 225cm2 tissue culture flasks. Once the cells had
formed a confluent monolayer, the flask was rinsed with sterile PBS which had been
pre-warmed to 37°C, and 2ml of a pre-warmed trypsin/versene (TV) mixture was
added. Most of the TV was tipped off, leaving a thin covering over the cells. The
flask was then incubated for 2-5 mins and sharply tapped to dislodge the cells. The
volume in the flask was made up to 20ml with maintenance medium and a small
sample (lOOpl) taken for assessment of the cell concentration. To do this, lOOpl of
cell suspension was diluted 1:1 with 0.04% trypan blue and the number of cells in
both sides of a Neubauer chamber counted under the light microscope. The
concentration of cells was adjusted to 2 x 105 cells/ml. 1ml of cell suspension was
pipetted into each "Trac" bottle (Sterilin) containing 1 x 16mm coverslip and the air
bubbles underneath the coverslip removed by flicking the bottle. This prevented
cells from growing on the underside of the coverslip. The "Tracs" were then
incubated overnight at 37°C, 5% CO2 and used the following day. 1ml of inoculum
was added to each "Trac" at ten-fold dilutions and centrifuged at 2000xg for 30 min.
The lids were loosened and the "Tracs" incubated at 37°C/5% CO2 for 3 days.
Coverslips were then fixed in methanol and stained for 20 min. in a 5% solution of
Giemsa (BDH). After rinsing coverslips in water and dehydrating and clearing
through graded concentrations of acetone-xylene mixtures, the coverslips were
mounted in DPX on to microscope slides. The number of inclusions per coverslip
was estimated by counting the whole coverslip at x200 magnification.
2.3.1. Sheep Inoculum
Challenge strains comprised S26/3 and S95/3, both of which were isolated from
outbreaks of OEA in Scotland and grown in embryonated eggs through 6 and 2
passages, respectively. Strains were mixed in a 1:1 ratio, giving a final titre of 5 x
104 ifu per ml in BHK-21 cells.
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2.3.2. Mice Inoculum
Strain S26/3, isolated from an outbreak of OEA in Scotland was used in both active
and passive immunisation experiments. Egg grown inoculum (5th passage) was
grown in L929 cells for a further 6 passages before titration in BHK-21 cells, giving
a titre of 1 x 108 ifu per ml in BHK-21 cells.
2.3.3. Serum Neutralisation Assay Inoculum
Egg grown inoculum, strain S26/3 (5th passage, as above) was passaged twice
through L929 cells to give a titre in BHK-21 cells of 8 x 106 ifu per ml.
2.4. Inoculation procedures
2.4.1. Sheep
Challenge inoculum was held on ice to reduce loss of viability whilst the flock was
injected. Each sheep received a 2ml dose given subcutaneously over the pre-clipped
left shoulder. A separate needle was used for each animal. Negative control animals
were left unchallenged.
2.4.2. Mice
Unless otherwise stated, all mice receiving inoculum were injected with a 1ml
volume by the peritoneal route,. In some experiments, intravenous inoculation via the
lateral veins was attempted.
All experiments involving passive immunisation of mice required preparation of
inoculum mixtures to be injected intraperitoneally as follows:- Serum samples were
defrosted and heat inactivated at 56°C for 30 mins. Chlamydial inoculum was
defrosted and allowed to reach 37°C as was RPMI. With all the reagents at the
appropriate temperature, serum samples were diluted to a working concentration of
1/2 in RPMI. Likewise, inoculum was diluted to a working concentration of 4 x 106
ifu/ml in RPMI (2 x 106 ifu/ml in some cases). Diluted serum samples and diluted
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inoculum were mixed in a ratio of 1:1 to give a final serum concentration of 1/4 and a
final concentration of inoculum of 2 x 106 ifu/ml (alternatively, 1 xlO6 ifu/ml) in
each inoculum mixture. The inoculum mixtures were vortexed thoroughly and
incubated at 37°C in a water bath for 45 mins with occasional mixing. After the
incubation time was complete, the inoculum mixtures were placed on ice before
injecting into mice. If several inoculum mixtures were used, preparation times were
staggered to minimise the length of time each was kept on ice before injection into
mice.
2.4.3. Serum Neutralisation Assays
Tissue culture grown chlamydial inoculum was thawed and allowed to reach 37°C in
a water bath. Heat inactivated serum samples were pooled and also warmed to 37°C,
before being added to an equal volume of diluted chlamydial inoculum (dilution
factors recorded with appropriate chapter) and vortexed to mix. Inoculum mixtures
were incubated at 37°C for 45 min. with occasional mixing, before inoculation of
lml of mixture on to cell monolayers. After 2 x 30 min. periods of centrifugation at
2000xg in a bench top centrifuge, the infected cells were incubated in a 37°C
incubator for 2h. Finally, the cell monolayers were washed with 3 changes of
warmed PBS (37°C) and incubated for 3 days at 37°C/5% CO2 in infection medium.
2.5. Antigen Production
2.5.1. ELISA
(Sarkosyl purified EBs were kindly prepared for use in the indirect ELISA by Judith
Machell using the methodology of Ian E. Anderson).
Tissue-culture grown C. psittaci was harvested from flasks using sterile glass beads
and centrifuged at 12K for 30 min. at 6°C. The pellet was resuspended in PBS,
homogenised with a glass homogeniser and sonicated for 2 x 30 sec. The sample
was then treated with 1% sarkosyl and incubated at 37°C with constant stirring.
After 2h, the sarkosyl treated EBs were recentrifuged, washed with 3 changes of PBS
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and stored in PBS at -20°C if not required immediately. The concentration of
MOMP in the sample was estimated by densitometric analysis of immunoblots. The
sarkosyl treated EBs (2.2mg) were then suspended in 0.1M PBE (4.66ml) and 1.0M
sarkosyl added (340pl). The EBs were incubated for lh at 37°C, during which time
the sample was vortexed and sonicated (4x5sec) every 15 min. After lh, the EBs
were dispensed into 5x1ml amounts in eppendorphs and pelleted on a microfuge
(13000rpm/30 min)". The supernatants were discarded*" and each pellet was
resuspended in 0.1M PBE (0.624ml). At this point, 1.0M sarkosyl (170pl), followed
by 0.1M octyl glucoside (1.71ml) was added and the sample treated as before (* to
*
*). The pellet was then resuspended in 0.1M PBE (0.956ml), transferred to a clean
vessel and 1.0M sarkosyl added (170pl) with 1.0M DTT (50pl). Steps * to ** were
repeated and the final supernatant collected for use as ELISA antigen, enriched for
the MOMP fraction.
2.5.2. Vaccine antigens
2.5.2.1. Native chlamydial antigen
Tissue culture grown chlamydiae were produced as in Section 2.3. and formulated
into vaccines as described in Section 2.5.3.
2.5.2.2. Purified MOMP
Chlamydiae were grown in tissue culture, harvested using sterile glass beads and the
cells disrupted using a Jencons-glass-Teflon homogeniser. The culture was clarified
by centrifugation (1500g/5mins/4°C) and then pelleted through a 10ml density
cushion of 30% (v/v) Urografin in Tris KC1 (20mM Tris KC1 pH 7.5 + 150 mM KC1)
by centrifugation (53000g/45mins/4°C). The crude chlamydial pellet was
resuspended in a small amount of Tris KC1 (1ml) and homogenised to disrupt
aggregates before layering on to a 30%-60% Urografin continuous density gradient.
Chlamydial EBs and RBs were ultracentrifuged (53000g/2h/4°C) to purify. Two
opalescent bands which appeared were collected using a syringe and diluted in Tris
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KC1. The samples were repelleted by centrifugation (53000g/45mins/4°C) and
resuspended in Tris KC1 (100-500pl) using a homogeniser.
2.5.2.3. Recombinant antigens
Recombinant MOMP constructs were kindly gifted by Dr Alan Herring (Department
of Biochemistry, Moredun Research Institute). A summary of the expression of
recombinant constructs of MOMP in standard Escherichia coli systems is given
below (A. J. Herring, personal communication).
The initial MOMP expression contructs were fusions of the first few amino acids
(AAs) of P-galactosidase with either full length mature MOMP, 367 AAs (fMOMP-
pD) or the C-terminal 288 AAs (fMOMP-pC). In the present study, construct
fMOMP-pD was used. The vector used in both fMOMP constructs was pUC-8 and
in each case, the leader sequence was removed before fusion. As a result, the
synthesised MOMP was not translocated across the inner membrane of E.coli.
Fusion MOMP (fMOMP) was therefore spatially restricted to the cytoplasmic region
where large amounts resulted in the formation of insoluble inclusion bodies.
The second type of recombinant MOMP investigated was designed in order to
overcome the potential problem ofMOMP forming insoluble cytoplasmic inclusions.
As such, translation was designed to start at the natural initiator codon i.e. the first
methionine. The inserted gene sequence thus included the signal sequence ofMOMP
(16 amino acids). With this arrangement, it was hoped that MOMP would be
translocated to the outer membrane and assume a native conformation. Hence, the
acronym, membrane MOMP (mMOMP). This construct was made in the pET-22
vector. Indications that MOMP was indeed present in the outer membrane came
from cell fractionation experiments and immunoblot analysis with and without
disulphide bond reduction. In contrast to fMOMP, mMOMP was found to be highly
cross-linked resembling the structure of native MOMP. However, both N-terminal
sequencing and size analysis revealed that signal peptide removal did not occur. The
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vaccine preparation ofmMOMP contained a suspension of detergent-extracted outer
membranes in which MOMP was the most abundant protein.
A further two forms of recombinant MOMP were examined as vaccine antigens.
Previously, the whole sequence coding for the native MOMP protein was placed
downstream of the vector pelB leader sequence using a Stu-I site introduced by PCR
mutagenesis and the natural EcoRI site downstream of MOMP. MOMP expression
in this contruct was found to be highly unpredictable and again signal peptide
removal did not occur. However, a small amount of correctly processed MOMP was
observed in the newly transformed cells without induction. This observation
prompted design of the first of these constructs, in which a Bgl-II/EcoRI fragment
from the pET-22b construct was cloned into the pUC-19 vector to give a bi-cistronic
system in which pelB MOMP was co-expressed with the N terminal part of the lac Z
gene. Tandem operator regions, one from pUC-19 and one from pET-22b, gave tight
control by the lac Iq repressor. This construct was termed mMOMP 19. Whilst
incomplete, evidence suggests that this construct is only translocated as far as the
periplasmic space and is not incorporated into the outer cell wall.
The final construct in pET-22b was designed to produce large amounts of MOMP
peptide for renaturation experiments. It consisted of the coding region for the C-
terminal 351 AAs ofMOMP cloned into the Nde-I and EcoRI sites of pET22b using
an Nde-I site in the MOMP coding region introduced by PCR and the natural
downstream EcoRI site. On induction, the construct produces a protein lacking the
first 16 AAs ofMOMP. This truncated form was thus termed tMOMP.
In addition, variable segments of MOMP were expressed as novel pGEX fusion
peptides expressed in E.coli with the enzyme glutathione GST. Purification of VS1
and 2 produced in this manner is described below.
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VS1: Growth in culture:- Three colonies expressing VS1 were grown from an agar
plate. Each colony was grown in 4ml L-broth + ampicillin. At mid-log phase the
colonies were induced by the addition of IPTG to ImM and grown for a further 3 h.
0.5ml was removed from each flask, centrifuged and washed in PBS. The pellets
were then resuspended in lOOpl of 2x sample buffer. lOpl of each sample was run on
an SDS-PAGE mini-gel to check for induction by staining.
Choosing the best sample, a 10ml culture was grown during the day to mid-log
phase. This was kept at 4°C over-night. The following day 8ml of culture was
centrifuged and used to inoculate 200ml of culture medium (L-broth + ampicillin
80pg/ml). The culture was allowed to grow for approximately 2h, until the broth
reached an optical density of between 0.6-0.8nm. lOOmM IPTG was then added to
induce production of VS1 by the E.coli vector. After 3h further growth, the culture
was removed from the incubator, centrifuged at 5K for 15 min. in lxPBS
(approximately 2x volume) to wash the pellet and then stored as a pellet at 4°C
overnight. The following day, the pellet was resuspended in PBS and purified as
described below.
Purification of VS1 by glutathione sepharose 4B gel:-Glutathione Sepharose 4B is
designed for rapid single step purification of recombinant derivatives of glutathione
S-transferase, other glutathione S-transferases or glutathione dependent proteins.
Variable segment 1 (VS1) of C. psittaci (abortifacient) was expressed as a GST
construct in E.coli as described above. Purification of VS1 was carried out on a
GST-sephadex column as follows:-
The gel was packed into a chromatography column and washed with 5-10 bed
volumes of PBS (containing 150 mM Na CI, 16mM Na2HP04, 4mM NaEyPO^ pH
7.3) to remove the preservative. The gel bed was equilibrated with 3 bed volumes
PBS + 1% Triton X-100. The sample was then applied to the column and the eluent
discarded. The column was washed again with 2x bed volumes of PBS. The bound
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material was then eluted with 5 bed volumes of elution buffer (5mM Glutathione in
50 mM Tris-HCl pH 8.0) and the fractions collected (300pl, 1M Tris-HCl + 300pl,
lOOmM Glutathione in 6ml DW). The fraction collector was set at flow rate 7,
Time, 040 (4 min), xl (small tubes). The flow rate was turned up to maximum when
packing the gel. Fractions were examined for VS1 content by SDS-PAGE. The
specificity of VS1 was determined by immunoblotting using a GST control.
Densitometry of SDS-PAGE gels was used to quantify the VS1 preparation.
The protocol described above for growth and purification of VS1 was repeated to
produce the VS2-GST construct and GST only, as a control.
Calculation ofVariable Segment Concentrations from Densitometry Curves:-
BSA Standard 1
Stock solution = 0.2 mg/ml; working dilution = 0.1 mg/ml
Loaded on to SDS page gel at 1.0 pg and 0.5 pg
Scan Number 3 Peak 1 = 829 Peak 5 = 1488
Peak 2 = 445 Peak 6 = 882
Peak 3 = 500 Peak 7 = 2359
Peak 4 = 959








Fig 2.1. SDS PAGE gel of induced and uninduced cultures of transformed E.coli -
VS1-containing fractions eluted from GST-Sephadex column






Fig 2.2. SDS PAGE gel of induced and uninduced cultures of transformed E.coli -
VS2-containing fractions eluted from GST-Sephadex column
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Loaded on to SDS PAGE gel as 2.5 jj.1
Scan Number 5 Peak 1 =6108 Peak 2 = 10203
Sum of peaks = 16311 units, in 2.5 pi.
Therefore, 1631 lx 1.5/7462 pg = 3.3 pg in 2.5 pi
GST concentration = 1.3 pg/pl
VS2
Loaded on to SDS PAGE gel as 1.0 pi
Scan Number 4 Peak 1 = 6558 Peak 2 = 3999
Sum of peaks = 10557 units, in 1.0 pi.
Therefore, 10557 x 1.5/7462 pg = 2.1 pg in 1.0 pi
VS2 concentration = 2.1 pg/pl
BSA Standard 2
Stock solution = 0.2 mg/ml; working dilution = 0
Loaded on to SDS page gel at 1.0 pg and 0.5 pg
Scan Number 1 Peak 1 =
Peak 2 = 903
Peak 3 = 1535
Sum of peaks = 7727units, in 1.5 pg. Therefore, 1
VS1
Loaded on to SDS PAGE gel as 2.5 pi
Scan Number 2 Peak 1 = 8263 Peak 2 = 7198
Sum of peaks = 15461 units, in 2.5 pi.
Therefore, 15461 x 1.5/7727 pg = 3.0 pg in 2.5 pi
VS1 concentration = 1.2 pg/pl
. 1 mg/ml
Peak 4 = 2636
Peak 5 = 1412
Peak 6 = 1241
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SCAN LENGTH= 25 MM. APERTURE UIDTH= 0.1 MM.
. 5A
LENGTH OF X-AXIS= 30 MM.
TOT. INTEGRAL= 9820








































SCAN LENGTH= 25 MM. APERTURE UIDTH= 0.1 MM.
0.5A
LENGTH OF X-flXIS= 20 MM.
TOT. INTEGRAL= 46892
PEAK POSITION RELZ INTEGRAL PEAK POSITION RELZ
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INTEGRAL PERK POSITION RELZ INTEGRAL
18 2 2.85 11.39 903
1535 4 6.95 33.24
.1412 6 13.4 15.65
20 3 17.2 0.37
22 10 20.4 0.29 23
2.5.3. Vaccine formulations
Reagents:- i) Montanide ISA 50, Lot 2011 Seppic/ Marcol Arlacel A
ii) Alhydrogel (Superfos).
iii) Glutaraldehyde (BDH), Product N°. UN2810, Concentration 50%.
iv) Thimerosal, stock solution 1% (w/v) in distilled water.
Method:-
Each vaccine was formulated by slowly mixing equal volumes of aqueous and
adjuvant portions using an Ystral homogeniser. Smaller quantities were emulsified
by the "syringe to syringe" method. The adjuvant phase comprised: Marcol Arlacel
A or Montanide ISA 50 as 50% of the final volume. The aqueous phase comprised:
Alhydrogel at 25% final volume; Antigen at 50-100pg/ml final concentration;
Glutaraldehyde at 0.1% final volume; Thimerosal (1%) at 0.01% final volume and
PBS to make up the volume to 50% of the final volume.
For 60ml of vaccine: Antigen was made up to 6ml with Tris buffer, 6pl of neat
glutaraldehyde added and the mixture held at room temperature for 15 mins. 24ml of
Alhydrogel (Tris) was added, followed by 60pl of thimerosal. Adjuvant was
dispensed into 4x7.5ml aliquots. Whilst holding over ice, 3ml of aqueous solution
was slowly added to 1 aliquot of adjuvant as the mixture was homogenised with an
Ystral homogeniser for 30 sees. The remaining 2ml were added in a similar fashion
and the whole emulsification process repeated with the remaining 3 aliquots of
adjuvant. The homogenised aliquots were pooled in a 100ml duran bottle and
homogenised for a further 30 sees. Vaccine aliquots were stored at 4°C and samples
submitted for bacteriological screening.
2.6. ELISA Protocols
2.6.1. Indirect serum ELISA
Sarkosyl purified chlamydial antigen (Section 2.5.1.) was ultrasonicated (2x5 sec
bursts), then diluted in CO3/HCO2 buffer to a concentration of 20 pg/ml. A fresh 96-
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well plate (Nunc) was taken and 100 pi of diluted antigen (2pg) was added to each
well in alternate rows. The rest of the plate was then filled with 100 pi CO3/HCO2
buffer as control wells. The plate was sealed and stored at 4°C overnight.
The following day, the plate sealer was removed and the plate contents vigorously
ejected. The plate was washed three times with PBS/Tween and blotted dry. 120pl
periodate solution was added to each well and the plate resealed and placed on a plate
shaker for 10 mins, followed by a 20 min stationary incubation at 37°C. After
washing the plates as before, 200pl of 10% horse serum in PBS/Tween was added to
all wells. The plate was again sealed, shaken for 10 mins and incubated for 20 mins.
After washing, 120pl of 0.5% glutaraldehyde in PBS/Tween was added and the plate
placed in the refrigerator at 4°C for 25 mins. Some plates were stored at 4°C in
sealed bags at this point for future use. To continue the assay, test samples were
applied at a dilution of 1/800 in PBS/Tween in quadruplicate in cubic formation.
The plate was sealed and incubated as before. After 30 mins, the plate was washed
and lOOpl of conjugated antibody added to each well. For detection of ovine
antibodies, donkey anti-sheep IgG conjugated to horseradish peroxidase SAPU) was
used at a dilution of 1/2000. Murine antibodies were detected with goat anti-mouse
gamma globulin conjugated to horseradish peroxidase (SAPU), diluted 1/500 in
PBS/Tween. After incubation as before, the plate was washed and lOOpl substrate
(OPD; Sigma Chemicals) added to each well. The plate was left in darkness for 10
mins until the colour of the positive control had developed sufficiently. The reaction
was stopped by the addition of 50pl 2.3M H2SO4. Absorbencies were read on an
ELISA reader (Titertek™ ) at 492 nm.
2.6.2. Variable segment capture ELISA
VS1 peptide was produced by the author as described in section 2.5.2.3. The ELISA
plate was coated with 0.2pg/well of antigen diluted in PBS/Tween and a GST
preparation was used as a control by coating adjacent wells. The plates were
prepared the day before use, covered and kept at 4°C overnight. The following day,
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the plate was washed and blocked with 200pl/well of 10% horse serum and incubated
as above. After washing the plate, serum samples were diluted 1/1000 in PBS/Tween
and lOOpl of each sample pipetted into adjacent wells in a rectangular formation.
The ELISA procedure now continued as above. VS2 was also prepared and used to
coat ELISA plates to detect antibodies specific for the second variable segment of
MOMP.
2.6.3. IgG isotyping ELISA
The indirect serum ELISA (section 2.6.1.) was used as the basis for this assay.
However, modifications were made and the system optimised using immune and
non-immune sheep sera. Plates were coated with sarkosyl antigen as before and
serum samples applied at a dilution of 1/100 in 1% horse serum. An additional step
involving the application of mouse a-sheep IgGl or IgG2 diluted 1/500 (Serotec)
was incorporated, before detection of antibodies by goat a- mouse gamma globulin
conjugated to horseradish peroxidase (SAPU), diluted to 1/500.
2.6.4. LPS-ELISA
An LPS-ELISA was developed at the Moredun Institute to analyse chlamydial
infection of sheep placental material (Jones, unpublished) and adapted for use with
mouse samples (this thesis). The ELISA plates were coated with 1 OOpl /well of raw
ascitic fluid for Mabs 13/4 and 13/5, mixed in a ratio of 1:1 and used at a final
dilution of 1/2500 in CO3/HCO2 buffer. The plate was sealed and stored for at least
12h at 4°C. The following day, the plate was washed with PBS/Tween three times
and the wells blocked with 200pl of 10% Marvel in CO3/HCO2 buffer. The plate
was sealed and placed on a shaker for 10 mins before incubation at 37°C for 20 mins.
This washing and incubating procedure was carried out after each step. Samples were
then applied to duplicate wells. Processed mouse organs were used at a dilution of
1/5 or 1/10, whilst peritoneal exudates were used at 1/2 in PBS/Tween. Positive
control samples comprised LPS from Salmonella minnesota. Detection of
chlamydial LPS was achieved by the addition of lOOpl Mab 13/4 conjugated to HRP
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at a dilution particular to each batch and development of a coloured product using the
substrate OPD. As before, 50pl/well, 2.3M H2SO4 was used to stop the reaction and
absorbencies were read on an ELISA reader at 492nm.
2.6.5. Competitive ELISA
IEA-antigen (section 2.5.1) was diluted 1/320 in 0.05M CO3/HCO3. An ELISA plate
(Greiner F) was coated with lOOpl diluted antigen to all wells except those in the first
column. The plate was sealed and placed at 4°C overnight. The plates were washed
according to standard practise and non-specific binding sites blocked by the addition
of 200pl 10% horse serum in PBS/Tween and incubated for lh at 37°C. 1ml of
positive and negative control sera were prepared at a dilution of 1/20 in PBS/Tween
containing 1% horse serum. Doubling dilutions of each test sample were similarly
prepared between 1/10 and 1/80 dilutions. After washing, lOOpl of each test sample
was added to duplicate wells. 8 wells were used for each control sample. The plate
was incubated for lh at 37°C and then without aspirating the sera, lOp.1 Mab 4/11 at a
dilution of 1/800 in 1% horse serum was added to each well. The plate was
incubated for a further lh at 37°C. After washing the plate, lOOpl of a-mouse
gamma globulin conjugated to HRP (SAPU) was added to each well. The plate was
incubated for lh at 37°C. Finally, the plate was washed and lOOpl OPD substrate
added per well. The plate was incubated in the dark for approximately 20mins and
then the reaction stopped by adding 50pl of 2.3M sulphuric acid. The optical
densities were read at 492 nm using a Titertek Multiscan reader (ICN Flow Ltd).
Percentage inhibition was calculated for each test sample as follows:-
mean absorbance negative control - mean absorbance test sample x 100
mean absorbance negative control - mean absorbance positive control
2.7. Serum Samples
Sheep were bled from the jugular vein into 10ml vacutainers. Samples were allowed
to clot overnight at room temperature and then centrifuged at 3000 rpm and the
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removed with a Pasteur pipette. Serum samples were aliquoted into medicine bottles
and stored upright at -20°C. Mice were bled from the lateral tail veins using a Gilson
pipette to collect blood from a small incision. Samples were collected in 1.5 ml
eppendorfs and treated as above.
2.7.1. Ammonium sulphate precipitation of polyclonal sheep serum
Sheep immune serum taken from a pool of ewes after aborting, was used to provide
antibodies against C. psittaci for use in the immunoperoxidase technique described
above. A saturated solution of ammonium sulphate was prepared by adding 76. lg of
ammonium sulphate to 100ml of distilled water. The amount of ammonium
sulphate solution to be added to 10ml of positive serum was calculated as follows in
order to arrive at a final concentration of 45% saturation, once the reagents were
mixed:-
VolumeofNHfSO^i = volume ofsample x final concentration
1 - final concentration
Precipitation of fibrinogen and transferrin was avoided by using a 45% rather than
50% saturated solution of ammonium sulphate. The ammonium sulphate solution
was added in a dropwise fashion over ice (approximately 2h) using a burette attached
to a peristaltic pump. The mixture was stirred constantly on a magnetic stirrer. After
all the ammonium sulphate solution had been added, the mixture was allowed to
stand at 4°C overnight. The following day, the solution was centrifuged in a bench
top centrifuge at 2000xg for lh. The resulting pellet was carefully resuspended in
PBS to 0.2 x original volume of serum with minimal agitation. Finally, the solution
of antibodies was dialysed against 3 changes of PBS at 4°C overnight. Titration to
determine the optimal working dilution for the immunoperoxidase technique was
performed on mouse tissue.
2.7.2. Affinity purification of antibodies against VS1 and VS2
VS1 was coupled to cyanogen-bromide sepharose beads and prepared as an affinity
column described below. Serum from a standard pool of sheep immune serum was
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poured down the column and the eluate quantified for total protein by Pierces BCA
method. The eluate was then dialysed against PBS until a concentration of
approximately half that found in the original serum sample was obtained. The same
procedure was repeated for VS2. This time, however, the fall through from the VS1
affinity column was used for the VS2 column.
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Coupling VS1 and VS2 to cyanogen-bromide sepharoser 4B: Cyanogen-bromide
activated sepharoser 4B (CNBr-sepharose) (Pharmacia Biotech) is a preactivated gel
for immobilisation of ligands containing primary amines. The peptides VS1 and
VS2 were coupled to the gel using the following protocol:- lg of freeze-dried CNBr-
sepharose was weighed out into a universal bottle. Approximately 10ml ImM HC1
was added and the gel allowed to swell for lhour on a spiral mixer. At this point,
0.5mg VS1 (or VS2) was measured into a centricon-10 filter and made up to 1ml
with carbonate buffer. This was centrifuged at 4600g for 40 mins at 4°C in a fixed
head rotor. The peptide was washed once with 1ml carbonate buffer and centrifuged
for a further 45 mins. The sample was collected in the adapter tube by inverting the
filter and centrifuging for 5 sees. Once the gel had completely swollen, it was
removed to a glass-sintered Buchaner filter and washed with 200ml ImM HC1.
Finally, the gel was washed with carbonate buffer. All preservatives should now
have been removed from the gel. The gel was centrifuged for 3mins in a bench-top
centrifuge and 2ml of gel slurry removed to a 5ml glass container. The washed
peptide was now added to the container and allowed to interact for lh on a spiral
mixer.
After lh, excess uncoupled peptide was washed away with 20ml carbonate buffer
through a Buchaner filter. Uncoupled active groups on the gel were blocked by
transferring the gel to 0.1M Tris-HCl buffer, pH 8.0. After 2h standing at room
temperature, the gel was washed through a Buchaner filter with 3 alternating cycles
of low and high pH buffers i.e. 3 x 5ml 0.1M acetate buffer + 0.5M NaCl, pH4 and 3
x 5ml carbonate buffer + 0.5M NaCl, pH8.3. The gel was equilibrated with PBS and
stored at 4°C .
Purification of VS1 and VS2 specific antibodies from sheep immune serum: The
technique of fast protein liquid chromatography (FPLC) was employed to purify
antibodies specific for VS1 and VS2 from sheep immune serum. Each gel coupled
with VS1 or VS2 antigen was pipetted into a chromatography column and slowly
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packed down by running PBS through the column at a rate of lml/min. Once the
bed volume was level, the piston was carefully pushed down to the top of the gel
excluding any air bubbles and 0.1M citrate buffer (+ 0.5M NaCl, adjusted to pH 2-5
with 1M NaOH +/- 6M urea) run through the column to gauge the background effect.
The pump was returned to PBS and the sample of sheep immune serum loaded into
the superloop using a syringe and adapter needle.
The sample was loaded onto the column at a flow rate of lml/min and fall through
fractions collected in 10ml volumes. The FPLC was linked up to a
spectrophotometer to allow progress of the column to be monitored. The print out
was obtained at a rate of 0.2cm/ml. When the initial peak of fall through had
levelled out (approximately 90-120 mins), the pump was switched to the elution
buffer ( citrate buffer +/- 6M urea) and the eluate collected at the appropriate peak on
the printer. The eluate was immediately neutralised by the addition of Tris.
The procedure was repeated with further additions of sheep immune serum and the
fractions pooled. The samples were kept at 4°C to minimise loss of activity and
dialysed over night with 3 changes of PBS using pressure dialysis through collodian
filters. The samples were then aliquoted and frozen at minus 20°C.
Quantification of affinity purified antibodies: Total protein content:- After
dialysis of the affinity purified fractions, the samples were tested for total protein
content by the Pierce Protein assay. Briefly, 10ml solution A was added to 200pl
solution B to prepare the working reagent. Protein standards were prepared by
diluting stock BSA solution (2mg/ml) in PBS to 8 doubling dilutions in a microtitre
plate. lOpl each standard was added in duplicate to adjacent wells, whilst lOpl
sample was added in triplicate to a series of adjacent wells neat and at a dilution of
1/5 in PBS. 200pl working reagent was added to each well including blank wells
and the plate tapped gently to mix the contents. The plate was sealed and incubated
for 30-60 mins at 37°C until a strong purple colour had developed in the positive
control wells. Absorbencies were read spectrophotometrically at or near 562 nm.
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Antibody activity:- The samples were compared to sheep immune serum in terms
of concentration of VS1 and VS2 specific antibodies. The fractions eluted by citrate
buffer and citrate buffer containing 6M urea were pooled for each peptide and the
overall antibody activity calculated.
A 96-well flat-bottomed plate was coated with the appropriate peptide, diluted in
CO2/HCO3 buffer to give 0.2pl/well, sealed and kept at 4°C overnight. The
following day, the plate was washed x3 with PBS/Tween and 200pl blocking
solution (10% horse serum in PBS) added to each well. The plate was sealed and
the contents mixed by placing the plate on a rotary shaker for 10 mins followed by 30
mins incubation at 37°C. Meanwhile, doubling dilutions were made of the samples
and of the whole sheep immune serum starting at a dilution of 1/50 to 1/6400. After
washing the plate, lOOpl each dilution was added to duplicate wells and the plate
incubated as before.
Positive wells were detected by the addition of lOOpl donkey a-sheep IgG conjugated
to horseradish peroxidase SAPU), diluted 1/500 in PBS/Tween. As before, lOOpl
substrate solution (OPD) was added to each well to develop the coloured product .
The reaction was stopped by the addition of 50pl 2.3M H2SO4 and the absorbencies
read at 492 nm.
Antibody specificity:- The specificity of each affinity purified antibody fraction was
determined by immunoblotting and by competitive ELISA:-
Immunoblot; VS1 and VS2 peptides were loaded onto a 12.5% SDS gel at a
concentration of 0.5pg/well. After electrophoresis at 150V for approximately lh, the
gel was transferred onto nitro-cellulose paper using the Transblot semi-dry blot
apparatus. The nitro-cellulose paper was then blocked at 4°C overnight in 10% horse
serum diluted in PBS.
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d, VS1-specific antibody fraction




g, VS1-specific antibody fraction
h, VS2-specific antibody fraction.
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Fig 2.4. Immunoblots of affinity column purified VS fractions
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Four,-5mm wide strips of nitro-cellulose paper were cut and individual strips placed
in the wells of a blotting tray. Between each step of the procedure, the strips were
washed 5mins x3 with PBS/Tween. Strips were probed with the affinity purified
antibodies or with whole sheep immune serum at a dilution of 1/50 in 1% horse
serum. The strips were agitated on a rotary shaker for lh. After washing, 2ml
donkey a-sheep/goat IgG conjugated to HRP was added to each well at a dilution of
1/1000. The strips were again agitated on a rotary shaker for lh. The strips were then
removed to a flat container and washed to remove unbound conjugate. Substrate was
added to the container in the form of 10ml DAB and the reaction allowed to proceed
until an intense brown band had developed at the appropriate level on the positive
control strip. The reaction was terminated by washing the strips in distilled water.
MAB 4/11 competitive ELISA; In order to determine if the VS2 specific fraction
contained antibodies which reacted to the same epitope as the mouse monoclonal
antibody 4/11, which was known to be VS2 specific, a competitive ELISA
(developed by Ian Anderson) was used (Section 2.6.5.).
2.7.3. Peripheral blood leukocyte collection and assay
Two recombinant forms ofMOMP available at the start of the project (fMOMP and
mMOMP) were used to vaccinate groups of 7 sheep on 2 occasions, 3 weeks apart.
Each vaccination contained approximately 50pg/ml protein and volumes of 1ml were
administered subcutaneously on each occasion. Venous blood was taken from each
animal approximately 21 days after second vaccination and collected into evacuated
tubes containing lithium heparin (no preservative) at a final concentration of 15
units/ml. Aliquots of 1.5ml blood were mixed with 100 pi of appropriate antigen and
the mixtures incubated overnight at 37°C. The following day, mixtures were
centrifuged and the upper layer comprising PBLs collected.
Reactivity of PBLs was tested in vitro using native MOMP in two forms; semi-
purified chlamydial elementary bodies and solubilised, purified MOMP. The assay
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was carried out using interferon-gamma (IFN-y) production as a measure of the
reactivity of PBLs (Central Science Laboratories, Bovine y- interferon kit). Non¬
specific activity of PBLs was measured by inclusion of an LPS control in the form of
a B-cell mitogen (,Salmonella minnesota Re mutant; Sigma Ltd) and a T-cell mitogen
(concanavalin A).
2.8. Analysis of Chlamydial Infection in Mice
The mice in all experiments unless otherwise stated were infected on day 0 and killed
on day 6 by exposure to CO2 and cervical dislocation. The carcasses were weighed.
The livers and spleens were dissected and a record kept of their weights. The organs
were then crudely homogenised using scissors and divided up for different assays:
2.8.1. Preparation of samples for LPS-ELISA
A small amount (0.5g) of crudely homogenised liver was added to 1ml PBS in an
eppendorph. The lid was pierced and the sample boiled for 15-20 min. Once the
sample had cooled, it was exposed to 4 x 5 sees bursts of sonication. The sonicator
was set at 50% duty cycle, 2.5 output and fitted with a microtip. The samples are
then microfuged for 15 min at 13,000 rpm before the supernatant was decanted off
and stored at minus 20°C. The spleen and where applicable, the lungs were treated
similarly, except the whole organ was used. Twice the organ weight by volume was
added as PBS and the procedure continued as for the liver. Spleens and lungs only
required 2 x 10 sees sonication, due to the small volumes used. Samples were
diluted 1/5 or 1/10 in PBS/Tween for analysis by the LPS ELISA and 100 pi used per
well.
2.8.2. Culture of murine tissue
A small amount (0.5g) of crudely homogenised liver was placed in 2ml CTM and
frozen at -70°C until required for culture. To culture the organs, the sample was
ground with a small amount of sand using a pestle and mortar. The sand was
centrifuged down at low speed (100 rpm) and the supernatant decanted. The
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supernatant was then diluted in warmed infection medium (RPMI + antibiotics + 2%
NBCS + lpg/ml cycloheximide) to 1/40 and 1/400 and 1ml used to infect McCoy
cell monolayers in duplicate trac bottles. The tracs were centrifuged at 3000rpm for
30 min and incubated in 5% CO2/ 37°C for 3 days. The coverslips were fixed in
methanol (10 min) and the tracs stained with 5% Giemsa (BDH Ltd) for 20 min. The
coverslips were washed in tap water followed by dehydration in acetone and clearing
through graded acetone/xylene mixtures. The coverslips were then mounted from
xylene in a xylene based mountant (DPX) and the dark stained inclusion bodies
enumerated under the light microscope.
2.8.3. Peritoneal exudates
Collection: Peritoneal fluid was extracted from each mouse immediately after
cervical dislocation to avoid posthumous changes. The mouse was pinned to a
dissection board and the outer fur dampened with alcohol. A lateral incision was
made through the outer skin and the skin pulled back to expose the underlying
peritoneum. Using a 26 gauge needle, 2ml of 10% horse serum in PBS was injected
into the peritoneal cavity. The abdomen was massaged gently and the flaps of skin at
either side extended and pinned to the board to create a reservoir in which to collect
the peritoneal fluid. As fluid drained to the two reservoirs, it was slowly removed
using a 26 gauge needle and a 2ml syringe.
Cells from the peritoneal exudate were prepared as cytospins the same day as
extraction. To do this, 200pl of peritoneal exudate was pipetted in to the funnel of
the cytospin carrier and centrifuged for 5 mins. The slide was allowed to air dry
(approximately 10 mins) and then fixed for one of the following procedures.
Leishman's stainingThe cytospin was air dried and the lower end of the slide
containing the cells covered with Leishman's stain (BDH Ltd) for 2 mins. The rest
of the slide was then flooded with distilled water to give a crude 1/2 dilution of the
stain. This was washed off with distilled water after 12 mins and the slides allowed
to air dry completely before mounting in DPX (BDH Ltd).
62
LPS-ELISA:- Samples ofmurine liver and spleen were prepared as described above
(section 2.8.1) and analysed by LPS-ELISA. Peritoneal exudates were also examined
by LPS-ELISA at a dilution of 1/2 in PBS/Tween.
Immunoperoxidase staining:- After air drying duplicate cytospins, peritoneal cells
were fixed in modified Bouin's fluid for 10 mins. The slides were then washed with
tap water and thoroughly dried in air before being frozen in upright slide boxes at -
20°C. Before staining by the immunoperoxidase technique described below, the cells
were allowed to thaw at room temperature (approximately 10-15 mins). Sections of
positive sheep placental material were used as positive controls and after mounting
on microscope slides, were dewaxed in 2x 10 mins rinses with xylene. They were
then rinsed in reagent grade ethanol and placed in 1% H2O2 in methanol for 30 mins
to quench any endogenous peroxidase activity in the tissue. Cytospins of peritoneal
exudates were also added to 1% H2O2 in methanol for 30 mins.
After 3x 5 mins washes in Tris/HCl, the slides were placed in 10% egg albumin for
30 mins. They were then rinsed in distilled water and washed as before. The slides
were carefully wiped around the tissue sections to remove excess fluid and incubated
with primary antibody overnight at 4°C in a humidity chamber. Primary antibody
comprised purified sheep IgG from an immune animal post-abortion and was used at
an optimal working dilution of 1/160 in high salt buffer (7pl primary antibody in
1.113ml high salt buffer).
The following day, the slides were washed 3x 5 mins with Tris/HCl buffer and
blotted to remove excess solution. The slides were then incubated for 90 mins in a
humidity chamber with donkey a-sheep/goat IgG conjugated to HRP (5pl conjugate
diluted in 1ml of high salt buffer). Titration of the conjugate indicated an optimal
working dilution of 1/200. The slides were washed 3x 5mins with Tris/HCl and
finally incubated with peroxidase substrate solution- (diaminobenzidine (DAB); 1
tablet dissolved with 1 tablet of H2O2 in 5ml of distilled water; Sigma Chemicals
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Ltd.) until brown staining was just visible (approximately 5-8 mins). Excess DAB
was drained into a container and the sections were washed in tap water to stop any
further colour development. The slides were counter-stained with haematoxylin and
Scott's tap water, dehydrated in graded alcohols and cleared in xylene. The slides




INDUCTION AND ANALYSIS OF CHLAMYDIAL INFECTION IN MICE
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3.1. Introduction
Animal models have been used extensively to study the immunopathology of human
chlamydial diseases (Mount et al., 1973; Rank et al., 1979; Rank and Barron, 1983;
Tuffrey et al., 1986a; Patton et al., 1989; Kaukoranta-Tolvanen et al., 1993; Westbay
et al., 1994). Ovine abortifacient C. psittaci infection has also been studied in mouse
models using both pregnant and virgin mice to: investigate the kinetics of infection
(Lammert, 1982); to compare the virulence of different strains of C. psittaci (Buzoni-
Gatel and Rodolakis, 1983; Anderson, 1986; Rodolakis and Lantier, 1989); to
determine susceptibilities of various inbred strains of mice (Buzoni-Gatel et
al., 1994); and to assess the contribution of cytokines to resolution of infection
(McCafferty et al., 1994). The first experiments in mice to assess the efficacies of
chlamydial vaccines were performed as early as 1954 (McEwan and Foggie), using
intranasal inoculation and analysis of lung consolidation as a measure of chlamydial
infection. Mouse protection models were not used extensively thereafter, until
twenty years later when the efficacy of the original vaccine was rapidly declining.
The potency of a live vaccine containing a temperature-sensitive mutant strain of C.
psittaci (abortifacient, AB7) is being investigated in mice (Rodolakis, 1983) and
represents one approach to this problem. This chapter describes the development of
two mouse models for investigation of potential vaccines, using intraperitoneal
inoculation to infect susceptible mice.
An integral part of any mouse model, is the accurate measurement of in vivo
infection levels. Chlamydial infection was originally determined by visual
assessment of infected organs or subsequently by titration of chlamydial infectious
bodies using either the plaque assay method (Banks, 1970) or the Trac method. In
both the latter cases, only chlamydiae in the infectious elementary body stage of
development are detected. The techniques require between 3 days (Trac method) and
2 weeks (Plaque assay) to complete and final quantification involves identification of
individual inclusions under the microscope. More recently a "sandwich" ELISA has
been developed (G. E. Jones et al., unpublished; Graham et al., 1995) which detects
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chlamydial lipopolysaccharide (LPS) and allows rapid and accurate quantification of
chlamydiae. The technique was originally developed for detecting C. psittaci in
sheep placentas. However in this chapter, adaptations of the tissue processing stages
are described which allow its use with mouse liver, spleen and lung.
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3.2. Materials and Methods.
3.2.1. Quantifying chlamydial infection in mice.
3.2.1.1. ELISA procedure.
The "sandwich" LPS-ELISA technique was utilised in which a mixture of two genus-
specific, anti-LPS monoclonal antibodies, 13/4 and 13/5 (1:1 ratio) was used in the
capture phase and 13/4 conjugated to horseradish peroxidase in the detection phase.
The epitope against which the MAbs react is repeated along the O-chain of the LPS
molecule, which allowed the use of the same MAbs in both the capture and detection
phases.
M129B ELISA plates (Greiner Labortechnik Ltd, Dursley, UK) were coated with
lOOpl/well of MAbs 13/4 and 13/5 (1:1 ratio) to give a final dilution of 1/2500 in
carbonate buffer, pH 9.6. The plates were stored at 4°C overnight and the following
day the coating MAbs were expelled from the wells and the plate washed with three
changes of PBS containing 0.05% Tween 20 (Sigma). After blotting the plate dry,
each well was blocked with 200pl of 10% Marvel, diluted in carbonate buffer. The
plate was covered and incubated at 37°C for lh after which time the wells were
washed as before. Samples were diluted in PBS-Tween (0.05%) to give a working
dilution of 1/5. Each sample was added to duplicate wells in lOOpl volumes and the
plate incubated as before. Salmonella minnesota Re 595 LPS (Sigma) was used as
the positive control. After lh at 37°C, the plate was washed and lOOpl ofMAb 13/4
conjugated to horseradish peroxidase was added to each well diluted to 1/160 (or
alternative for other conjugate batches) in PBS-Tween (0.05%). After a final
incubation at 37°C for lh, the plate was washed and lOOpl/well of
orthophenylenediamine dihydrochloride (OPD, 0.8mg/ml;Sigma) in citrate
phosphate buffer, pH5.0, containing 0.8pl/ml of 30% H2O2 added to each well. After
approximately 1 Omin incubation in the dark, the colour reaction was stopped by the
addition of 50pl 2.3M H2SO4 to each well. Absorbances were read at 492-nm using
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a Titertek Multiscan ELISA reader (Flow, High Wycombe, UK) and converted to
units of concentration { ng of LPS/g ofwet tissue }.
3.2.1.2. Adaptation of the LPS-ELISA technique to detect C. psittaci in mouse
tissue.
Various processing techniques were tested in order to obtain the maximum levels of
chlamydial LPS from mouse tissue. Extraction of chlamydial LPS from infected
liver tissue was examined by both detergent and physical methods, which included
solubilisation with either:-
1) Tween 20 (Sigma); 0.05-0.5%,
and/or 2) sodium deoxycholate; 0.1-1%
and disruption of intact cells by sonication and/or boiling.
3.2.1.2.1. Procedure
Briefly, a pool of infected mouse liver was crudely homogenised with sterile scissors
and 0.5g amounts weighed into 1.5ml eppendorf tubes. The contents of each
eppendorf were mixed with 1ml of solution as shown in Table 3.1. and then
processed by one of three methods:-
1) boiled for 10 mins,
2) sonicated for 2xl0sec., (50% duty cycle, 2.5 output) or
3) boiled for 10 min. followed by sonication as in 2.
After each treatment, the samples were microcentrifuged for 5min. and the
supernatants decanted for analysis by LPS-ELISA. Non-infected mouse tissue was
also processed to identify treatments which gave high background results in the
ELISA. Net absorbances after subtraction of negative control values (non-infected
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tissue) are given in Table 3.1. Optical density values were not converted to units of
concentration at this stage.
3.2.1.3. Correlation between in vitro culture and LPS-ELISA of infected mouse
tissue.
The LPS-ELISA was considered as an alternative method to culturing samples in
vivo, in order to quantify chlamydial infection in internal organs. A comparison was
made between the 2 methods using C. psittaci strain (avian Z10).
3.2.1.3.1. Procedure for culturing samples.
In vivo culturing was performed in McCoy cell monolayers, which had been seeded
at 2x105 cells/ml and allowed to monolayer overnight in Tracs. Each tissue sample
(0.5g) had been stored in 4ml CTM at -70°C. Samples were thawed and
homogenised with a small quantity of sterile sand using a pestle and mortar, until a
uniform consistency was obtained. The sand was gently sedimented by centrifuging
at lOOrpm for 5min., after which the supernatant was decanted into a sterile
container. A 1/400 dilution of the supernate was made in RPMI medium (pre-
warmed to 37°C) containing 5% serum and lpg/ml of cylcoheximide. Duplicate
Tracs were infected with 1ml of diluted sample and centrifuged for 30min. at
3000rpm. Tracs were then incubated at 37°C for 3 days before fixing in methanol
and staining in 5% Giemsa solution. Inclusions were counted per coverslip and the
mean number for duplicates was calculated. Correlations are shown in Fig. 3.2.
comparing infection titre of samples with concentration of chlamydial LPS.
3.3. Results
Treatment of liver samples by boiling and sonicating resulted in consistently high
values in the LPS-ELISA (mean 1.120; sem 0.166) regardless of the solute (Table
3.1.). Sonication alone resulted in high background contamination which reduced the
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net values to zero, except where LPS levels were greater than the background value
(0.1% D.O.). This would not therefore be a suitable method for detecting low levels
of LPS. Boiling alone did not result in high background, however the overall LPS
levels were lower than in equivalent samples which were both boiled and sonicated
(p<0.01). One exception to this was 0.5% D.O., which resulted in a high LPS level
with boiling alone. No other concentrations of D.O. or Tween gave comparable
results with this method, whilst boiling followed by sonication gave generally higher
values (p<0.01) in both cases.
The highest LPS levels were detected by boiling and sonicating samples with PBS
compared to PBS + Tween or D.O. (p<0.01).
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Table 3.1. Extraction and detection ofchlamydial LPS from infected mouse
livers by LPS ELISA.
Treatment; Absorbance at 492nm
(PBS +) boil sonicate boil/sonicate
PBS only O.061 0.041 1.787
0.05% Tween 0.097 0.000 1.664
0.1% Tween 0.174 0.000 1.236
0.2% Tween 0.194 0.000 1.174
0.5% Tween 0.643 0.000 1.122
mean background 0.047 2.316 0.006
0.1% D.O. 0.074 1,748a 1.498
0.5% D.O. 1.714 0.000 0.703
1.0% D.O. 0.664 0.030 0.375
0.05% Tween +1% 0.022 0.000 0.524
D.O.
mean background 0.000 0.490 0.060
PBS - Phosphate buffered saline; Tween - Tween 20 (Sigma); D.O. - sodium
deoxycholate.
• Samples tested in duplicate
• Mean background absorbance from uninfected samples subtracted
• samples mixed with solution (0.5g crudely homogenised tissue per ml of
solution).
• samples boiled (lOmin), or sonicated (2xl0sec; 50% duty cycle, 2.5 output), or
boiled (lOmin), and sonicated, followed by microcentrifugation (5min, 13000
rpm
• a high background (0.490nm)
StatisticalAnalysis (Student's t-test):-
Betweenphysical treatments; Boil/sonicate> boil (p<0.01)
Between chemical treatments; Tween> D.O. (p>0.05), PBS> Tween; (p<0.01).
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No advantage was gained by adding Tween to PBS and there was a trend towards a
negative correlation between LPS levels and concentration of Tween in the solution
(correlation coefficient , -0.68). A similar effect also occurred with the addition of
increasing concentrations of D.O. to PBS (correlation coefficient, -0.96). However,
neither statistic was significant (p>0.05) since sample sizes were small.
In summary, the optimal processing technique for mouse tissue was boiling for 10
min. in PBS (0.5g tissue/ml PBS), followed by 2xl0sec sonications using a tapered
microtip and collecting the supernatant after 5min. microcentrifuging at 13000rpm.
All subsequent mouse samples were treated this way for analysis by LPS-ELISA.
3.4. Induction of a systemic infection in ADRA/CBA mice
3.4.1. Model 1- Active Immunisation.
Active immunisation of mice was considered to assess the efficacies of recombinant
vaccines. Experiments were designed using chlamydial inocula and ADRA/CBA
mice. Initial parameters to be standardised were, titre of inoculum, day of killing and
the route of infection.
3.4.1.1. Experimental procedure
1) Infection ofmice
Forty eight, 12 week old ADRA /CBA mice were randomly allocated to 4 groups of
20 and 1 group of 8 mice with a restriction on age and sex. The mean weight of each
group was recorded and showed no significant differences between groups. The mice
were bled from the right lateral tail vein and the sera assayed by indirect ELISA
(Materials and Methods, section 2.6.1.) to ensure negativity for anti-chlamydial
antibodies. After allowing the mice to become accustomed to their new surroundings
(2-3 days), each was inoculated intraperitoneally with 1ml of tissue-grown
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chlamydia] inoculum (Section 2.3.), such that group 1 received 1x10 6 ifu and groups
2, 3 and 4 received 1x10 5 ifu, 1x10 4 ifu, and 1x10 3 ifu, respectively; group 5
received no inoculation. Four mice from each group were killed daily between days
4 and 8 post-inoculation (inclusive), except group 5 in which 4 mice were killed
only on days 4 and 8 (Table 3.2.).
3.4.1.2. Results
3.4.1.2.1. LPS levels in internal organs
The extent of infection in the liver, lung and spleen was estimated using the LPS-
ELISA to detect chlamydial LPS in these organs. Infection was only detected in
Group 1 (1 x 106 ifu/ml) using this technique, therefore only data for this group and
that of the negative control group (Group 5) are shown in Fig. 3.3. Inoculum injected
at a titre of 1 x 105 ifu/ml or less, did not result in levels of infection which were
detectable by this assay .
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Table 3.2. Experimental design defining the parameters of infection in Model 1.
group challenge titre
(ifu/ml)
n number of mice killed on day
day 4 day 5 day 6 day 7 day 8
1 1 x 106 20 4 4 4 4 4
2 lx 105 20 4 4 4 4 4
3 1 x 104 20 4 4 4 4 4
4 1 x 103 20 4 4 4 4 4
5 none 8 4 0 0 0 4
n number ofmice per group at start ofexperiment (day 0).
• ADRA/CBA mice; 6-16 weeks old, 18-25g weight.
• each group received lml of chlamydial inoculum (Batch A) at stated litre by
intraperitoneal injection on day 0.
• 4 mice from each group were killed daily between days 4 and 8 post-infection (p.i.),
except Group 5 in which 4 mice were killed only on days 4 and 8.
• organ infection analysed by LPS-ELISA.
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Levels of chlamydial infection in Group 1 varied over the 5 days of sampling.
Significant levels of infection were detected in the livers (p<0.01) and spleens
(p<0.05) of group 1 by day 4 p.i., but not in the lungs (p<0.01) until day 5. As the
mean level of infection increased in the liver (day 7 p.i.), the results became
statistically non-significant (p>0.05) due to substantial between sample variations.
Likewise, infection levels in the spleen were statistically non-significant on day 7 and
only marginally significant (p<0.05) on day 5. Infection of the lung was, however,
significant (p<0.05) at all samplings post-infection except on day 4, when chlamydial
levels were low. No significant differences were calculated between infection levels
in the three organs, except on day 4 when infection in the lung was significantly less
than in the liver (p<0.01) or spleen (p<0.05). The optimum time to detect significant
(p<0.05) levels of chlamydiae in internal organs was therefore chosen as day 6, since
significantly (p<0.01) high infection levels on this day were accompanied by low
validity in all three organs.
3.4.1.2.2. Spleen weights
Although LPS was not detected in Groups 2 to 4, spleen weights of mice in these
groups and in Group 1, were significantly higher on days 4 (p<0.05) and 8 (p<0.01)
than spleen weights in uninfected controls (Table 3.3.). There were no significant
differences (p>0.05) between spleen weights of groups 1 to 4 on day 4. However, on
day 8, group 2 spleens were significantly (p<0.01) heavier than those in group 1.
This was interesting since group 1 had the highest levels of splenic infection
(Fig.3.3.). Spleen weights on day 8 were significantly higher in groups 1 (p<0.05)
and 2 (p<0.001) compared with weights on day 4.
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Day (fii.)
♦— liwsr 1 1 lung 1 A spleen 1 —X— livsr 5 X lung 5 —•— spleen 5
Fig 3.3. Chlamydial LPS levels in internal organs in Model 1.
• n = 4.
• Group 5 = uninfected controls (all values zero)
• mice in Group 1 inoculated intraperitoneally with lxl 06 ifu/ml viable chlamydiae on day
0.
• chlamydial infection estimated by LPS-ELISA (ng/g).
StatisticalAnalysis (Student's t-test):-
• LPS levels significantly higher (p<0.05) than in controls (group 5) on Day 4 (spleen)
and on Day 5 (liver + spleen).
• LPS levels significantly higher (p<0.01) than in controls (group 5) on Day 4 (liver),
Day 5 and 7 (lung), Day 6 and 8 (liver, lung + spleen).
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3.4.1.2.3. Clinical signs
A set of criteria were taken to standardise the clinical signs associated with
increasing degrees of chlamydial infection. These were as follows, in order of
increasing severity:-







Each mouse which displayed abnormal signs post-infection, was classified under one
of the designated headings (Table 3.4.).
Mice rapidly displayed signs of illness soon after injection, with damp looking,
ruffled fur over the first 2 days post-infection. By day 5 post-infection, one mouse in
group 1 had developed a white eye, a classical sign of chlamydial infection in mice.
Day 6 post-infection, was marked by all 12 mice in group 1 showing ruffled fur with
additionally, 1 mouse which demonstrated a hunched posture and another which was
reluctant to move. On day 7 post-infection, the mouse which had developed a white
eye died. No other deaths occurred. Group 2 (1 x 105 ifu/ml), was the only other
group to show any signs of infection, with 1 mouse having ruffled fur on days 3 and
4.
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Table 3.3. Mean spleen weights ofmice on days 4 and 8 after infection with abortifacient
C. psittaci, strain S26/3 in Model 1.
group challenge n
mean spleen weight (mg)
day 4 day 8
titre (ifu/ml) mean3 sem mean6 sem
1 lxl 06 4 93c 11 165c 26
2 1x10s 4 115d 16 300d 23
3 lxl 04 4 160 15 203 37
4 lxl 03 4 143 28 203 17
5 none 4 46 8 75 12
n number ofsamples contributing to mean value.
• mice infected intraperitoneally on day 0 with 1ml challenge at stated litre. Four mice
per group killed on days 4 and 8 post-infection and spleens weighed as wet tissue.
StatisticalAnalysis (Student's t-test):-
"
spleen weights in groups 1-4 significantly greater (p<0.05) than in group 5 (control). No
significant difference (p>0.05) between spleen weights in groups 1-4.
b
spleen weights in groups 1-4 significantly higher (p<0.05) than in group 5 (control).
Spleen weights in group 1 significantly (p<0.01) lower than in group 2. No significant
differences (p>0.05) between spleen weights in groups 1, 3 or 4.
c
spleen weights on day 4 significantly (p<0.05) lower than on day 8.
d
spleen weights on day 4 significantly (p <0.001) lower than on day 8.
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3.4.1.3. Route of inoculation
The route of inoculation has been investigated previously with different strains of C.
psittaci (Buzoni-Gatel and Rodolakis , 1983). An abortifacient strain was shown to
be virulent when injected either intraperitoneally or via the footpad. However,
inoculation via the footpad resulted in a slight inflammatory reaction which was
associated with reduced infectivity of the less virulent intestinal strains of Chlamydia
spp. The strain used in this study, S26/3 has been categorised as invasive although
not as highly as other strains (Rodolakis et al., 1989). In order to induce maximal
organ infection therefore, intravenous challenge using approximately lxlO6 - lxlO7
ifu/O.lml was compared to the previous intraperitoneal challenge (Fig. 3.3.).
Table 3.5. Experimental design defining the parameters of intravenous infection.
group challenge titre n number ofmice killed on day
(ifu/O.lml) day 4 day 5 day 6 day 7
1 1 x 106 26 6 6 7 7
2 1 x 107 23 5 6 6 6
n, number ofmice per group at start ofexperiment (day 0).
• each group received 0.1ml of chlamydial inoculum at lxl 06 or lxl 07 ifu/ml by
intravenous injection on day 0.





—♦— livsr 1 lung k spleen
Fig 3.4. Chlamydial LPS levels in internal organs after intravenous inoculation.
• n, number ofsamples contributing to mean value.
• mice infected intravenously with 1x107 ifu/O.lml.
• analysis oforgan infection by LPS-EL1SA (ng LPS/g wet tissue).
• no LPS values greater than 83 ng/g (sem 26) detected in group 1.
StatisticalAnalysis (Student's t-test):-
LPS levels significantly higher (p<0.05) than control (group 5, Fig. 3.3.) on Day 4 in the
liver and lung.
LPS levels significantly higher (p<0.01) than control (group 5, Fig. 3.3.) in spleen on Days
4, 5, 6 and 7; lung on Day 7 and liver on Days 5 and 7.
c LPS levels not significantly different (p>0.05) to control (group 5, Fig. 3.3.).
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The results of infecting CBA/ADRA mice intravenously can be seen in Table 3.5.
Significant chlamydial LPS was detected in the liver (p<0.05) and spleen (p<0.01)
by day 4 post-infection as in the previous experiment. In contrast to inoculation via
the peritoneal route however, peak LPS levels occurred on day 5 in the spleen and
liver (p<0.01). Although LPS levels in the liver on this day were higher than those in
the spleen, the difference was not statistically significant (p>0.05) . Overall,
intraperitoneal inoculation was the preferred route of administering chlamydial
challenge, since it was technically a more simple procedure and resulted in
significant (p<0.01) LPS levels in the spleen, lungs and liver detectable by the LPS-
ELISA.
3.4.2. Model 2 - Passive protection and infection.
A second model was assessed in order to compare its action in protection studies
against Model 1. In this case, C. psittaci was incubated with an equal volume of non¬
immune sheep serum for 45 min at 37°C, before injecting 1ml of the reaction mixture
into mice intraperitoneally. Because of the delay between thawing and injecting the
inoculum, the use of a higher titre of chlamydiae was examined to compensate for
those dying during the 45 min incubation period.
3.4.2.1. Experimental procedures.
3.4.2.1.1. Comparison of inoculum titres.
Two separate experiments were compared in which the same batch of inoculum was
used, but at different titres. Both experiments involved incubating the inoculum with
an equal volume of heat inactivated non-immune sheep serum at 37°C for 45 min.
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3.4.2.2. Results.
Incubating the inoculum with non-immune sheep serum for 45 min. at 37°C,
significantly (p<0.01) reduced LPS levels in the liver compared to immediate
injection as in Model 1 (Fig. 3.5). LPS levels were significantly enhanced (p<0.01)
by increasing the inoculum titre to 2xl06 ifu/ml. The higher titred inoculum did not
result in significantly different LPS levels (p>0.05) to those seen in Model 1. In
contrast, splenic LPS levels occurred at significantly (p<0.01) lower levels compared
to liver LPS levels when mice were inoculated with 2xl06 ifu/ml chlamydiae.
However, the weaker inoculum did not result in any difference between organ LPS
levels (p>0.05).
3.5. Variation in infection levels between experiments
3.5.1. Model 1.
In order to assess the repeatability of Model 1, data was collated from 7 experiments
performed on separate occasions. Infection levels in the liver and spleen of mice
injected with lxlO6 ifu/ml intraperitoneally, were compared between experiments,
between inoculum batches and, where mice had previously been immunised with

















■ liver □ spleen
Fig. 3.5 Comparison of Inoculum Titres in Model 2
• n = 12, inoculum titre lxl06'; n = 9, inoculum titre 2x106
• inoculum mixed with sheep non-immune serum (1:1) ratio; incubated at 37 °Cfor 45 min.
• lml injected intraperitoneally into mice.
• Mice killed on day 6post-injection; organs analysed by LPS-ELISA.
• inoculum batch C - 11th passage.
StatisticalAnalysis (Student's t-test):-
Liver LPS levels significantly higher with 2xl06 ifu/ml inoculum compared to lxl06
ifu/ml (p<0.01).
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3.5.1.1. Results - Model 1.
Comparing LPS levels in spleen and liver between the 7 experiments (Table 3.6.), it
was found that consistency was low and in particular, there was a significant
difference (p<0.01) in liver infection between the experiments. LPS levels in the
spleen were more consistent (no significant difference; p>0.05). especially when
analysis was restricted to experiments using a single inoculum (Batch A). Variability
in liver LPS levels however, remained high (p<0.01). Statistical analysis revealed no
correlation between LPS levels in the spleen and liver when mice were injected
intraperitoneally with lxl06 ifu/ml of chlamydial inoculum (correlation coefficient,
0.33; no significant correlation, p>0.05). Consistency in spleen LPS levels between
experiments could be extended to include experiments performed with any of inocula
A, B or C, but did not include inoculum D which gave significantly (p<0.01) lower
levels of LPS. The six experiments showing no significant differences in spleen LPS
levels (1, 3a, 3b, 5, 9 and 11) contained a further variable, namely alternative
adjuvants where challenge with chlamydiae had been pre-empted by 2 placebo
vaccinations. Therefore, the results also indicated that there was no significant
(p>0.05) effect on spleen LPS levels of immunising mice with placebo vaccine in a
variety of adjuvants, compared to each other and to Experiment 1 (no immunisations
pre-challenge).
To summarise, infection ofmice intraperitoneally with lxlO6 ifu/ml produced levels
of LPS and presumably, of infection in the spleen which could be reproduced in
subsequent experiments using the same inoculum batch. This was not the case for
the liver. In all, three out of four inoculum batches produced comparable results in
the spleen, whilst one batch failed to induce sufficient levels of LPS and was
significantly (p<0.01) lower than the others. No significant (p>0.05) effect was
produced by immunising mice with placebo in a variety of adjuvants, (Marcol
Arlacel A + Alhydrogel, Montanide ISA 50 or Montanide ISA 50 + Alhydrogel) prior
to challenge, compared to no immunisation. This indicated a lack of either protection
or enhancement of infection due to adjuvant alone.
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3.5.2. Model 2
Variation in organ LPS levels between experiments, was estimated using nine
separate experiments performed by the procedure for Model 2. Briefly, 8-15 week
old mice were infected intraperitoneally with 2xl06 ifu/ml chlamydiae, containing
25% non-immune sheep serum. In addition, Experiments 8 and 19 contained guinea
pig serum at 5% (final volume). The reaction mixtures (chlamydiae + 25% serum
diluted in RPMI) were incubated at 37°C for 45 min. prior to injection. Data from the
9 experiments were compared and the variation between experiments calculated in
terms of organ LPS values. The liver and spleen were treated separately. Variation
arising from the use of different inoculum batches was assessed, as was variation
between infection levels in experiments using the same inoculum. Correlation
coefficients were calculated to determine whether any correlation existed between
LPS levels in the liver and spleen.
3.5.2.1. Results - Model 2.
The coefficient of correlation (0.49; p>0.05) indicated that there was no relationship
between LPS levels in the liver and those in the spleen of individual animals infected
by the method used in Model 2 (Table 3.7). In order to assess if infection occurred
randomly in one or both organs, 5 experiments were compared in which the same
inoculum (batch C) had been used. There was a significant (p<0.001) degree of
variation in spleen LPS levels between these 5 experiments, however levels of LPS
in the liver were more consistent and variation between experiments was not
significant (p>0.05). A wider comparison was performed to calculate the variation in
organ LPS values over all 9 experiments. A total of 5 different inoculum batches (A,
B, C, D and F) were used in this range of experiments. The results showed
significant variation in LPS levels of both the liver (p<0.05) and spleen (p<0.001),
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In summary, statistical analysis of LPS values in 9 experiments using Model 2,
demonstrated that infection in the liver could be achieved at a constant level in
different experiments, but that this was restricted to the use of one batch of inoculum
for all such experiments. Consistency was lost when a different batch of inoculum
was used, even when the same titre of chlamydiae (quantified in tissue culture) was
present. LPS levels in the spleen, in contrast to the liver, were highly variable
between experiments using this method.
Conclusions
Models 1 and 2 both displayed consistencies in levels of organ infection, after
intraperitoneal inoculation of mice with lxlO6 or 2xl06 ifu/ml, respectively.
However, whereas in Model 1, the levels of chlamydial LPS in the spleen remained
constant between experiments, in Model 2 consistent LPS levels were only seen in
the liver.
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mean sem n mean sem n
8 A 840 152 8 3259 1423 8
7 D 82 97 10 378 134 10
10 B 249 79 7 367 134 7
12 C 1965 246 9 2286 409 10
15 C ND. ND. ND. 3034 1235 10
18 c 950 52 9 347 44 9
19 F 1703 275 5 2280 497 5
20 C 648 128 10 1256 162 10
22 C 1919 720 4 1000 241 4
• n, number ofsamples contributing to mean value
• mice inoculated intraperitoneally with lml of live chlamydiae at 2x10 ifu/ml, pre-
incubated with non-immune sheep serum (1:1 ratio).
• lnocula:- A - 7,h passage; B - 8th passage; C - 11th passage; D - 8lh passage + 10'h
passage, (1:1); F - 7thpassage + 12th passage (1:1).
StatisticalAnalysis (Student's t-test):-
"
p<0.001; significant difference in spleen LPS levels between experiments.
b
p<0.05; significant difference in liver LPS levels between experiments.
c
p>0.05; no significant difference in liver LPS levels between experiments using same
inoculum (C); spleen LPS levels significantly (p<0.001) different.




The results described in this chapter illustrate that the LPS-ELISA provides a simple
and effective assay for measuring chlamydial infection in murine tissue. Recovery of
chlamydial LPS from heat-treated/sonicated tissue correlated well with estimated
titres of viable chlamydiae using a cell culture technique. This is consistent with the
observation that chlamydial LPS is secreted on to the surface of infected cells
(Karimi et al, 1989) in increasing quantities as the chlamydiae develop (Campbell et
al, 1994). Not only were the results obtained considerably faster by LPS-ELISA
compared with cell culture, but the mode of detection was also less laborious,
replacing microscopic counting of inclusions with spectrophotometry. In contrast to
sheep placental tissue where detergent extraction was required to solubilise
chlamydial LPS (Jones, unpublished), murine liver was successfully treated by
boiling and sonicating in PBS only. The reason for this discrepancy may reflect the
exposure of liver cells in situ to bile secretions of which sodium deoxycholate is one,
thereby increasing the concentration of detergent in the sample. An excessively high
concentration of alkaline detergent may firstly affect the LPS structure which
normally resides in an acidically charged environment within the outer membrane
and secondly, may remove bound material from the microtitre plate.
The standard LPS control used in the ELISA originated from Salmonella minnnesota
Re, indicating that the monoclonal antibodies used were indeed specific for the
epitope shared by Chlamydia spp. and other Gram-negative bacteria, (a-2,4-linked
disaccharide) (Brade et al., 1985; 86; 90; Nurminen et al., 1983; 84), rather than the
genus-specific epitopes unique to Chlamydia spp. (a-2,8-linked disaccharide or
aKdo-(2,8-aKdo-2,4-aKdo) trisaccharide).
It was also demonstrated that CBA/ADRA mice were exceedingly susceptible to
chlamydial infection which could be detected in the liver and spleens of inoculated
mice. It was previously shown (Rodolakis et al, 1989 ) that the route of injection of
inoculum into mice, influenced the spread of infection throughout the body. If the
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inoculation strain was of low virulence, then inoculation via the foot-pad could
prevent infection progressing beyond the popliteal lymph node. However,
intraperitoneal inoculation resulted in even the less virulent intestinal strains
becoming systemic and colonising spleen and liver and in pregnant mice could even
induce abortion although a much greater (x500) titre of intestinal chlamydiae was
required than when abortifacient strains were injected. Similar titres of abortifacient
chlamydiae were used in the present study and these produced considerable infection
in both the spleen and liver by intraperitoneal injection. Thus, the strain of
chlamydia used in the present study was comparable to the abortifacient strains used
in the work of Buzoni-Gatel et al (1990). In the current study, no significant
difference was associated with intravenous injection compared with intraperitoneal
injection and both methods resulted in systemic spread of infection. It was
hypothesised that the ability of C. psittaci to colonise macrophages and thus avoid
exposure to the immune system, could explain the systemic nature of ovine
chlamydial infection (Wyrick and Brownridge, 1978). In the protocol used in this
chapter, peritoneal macrophages may indeed be engaged in dispersal of chlamydial
EBs to various organs, including the liver and spleen.
Susceptibility to chlamydial infection in mice is thought to involve both H-2 and
non-H-2 related genes. In a pilot study preceding the current work, CBA and
CBA/ADRA mice were found to be exceedingly susceptible to chlamydial infection
compared with either Balb C or DBA strains of mice (Jones, unpublished). Thus
CBA/ADRA mice were chosen for the present study. Rodolakis et al (1994)
demonstrated the lack of infection in Balb C mice which carried the H-2b locus,
whilst H-2k mice were much more susceptible. This is in agreement with both the
pilot study and the data presented here in which CBA/ADRA mice appeared to be
highly susceptible to chlamydial infection.
Spleen weights of infected mice were significantly higher than in non-infected mice,
both at 4 and 8 days after inoculation, indicating that blastogenesis was probably
occurring in response to chlamydial infection (McCafferty et al., 1994). Spleen
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weights were significantly higher on day 8 than day 4 which is consistent with long
term resolution of infection over weeks rather than days. In addition, by day 8,
spleen weights were significantly higher in mice injected with a lower, but still
virulent titre of chlamydiae, reflecting possibly less stimulation of suppressive factors
which have been shown to act on lymphocytes in vitro, e.g. activated splenic
macrophages (Tomioka et al, 1990) and IFN-y (Richard et al, 1991).
It was interesting that although inoculum titres were standardised between all
experiments, varying mean infection levels were detected in mouse tissues between
experiments. Peeling and Brunham (1991) reported that the kinetics of infection
could be grossly affected by the ratio of dead to live chlamydial particles in the
inoculum. Since only viable chlamydiae contribute to the titre in tissue culture, it
was unknown what proportions of the inocula were dead chlamydiae. It is possible
therefore, that differences in the amounts of chlamydiae recoverable from spleen and








Since the demise of the original chlamydial vaccine (McEwan and Foggie, 1954),
and the subsequent increase in abortions due to C. psittaci, an alternative vaccine has
been sought. In this chapter, the mouse models described in Chapter 3 demonstrating
susceptibility of CBA/ADRA mice and detection of chlamydial infection in liver and
spleen were applied to protection studies with native C. psittaci. Protection was
calculated as the percentage difference in chlamydial LPS levels between positive
and negative control groups (Jones et al., 1989). Other groups have assessed
protection in pregnant mice (Rodolakis, 1983) afforded by murine polyclonal and
monoclonal antibodies as the increase in surviving offspring or in non-pregnant mice
as a reduction in cultivable chlamydiae from spleen tissue (McCafferty et al., 1994).
Reduction in mouse mortality has also been used to indicate a reduction in
chlamydial multiplication in vivo (Williams et al., 1990). The latter two examples
investigated effects due to cytokines rather than vaccines, however, the principles
involved in measuring the effects are equivalent.
Both Models 1 and 2 were examined. In the first, the protective effect of a native
chlamydial vaccine was directly measured by immunisation of mice. In the second,
passive transfer of serum antibodies from sheep which had aborted due to C. psittaci
infection was assessed with regards to reducing chlamydial LPS levels in mice. Both
models relied on in vitro analysis (section 3.2.) of organs by LPS-ELISA.
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4.2. Protection in Model 1 - Active immunisation of mice
The aim in this section was to demonstrate that the infection induced in mice by
intraperitoneal injection with live C. psittaci, could be reduced to a significant extent
by vaccination with an adjuvanted MOMP-enriched preparation. Protection induced
by this protocol was compared over 3 experiments in which either the inoculum
batch or the adjuvant was altered between experiments.
4.2.1. Materials and Methods.
4.2.1.1. Vaccine preparation.
A MOMP-enriched preparation was used as the antigen phase of a native chlamydial
vaccine (Materials and Methods, section 2.5.2.). Briefly, C. psittaci, strain S26/3,
was harvested from tissue culture and semi-purified by the addition of sarkosyl to
solubilise the MOMP fraction. The resulting preparation comprised predominantly
MOMP, which constituted approximately 25% of the total chlamydial protein. The
antigen phase was emulsified (1:1) with either Marcol Arlacel A + Alhydrogel or a
second adjuvant, Montanide ISA 50 (+/- Alhydrogel) to form a vaccine. Details of
vaccine compositions are given in section 2.5.3.
4.2.1.2. Vaccination protocol.
In the Model 1, mice were immunised with 0.1ml of native chlamydial vaccine on 2
occasions, 3 weeks apart. Immunisation was subcutaneous on both occasions over
alternate shoulders. Three weeks after the second vaccination, mice were bled from
the right lateral tail vein and the sera analysed for anti-chlamydial antibodies. The
following day, each mouse was challenged intraperitoneally with lxlO6 ifu/ml C.
psittaci in 1ml and was killed 6 days later. Results of 3 such experiments are given
in Table 4.1., where infection is expressed as levels of chlamydial lipopolysaccharide
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in liver and spleen (ng/g) and protection as a percentage compared to the placebo
vaccinated controls.
4.2.2. Results
4.2.2.1. Reduction in chlamydial LPS levels in mouse tissues.
Protection was assessed as a reduction in chlamydial LPS levels in liver and spleen of
mice vaccinated with MOMP enriched antigen, compared to those immunised with
placebo vaccine. As in Chapter 3, the variation in LPS levels within a group was
extremely high (Table 4.1). This made determination of protection difficult, and
consequently the data lacked statistical significance. It was not therefore possible to
compare the results of the 3 individual experiments, except to conclude that antigen
adjuvanted in Montanide ISA 50 may induce greater protection than Marcol Arlacel
A + Alhydrogel.
Several points are exemplified by the tabulated data. Initially, example 3b showed
the effect that a single outlying value could have on the data. In this case, a
mathematical transformation was required to improve statistical evaluation (Table
4.2). By taking a log function of each value (log{x+l}), the distribution was
condensed as shown in Fig.4.1. and significance of difference then resolved as
p<0.01 in the spleen as well as in the liver.
A similar effect was achieved by categorising each individual value in experiment 3b
as either positive or negative and applying Fisher's Exact Test (Table 4.2). In this
case, the distinction was straight forward due to the high number of negative mice
(x=0) in the vaccinated group. Only 2/9 (22%) of vaccinated mice were positive for
LPS in the spleen, compared to 7/9 (78%) in the placebo group. If, however, the LPS
level was not reduced to zero, but rather was a series of declining values as in
Experiment 6, it was preferable to calculate a level above which mice could be
classed as positive. In this experiment, a placebo vaccinated, non-infected group was
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available which allowed a cut-off value of {p+3SD} to be calculated. Transforming
the data with the log{x+l} function had little effect in this case, presumably because
of the low LPS values in general. However, using the calculated cut-off value (4.28
± 2.44; n=10), only 50% of the vaccinated group were positive compared to 85% of
the placebo vaccinated group.
It was also apparent from the data (Table 4.1), that the frequency with which negative
LPS levels could be expected in a placebo vaccinated, infected group varied
considerably depending on the group size. If a low sample size was considered
(Experiment 3a; n=3), then the negative animal carried an unnaturally high weighting
(approximately 33% of total) and the overall variation was exceedingly large. In
contrast, a sample of size 20 was shown only to have a maximum of 15% negative
mice.
4.2.2.2. Serological response to vaccination with native chlamydial antigen.
Immunoblotting using sarkosyl-purified chlamydial elementary bodies as antigen,
showed a distinct band at approximately 38Kd indicating good seroconversion to the
MOMP component of the vaccines (Fig. 4.1.).
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Fig 4.1. Immunoblot ofchlamydial antigen probed with sera from mice immunised
with native chlamydial vaccine in adjuvant a) Marcol Arlaccl A + Alhydrogcl or b)
Montanide ISA 50. (arrow indicates position of MOMP
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4.2.3. Summary.
LPS levels in the spleen, but not the liver in mice inoculated with lxl06 ifu/ml of C.
psittaci, strain S26/3, were shown to reach consistent levels when the same batch of
inoculum was used in different experiments (Chapter 3). In this chapter, protection
against chlamydial multiplication was attempted by immunisation of mice with
native chlamydial antigen in 2 different adjuvants. LPS levels in mice injected with
placebo vaccine were in the same range for each experiment performed with batch A
inoculum (Experiments 3a and 3b), showing no significant differences between mean
values (p>0.05). However, high variation in LPS levels in all 3 experiments, directly
affected the statistical validity of the protective effect of the chlamydial vaccine.
None of the results for spleen protection were therefore significant (p>0.05). In one
such case (Experiment 6- batch D inoculum), LPS levels were low in comparison to
batch A inoculum, and whilst 89% protection was achieved, the results were non¬
significant (p>0.05).
Use of an alternative statistical method to the Student's t-test however, allowed a
valid assessment of protection to be made based on the percentage positive values in
the vaccinated compared to the placebo vaccinated groups. The effect of a large
group variation was also reduced in Experiment 3b, by mathematical transformation
of the data by log{x+l}, resulting in a significant effect (p<0.01) of the vaccine. No
significant effect could be calculated for Experiment 3a, in which the placebo group
contained only 3 members. This highlighted the importance of adequate group
numbers in order to validate the data, statistically.
In Chapter 3, a larger range of experiments indicated that over 1/4 (29%) of
experiments would be statistically invalid using this model, solely because of high
variation within the infected control group. The data presented in this chapter
corroborates this, but despite these difficulties appropriate statistical analysis was
able to select the adjuvant Montanide ISA 50 for future vaccine studies.
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Thus, Model 1 appears to depend on several factors including the effects associated
with large group variations, small sample sizes, low inoculum infectivity, outlying
values which may require transformation of the data, preferential multiplication of
chlamydiae in the spleen and finally the contributing effect of adjuvant to
protection.
4.3. Protection in Model 2 - Passive immunisation of mice with immune sheep
serum.
Whereas Model 1 probably involved both humoral and cellular immune responses
after vaccination of mice with MOMP enriched antigen, Model 2 was designed to
test the protective capacity of anti-chlamydial antibodies only. Unlike Model 1,
where the immune system was stimulated by a MOMP enriched preparation,
antibodies used in Model 2 originated from sheep in response to abortion caused by
viable chlamydial organisms. In the latter case, sera from ewes which had aborted
due to chlamydial infection were pooled and shown to be positive for chlamydia-
specific antibodies by ELISA. The protective capacity of this pool of "immune"
serum was determined by incubating an equal volume of the serum pool with
chlamydial inoculum in order to allow interaction between antibodies and antigen.
The mixture was then injected intraperitoneally into mice and infection levels
assessed as before, by detection of chlamydial LPS levels in liver and spleen. The
importance of complement at the in vitro incubation stage was assessed by heat
inactivation of the serum and the addition of either heat inactivated or intact guinea
pig serum.
4.3.1. Materials and Methods.
Model 2 comprised 2 phases; Phase 1:- pregnant adult sheep were infected by s.c.
injection with 2 strains of C. psittaci (S95/3 and S26/3; 5x105 ifu) at 70-73 days
gestation. Blood samples collected approximately 6 weeks after abortion were
pooled and tested by ELISA for high chlamydia-specific antibody titre.
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Phase 2:- equal volumes of pooled "immune" serum (heat inactivated) and
chlamydial inoculum were incubated for 45 min. at 37°C with occasional mixing.
The mixture contained a final inoculum titre of 2 x 106 ifu/ml and serum
concentration of 25%. Each mouse was challenged intraperitoneally with 1ml of
mixture and killed 6 days later. Chlamydial infection in the liver and spleen was
assessed by capture EL1SA of LPS.
4.3.1.1. Requirement for exogenous complement.
Initially, the effect of exogenous complement on the system was examined. In vitro
neutralisation often requires the presence of complement in the medium. Whilst the
mouse strain used in the present study had an intact complement system, the
exogenous addition of complement before inoculation may pre-empt endogenous
complement and affect neutralisation. Mixtures of heat inactivated immune serum
(25% final volume) and chlamydial inoculum (2xl06 ifu/ml final concentration) were
incubated as in section 4.3.1., with the addition of either intact or heat inactivated
guinea pig serum at a level of 5% (final volume). Naive lambs were also bled and the
pooled sera used to form a control serum pool (naive serum) which tested negative
for anti-chlamydial antibodies by ELISA.
Design of experiment to investigate the requirement of exogenous complement for
protection in Model 2.
group n 'serum source complement (5% final vol.)
1 7 immune serum intact guinea pig serum
2 7 immune serum 'H.I. guinea pig serum
3 8 naive serum 'H.I. guinea pig serum
immune serum; standard pool of sera from ewes which had aborted due to C. psittaci
infection; naive serum; standard pool of sera from naive sheep; 1 H.I., heat inactivated for
30 min at 56°C.
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Inoculum mixtures comprised equal volumes of chlamydial inoculum (2 x 106 ifu/ml, final
titre) and H.I. sheep serum (25% final volume). Guinea pig serum was added either intact or
H.l. at 5% final volume.
4.3.1.2. Variation in protection between experiments.
Several experiments were performed using the procedure described for Model 2,
without an additional source of complement. The results for immune and naive
sheep serum pools were compared over a range of 9 experiments, in order to assess
the degree of variation between experiments carried out on different days and with
different inocula. Pools of immune and naive sheep sera remained constant
throughout.
4.3.2. Results
4.3.2.1. Requirement for exogenous complement.
The result of this study established that an exogenous source of complement was not
required. Thus, Group 3 (naive serum), produced significantly higher (p<0.01)
concentrations of chlamydial LPS in liver samples, compared to either Group 1 or 2
(Table 4.3.). No significant difference (p>0.05) was apparent between Group 1
recipients of immune serum/ C. psittacil complement and Group 2 mice given
immune serum/ C. psittacil H.I. complement. This did not, however, rule out an
involvement of complement in vivo. Three mice out of 8 in Group 3 had no
detectable chlamydial LPS in either liver or spleen samples. This accounted in part
for the high variation seen in Group 3. No LPS was detected in splenic tissue of any
of the mice. However analysis of this model in Chapter 3, showed that LPS levels
were more reliably detected in the liver on day 6 after infection rather than the spleen
and thus the results from the liver were considered sufficient to assess protection in
the current experiment.
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Table 4.3. Requirement ofModel 2 for exogenous source ofcomplement.
Chlamydial LPS in liver
Group n inoculation mixture (ng/g)
mean sem
1 7 'immune serum/ C. psittaci / intact GPS 0 0
2 7 'immune serum/ C. psittaci / H.I. GPS 0 0
3 8 'naive serum/ C. psittaci / H.I. GPS 2961 1055
Refer to legend attached to Table 4.3.
• 'All serum aliquots were heat inactivated at 56°C for 30 min. immediately before use.
Mixtures comprised equal volumes of chlamydial inoculum (2 x 106 ifu/ml, final titre)
and H.I. sheep serum (25% final volume).
• Guinea pig serum was added either intact or heat inactivated at 5% final volume and
mixtures incubated 45 min./37°C.
• Each mouse was injected intraperitoneal^ with 1ml mixture and killed 6 days later.
Infection in the liver was assessed by capture ELISA of LPS.
Statistical analysis (Student's t-test)
• significant difference between Group 3 and either Group 1 or 2 (p<0.01).
• no significant difference between Groups 1 and 2 (p>0.05).
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4.3.2.2. Reduction in splenic and hepatic chlamydial LPS after passive transfer
of immune sheep serum - Model 2.
Immune serum containing a high titre of chlamydia-specific antibodies which were
produced in response to abortion, was tested in mice for its protective capacity by
incubating with an equal volume of chlamydial inoculum prior to injection
intraperitoneally into mice. Table 4.4. indicates the percentage reduction achieved in
chlamydial LPS levels in each of 9 experiments. Standard immune sheep serum
caused a 81-100% reduction of LPS in the liver, with a consistently high degree of
significance over the 9 experiments (p<0.01; 7/9 experiments). In contrast, levels of
reduction ranging from 72-100% were noted in the spleen and 2/8 experiments were
not significant (p>0.05) and only 3/8 reached a highly significant level (p<0.01). The
variation in reduction of LPS was, as described in Chapter 3, reduced by arranging
experiments into blocks according to the inoculum used. With this arrangement, LPS
reduction in the liver ranged from 91-100% incorporating inocula A, C and D and
99-100% where inocula A and D only were considered.
4.3.3. Summary.
In general, the reduction in LPS levels in the liver was statistically more significant
than in the spleen. This reflects the findings of the previous chapter, where LPS
levels in the liver were more consistent between animals of the same group than in
the spleen. In this case, there was no apparent need to mathematically transform the
data in order to reduce the variation between groups. Not only was variation in
general lower in this model than in Model 1, but reduction in LPS levels by immune
serum was sufficient to yield significant protection. It is worth considering, however,
that the purpose of the model was to test potential vaccine antigens which would not
be expected to induce such high seroconversion as was present in serum from sheep
recovering from an acute infection. This being the case, it proved necessary to
employ other statistical applications to data in later chapters, such as Fisher's test or
mathematical transformations, in order to highlight differences between vaccines.
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The above results, however, demonstrated that immune serum taken from sheep 6-8
weeks after aborting, was able to significantly reduce chlamydial LPS levels in
mouse liver and spleen tissue, thus confirming a role for humoral immunity in
protection against C. psittaci infection.
Legend for Table 4.4.
A - 7th passage; B - 8th passage; C - 1 llh passage; D - 8th passage + 10th passage (1:1); F - 7th
passage + 10th passage, (1:1).-, naive serum; +, immune serum; ND, not determined;
NS, not statistically significant (p>0.05).
Live chlamydiae (2x106 ifu/ml, titre at injection) incubated at 37°C/45min. with an equal
volume of H.I. sheep immune (+) or naive (-) serum.
8-14 week old mice inoculated intraperitoneally with 1ml mixture.
mice killed on day 6 p.i.; infection of spleen and liver assayed by capture ELISA of
chlamydial LPS.
• % Protection (% P) = 1 - [ LPS in immune serum group ] x 100
[ LPS in naive serum group ]
• Statistical analysis by Student's t-test (p<).
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Table 4.4. Reduction in splenic and hepatic chlamydial LPS levels after passive







%P P< mean LPS
(ng/g)±sem
% P P<
8/A1- 8 840±152 100 0.01 3259± 1423 99 0.05
+ 8 0±0 33 ± 16
14/Al- *12 ND ND ND 494± 146 100 0.01
+ *12 ND 0±0
16/AJ- *10 76 ±42 100 NS 296± 106 100 0.01
+ *7 0±0 0±0
10/B/- 7 249 ± 79 79 0.05 367 ± 134 81 0.05
+ 9 53 ±9 71 ±21
18/C/- 9 950 ± 52 99 0.01 347 ± 44 100 0.01
+ 9 13 ±4 0±0
20/C/- 10 648 ±128 83 0.01 1264 ± 160 98 0.01
+ 10 109 ±73 26 ±3
22/C/- 4 2244 ± 445 85 0.05 1000 ±241 91 0.01
+ 4 281 ±50 93 ± 8
7/D/- 10 82 ±97 99 NS 378± 134 100 0.01
+ 15 1 ± 1 0±0
19/F/- 5 1703 ±275 72 0.05 2280 ± 497 82 0.01
+ 7 479 ± 244 405 ± 79
• See previous page for legend
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4.4. Discussion.
Two murine models were developed in which chlamydial infection could be
measured as chlamydial LPS content of spleen and liver tissue. In the first model
mice were injected subcutaneously with native antigen prepared as a MOMP-
enriched fraction. CBA/ADRA mice seroconverted strongly to MOMP when
vaccinated with this preparation adjuvanted in Montanide ISA 50 and were
subsequently protected from chlamydial infection. The contributions of cell-
mediated and humoral immune responses to protection were not determined,
however, both systems have been demonstrated to function simultaneously, although
cellular immunity may be the more dominant (Buzoni-Gatel et al., 1992).
In the present study, passive transfer of immune serum resulted in greater protection
against chlamydial infection than did immunisation with a MOMP-enriched vaccine.
It is possible that the high titre of the immune serum was responsible for the observed
effect and that if serum from vaccinated ewes had been used instead, the protective
effect would not have been so absolute. For further experiments, however, it was
useful to include the current immune serum pool as a control to ensure that lack of
protection was not due to a fault in the model.
In addition, it has been shown that both susceptibility of mice to chlamydial infection
(Tuffrey et al, 1992) and production of antibodies (Zhong and Brunham, 1992;
Westbay et al, 1994) are under genetic control. In particular, Buzoni-Gatel et al
(1994) demonstrated that infection ofmouse spleens varied according to both the H-2
locus and the genetic background of each strain. Mice carrying the H-2k locus such
as the CBA strain, were highly susceptible to infection as was the case in the present
study. Furthermore, some strains of mice, differing at the H-2 locus produced
varying antibody responses against chlamydial MOMP (Westbay et al, 1994) and
against the heat shock proteins, hsp60 and hsp 70 (Zhong and Brunham, 1992).
Again the H-2 locus was investigated and antibody responses against chlamydial
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MOMP were shown to be low in mice carrying the H-2k haplotype. Since a good
MOMP-specific antibody response was detected by immunoblotting in the current
work, the haplotype of the mice used here is likely to be different from the parent
strain ofCBA.
Whilst infection levels in control animals were comparable between the models,
Model 2 appeared to result in less variation within a group than Model 1, resulting in
stronger statistical analysis. Variations in infection levels were no higher than other
groups had found. The lower variation obtained between mice in Model 2 could
have been due to the use of pooled sera which would eliminate variation due to
individual sheep responses to vaccination and essentially result in an indication of the
average protective antibody response in sheep. In contrast, Model 1 had at least two
opportunities to show variation between animals a) in immune response to
vaccination and b) in susceptibility to infection. In addition, opsonisation of
chlamydiae with naive sheep serum may have increased the rate of uptake into host
cells via FcyRIII receptors in comparison to chlamydiae which had not been pre-
opsonised (Model 1). This could have resulted in less exposure of chlamydiae to the
immune system, in particular to polymorphonuclear leukocytes which have been
shown to have an important role in the early control of intraperitoneal infection by
chlamydiae (Barteneva et al, 1996). Differences in infection levels may therefore
represent a difference in either neutrophil response or chlamydial internalisation by
macrophages in individual mice.
The protocol used in Model 1 indicated that Montanide ISA 50 was a suitable
adjuvant in which to formulate native chlamydial antigen in order to elicit protection
in mice against chlamydial infection. Seroconversion occurred against the vaccine
antigen (MOMP-enriched preparation), in particular against the MOMP, indicating
that the strain ofmouse used in the present study was able to recognise MOMP in its
native conformation and respond with a strong antibody response. T-cell help has
been documented between MOMP and Omp 2, whereby priming with MOMP results
in an amenestic response towards Omp 2 (Westbay et al., 1994; Allen and Stephens,
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1993). Evidence for the reverse is limited, however, such events could have
important connotations on the effects ofmice to a sub-unit or recombinant vaccine in
which only one of these domains is present.
The following chapter examines the mode of action of protection in vivo by Model 2,
considering the early events occurring in the peritoneal cavity immediately after
injection with inoculation mixture.
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CHAPTER 5
KINETICS OF IN VIVO NEUTRALISATION
114
5.1. Introduction
The previous chapter showed that Model 2, passive immunisation of mice,
represented an efficient model by which serum containing protective antibodies
could be identified. Briefly, immune sheep serum was able to reduce chlamydial
LPS levels in mouse spleen and liver when incubated with an equal volume of
chlamydial inoculum prior to intraperitoneal injection. In this chapter, local
immune responses occurring at the site of injection of the inoculum/serum
mixture were investigated.
The mode of chlamydial neutralisation in vivo remains unresolved. The original
work of Friis (1972) and others (Byrne, 1976; Byrne and Moulder, 1978; Wyrick
and Brownridge, 1978; Brownridge and Wyrick, 1979) demonstrated that
internalisation of chlamydiae was induced by the organism itself and not by the
host cells and that the survival of chlamydiae within host cells occurred by
avoidance of phagolysosomal fusion. Both these events were attributed to
surface components on the elementary body (Levy and Moulder, 1982;
Eissenberg et al., 1983). Uptake of chlamydiae was shown to occur by two
possible mechanisms: by non-clathrin coated pit entry (Kihlstrom and Soderlund,
1983) and alternatively by receptor-mediated endocytosis via clathrin-coated pits
(Hodinka et al., 1988; Reynolds and Pearce, 1990). Both modes of entry,
however, resulted in the same internal destination for ingested particles (Hansen
et al., 1993). Heat-inactivation of chlamydiae, however, was unable to prevent
phagolysosomal fusion (Friis, 1972), and acidification and destruction of
chlamydia-laden vesicles was completed within 30 mins in macrophages
(Eissenberg et al., 1983) and 2h in epithelial cells in vitro (Schramm et al.,
1996). Only heat-inactivated inclusions were shown to be directed to vacuoles
containing lysosomal enzyme (Anderson et al., 1984), further indicating that the
intracellular fate of chlamydiae is controlled by surface-exposed components.
Serum from ewes recovering from an acute chlamydial infection reacted strongly
with MOMP by immunoblotting. Furthermore, opsonisation of chlamydial
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particles with immune sheep serum reduced multiplication of viable chlamydiae
in vivo using the protocol of Model 2 (Chapter 4). However, it was unknown
whether 'neutralisation' of chlamydial infectivity occurred in the peritoneal
cavity i.e. at the site of injection, and which cells in a mixed population were
responsible for the destruction of chlamydiae. Thus, the current chapter sought
to identify the stage at which development of infectious chlamydiae was arrested
and to compare the events leading up to destruction of chlamydiae coated with
immune sheep serum, with destruction of heat-killed chlamydiae and with
survival of chlamydiae opsonised with naive sheep serum.
116
5.2. Materials and Methods.
A serial kill experiment was performed using the protocol for Model 2, in which
sheep serum was used to passively immunise CBA/ADRA mice. Four groups
were included in the experiment as follows:-
Group 1 - C. psittaci + immune sheep serum
Group 2 - C. psittaci + naive sheep serum
Group 3 - heat inactivated C. psittaci + naive sheep serum
Group 4 - L929 cells + naive sheep serum
Group 4 was included as a control to show that the observed responses were due
to C. psittaci and not to the presence of other cells in the original culture.
Additionally, Group 3 represented a control to show that the observed responses
were due to viable C. psittaci and could not be duplicated by dead organisms.
At necropsy, peritoneal lavages were taken as described in Materials and Methods
(Section 2.8.3.). Each sample of peritoneal exudate was divided between 4 different
assays:-
a) total cell count
b) Leishman's differential cell count
c) chlamydia-specific immunoperoxidase staining
d) LPS-ELISA
Liver and spleen samples were also taken for LPS-ELISA analysis.
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5.2.1. Design of experiment
Table 5.1 Experimental Design
Number of mice killed (hours p.i.)
Group 0 3 8 24 48 72 120 144 240
1 4 4 4 4 4 4 4 4
2 4 4 4 4 4 4 4 4
3 4 4 4 4 4 4 4 4
4 4 4 4 4 4
Group 1; C. psittaci and immune sheep serum.
Group 2; C. psittaci and naive sheep serum.
Group 3; Heat inactivated C. psittaci and naive sheep serum.
Group 4; L.929 cells and naive sheep serum.
• 12 week old mice were injected intraperitoneal!}) with lml ofchlamydial inoculum/serum
mixture (Oh).
• Peritoneal lavages were taken from 4 mice per sampling (hours post-infection, p.i.) for
analyses of total cell counts, differential cell counts, immunoperoxidase staining and
chlamydial LPS content.
• Cytospins were stained with Leishman's stain and the number of individual cells in
approximately 10fields ofview (=500 cells) calculated.
• Liver and spleen samples removedfor LPS-EL1SA analysis.
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5.3. Results.
The purpose of this experiment was to investigate the cells involved in host defence
against C. psittaci infection at the site of injection, and to compare the cell
population profiles in the presence of immune and naive sera. Briefly, chlamydial
inoculum pre-incubated with either sheep immune or naive serum was injected
intraperitoneally into groups of mice. Peritoneal lavages were taken over the
following 21 Oh and the total number of cells per ml counted as well as the number of
lymphocytes, neutrophils, monocyte/macrophages and mast cells per ml. Viability of
the inoculum was determined by immunoperoxidase staining of peritoneal cells to
show the development of chlamydial inclusions and by capture ELISA of LPS in the
peritoneal cells, spleen and liver.
5.3.1. Differential response of cells in the peritoneal cavity
Total cell counts were made on a Neubauer counting chamber using trypan blue
exclusion. Cytospins were stained with Leishman's stain and the percentages of each
cell population counted for approximately 500 cells over at least 10 different fields of
view. The two parameters were combined to estimate the number of specific cell
types (cells/ml). Cells were divided into 4 predominant populations in the peritoneal
exudates; polymorphonuclear leukocytes (PMNLs), monocyte/macrophages (MO),
lymphocytes and mast cells. Other cell types which may have been present occurred
so infrequently that total numbers were not recorded.
5.3.1.1. Total cell counts
Mice in all groups had similar numbers of cells in the peritoneal cavity over the first
48h post infection (p.i.) (Fig 5.1); approximately 2.8xl06 cells/ml (sem<5.0xl04
between groups). This was unchanged over the duration of the experiment for
Groups 2, 3 and 4. However, there was a significant increase (p<0.05) in the total
cell population at 72h in group 1 which was more pronounced , increasing by at least




At 3h post-injection (p.i.), an acute inflammatory response was apparent in Groups 1,
2 and 3 with a significant (pcO.OOl) influx of polymorphonuclear leukocytes
(PMNLs) into the peritoneal cavity compared to Group 4 (Fig 5.2). A significant
difference (p<0.05) was also calculated between Groups 1 and 3 at this time, with a
higher number of PMNLs present in Group 3 than 1. The neutrophil response
persisted over the following 24h p.i. with no significant difference between the three
infected groups (p>0.05). Gradually, PMNL counts decreased towards control levels.
Group 2 showed the slowest decline in numbers of PMNLs, with control levels not
being reached until 72 h p.i. compared with 48h p.i. in Groups 1 and 3 (48h; Group 2
significantly higher than Groups 1 and 3,p<0.01). A second influx of neutrophils was
observed at 120h p.i. in Group 1 only (p<0.05). All other groups remained at
baseline levels.
5.3.1.3. Monocytes/Macrophages
Both cell types in this category originate from the same precursor and represent
different stages of cell development and activation. Since it was not possible to make
a definitive distinction between cells at different developmental stages, monocytes
and macrophage cells (MO) were counted together.
Initially, mice in Groups 1-3 had significantly (p<0.05) fewer MO compared to a
control value of approximately 2x106 cells/ml in Group 4 (Fig 5.3.). Over the
following 24h p.i., the number ofMO in each group approached that seen in Group 4
with no significant difference between any of the groups (p>0.05). However, by 48h
p.i., mice in Group 2 again had a significantly (p<0.05) lower number of MO in the
peritoneal cavity than mice in either Group 1 or 4. In contrast, MO numbers at 48h
p.i. were higher in mice in Group 1 than in Group 4 and continued with this trend up
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to 120h p.i. The observed increases were significant (p<0.01) at both 72 and 120h
P-i-
5.3.1.4. Lymphocytes
There were no significant differences between Groups 1-4 over the first 24h p.i.
(p>0.05) with respect to lymphocyte numbers in the peritoneal cavity (Fig 5.4.).
However, at 120h p.i., mice in Group 1 had a large and significant increase (p<0.01)
in lymphocyte numbers compared to other sampling times. In contrast, Group 2 mice
had a significantly (p<0.05) lower number of lymphocytes at these times (48h and
120h p.i.). Clearly, a strong divergence in lymphocyte response between Groups 1
and 2 had developed by day 5 p.i..
5.3.1.5. Mast cells
These cells did not feature significantly in response to inoculation with any of the
reaction mixtures. No group showed any significant difference (p>0.05) from the
control group which itself contained only 1-2% of the total cell number as mast cells
(Fig 5.5.). The only significant (p<0.05) increase in this cell population occurred in
Group 1 at 5d p.i..
5.3.1.6 Summary.
Total cell counts did not differ significantly (p>0.05) between the baseline value
(Group 4) and Groups 1-3, except in Group 1 at 72h and 120h p.i. (p<0.05, p<0.01,
respectively). However, the initial response to injection was a significant increase in
PMNLs (pcO.OOl). In order to maintain a constant total cell count in the peritoneal
cavity, the concentration of other cell populations would be expected to decrease.
This was seen with the population of MO, where levels were significantly (p<0.05)
lower than the control value (Group 4) in all infected groups.
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The significant increase in total number of cells which occurred at 72h and 120h in
Group 1, could be attributed to fluctuations in the numbers of 2 cell populations; at
72h p.i., numbers ofMO significantly increased (p<0.05), followed by an increase in
the number of lymphocytes at 120h p.i. (p<0.01). In contrast, although not large
enough to exert a significant effect on overall cell numbers, Group 2 demonstrated a
significant decrease (p<0.05) in lymphocyte numbers at 120h p.i.. The MO
population was also depressed in Group 2, in this case at 48h p.i. (p<0.05).
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Fig 5.1. Total number of cells per ml in the peritoneal cavities of mice after
intraperitoneal inoculation with Chlamydia psittaci.
Statistical analysis (Student's t-test)
Number of cells in peritoneal lavages differed significantly in the following cases
At 72h p.i. - Group 1 > Groups 2 or 3 (p<0.05).
At 120h p.i. - Group 1 > Groups 2, 3 or 4 (p<0.01).
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Fig 5.2. Mean number of polymorphonuclear leukocytes (PMNLs) per ml in the
peritoneal cavities ofmice after intraperitoneal inoculation with Chlamydia psittaci.
Refer to Table 5.1 for legend
Statistical analysis (Student's t-test)
Number of cells in peritoneal lavages differed significantly in the following cases:-
At3hp.i. - Groups 1, 2 and 3 > control (p<0.001).
Group 3 > Group 1 (p<0.05).
At 48h p.i. - Group 2 > Groups 1 and 3 (p<0.01).
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Fig 5.3. Mean number ofMonocyte/Macrophage cells (MO) per ml in the peritoneal
cavities ofmice after intraperitoneal inoculation with Chlamydia psittaci.
Refer to Table 5.1 for legend
Statistical analysis (Student's t-test)
Number of cells in peritoneal lavages differed significantly in the following cases:
At 3h p.i. - Groups 1, 2 and 3 < control (p<0.05).
At 48h p.i. - Group 2 < Groups 1 and control (p<0.05).
At 120h p.i. - Group 1 > Groups 2, 3 and control (p<0.01)
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Fig 5.4. Mean number ofLymphocytes per ml in the peritoneal cavities ofmice after
intraperitoneal inoculation with Chlamydia psittaci.
Refer to Table 5.1 for legend
Statistical analysis (Student's t-test)
Number of cells in peritoneal lavages differed significantly in the following cases:-
At 48h p.i. - Group 2 < control (p<0.05).
Group 3 < Groups 1, 2 and control (p<0.05)
At 120h p.i. - Group 1 > Groups 2, 3 and control (p<0.01)





















Fig 5.5. Mean number ofMast cells per ml in the peritoneal cavities ofmice after
intraperitoneal inoculation with Chlamydia psittaci.
Refer to Table 5.1 for legend
Statistical analysis (Student's t-test)
Number of cells in peritoneal lavages differed significantly in the following cases:
At 120h p.i. - Group 1 > Groups 2, 3 and control (p<0.05)
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5.3.2. Characterisation of peritoneal cells infected with C. psittaci
5.3.2.1. Materials and Methods.
Chlamydia-specific, immunocytochemical staining was performed on peritoneal cell
cytospins. Primary antibody comprised chlamydia-positive sheep serum, semi-
purified by ammonium sulphate precipitation. Secondary antibody comprised
(donkey) anti-sheep IgG conjugated to horseradish peroxidase (HRP). No staining
was evident with Group 4 which contained sheep serum but no Chlamydia.
Likewise, controls comprising a) no primary antibody b) no secondary antibody
conjugate c) DAB only, were negative, indicating the specificity of the staining
technique for chlamydiae.
5.3.2.2. Results.
Two questions were being asked in this section. Initially, immunoperoxidase
staining was used to identify which cells had ingested chlamydiae after
intraperitoneal injection of mice and secondly, whether chlamydial inclusions were
able to develop in peritoneal cells after pre-incubation with immune serum.
5.3.2.2.1. 3h post infection.
At the first sampling of peritoneal cells post-infection, only cells in Group 3 stained
positively for chlamydial antigen indicating rapid uptake of heat-inactivated
chlamydiae after injection. The main cell population identified as positive was
PMNL, which was the predominant cell type at this time. No positive staining was
evident in cells of either Groups 1 or 2.
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5.3.2.2.2. 8h post infection.
At 8h p.i. there was still no staining visible in any of the cells in Group 2. In
contrast, however, there was now obvious positive staining inside both MO and
PMNLs in Group 1. Again, there appeared to be greater staining of PMNLs than of
MO within the peritoneal cavity in this group. The positive staining in cells of
Group 3 at 3h p.i. had now disappeared and no internal staining of cells was visible
in this group.
5.3.2.2.3. 24h post infection.
As above, no staining was visible in cells of Group 2 and although some staining of
MO was apparent in Group 1, this was less than was seen at 8h p.i.. PMNLs did not
appear to be positive any longer in Group 1. Cells in Group 3 again gave a negative
result.
5.3.2.2.4. 48h post infection.
A sharp contrast was seen between Groups 1 and 2 at 48h p.i.. Small amounts of
positive staining were visible within MO in Group 1, however, much denser,
granular and more frequent staining of MO, was seen in Group 2 similar to the
inclusion bodies seen within infected tissue-culture cells. Some PMNLs also
demonstrated positive staining, although these were not the main cells stained due to
their comparatively low numbers at this time. Cells in Group 3 continued to remain
negative.
5.3.2.2.5. 72h post infection.
By 3 days p.i., large inclusions were visible within MO in Group 2. Dense areas of
staining were apparent within the cytoplasm, thinning out as the cytoplasm passed
over the MO nucleus. No staining occurred in cells of either Groups 1 or 3.
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Fig 5.6. Immunoperoxidase staining of peritoneal cells at 0 hours
(x360 magnification)
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Fig 5.7. Immunoperoxidase staining of infected peritoneal cells at 48 hours post
infection (x360 magnification)




Immunoperoxidase staining enabled progress of the chlamydial inoculum to be
followed after intraperitoneal injection. This highlighted clear differences between
the fate of C. psittaci pre-incubated with either immune or naive sheep sera. In the
first case, chlamydiae incubated with immune serum appeared to be taken up by cells
more slowly than heat-inactivated C. psittaci, which was visible after 3h in
comparison to 8h with the addition of immune serum to the reaction mixture. By 8h
p.i., heat-inactivated C. psittaci had disappeared from peritoneal cells. In contrast,
inoculum containing immune serum was visible up to 48h p.i., albeit in decreasing
amounts. The presence of naive serum in live inoculum however, appeared to delay
the detection of C. psittaci inside cells until the organism had formed large
inclusion bodies, (48h p.i.). This granular staining was also visible at 72h p.i., when
the size of the stained inclusion body appeared greater than at 48h.
5.3.3. Concentrations of chlamydiae in the peritoneal cavity
This analysis was carried out to confirm the results of the immunoperoxidase
staining, by demonstrating that even though chlamydiae would be expected to
disperse from the site of injection, multiplication of remaining organisms could be
detected by increasing amounts of chlamydial LPS in the peritoneal cavity.
"Neutralisation" of chlamydiae at this stage would not result in increased LPS levels.
5.3.3.1. Materials and Methods.
The LPS-ELISA was used to quantify the amount of Chlamydial LPS in the
peritoneal cavity for each mouse. Peritoneal fluid was diluted 1/2 in PBS/tween and
all samples tested in duplicate following the standard procedure.
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5.3.3.2. Results.
An initial peak of chlamydial LPS was detected at 3h p.i. in all mice except those in
Group 4 which did not receive any chlamydiae (data not shown). Subsequent
samplings revealed continuously higher levels of chlamydial LPS in mice in Group 2
than in mice in either of the other infected groups. At 6 days p.i., only samples from
mice in Group 2 had raised chlamydial LPS levels, in parallel with high infection
levels in the liver and spleen (see next section).
5.3.4. Appearance of infection in internal organs
The purpose of this section was to demonstrate that the chlamydial inoculum used
throughout the experiment (not heat inactivated) was viable in the presence of heat
inactivated naive sheep serum and that the lack of apparent infection in the liver or
spleen was due to the presence of sheep immune serum.
5.3.4.1. Materials and Methods.
The LPS-ELISA was used to quantify the amount of Chlamydial LPS in the liver and
spleen for each mouse. Organ samples were treated as described in Chapter 3,
diluted 1/5 in PBS/tween, and tested in duplicate following the standard LPS-ELISA
procedure (section 2.7.4.).
5.3.4.2. Results.
No chlamydial LPS was detected in significant quantities in either the liver or spleen
of mice in any group until day 2 p.i. (data not shown). At this point, a significant
(p<0.001) amount of chlamydial LPS was detected in the spleen of Group 2 mice. A
small increase in chlamydial LPS was also detected in the spleens of Group 1 mice,
however, the levels were not statistically significant (p>0.05). From 48h onwards,
the levels of chlamydial LPS in splenic tissue continued to rise in mice in Group 2.
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At 5 days p.i., the quantities were significantly higher (p<0.001) than in mice in
Group 1.
Infection of the liver showed a similar profile to splenic infection. Establishment of
colonisation, however, appeared to be delayed by approximately 24h compared to the
spleen. Only Group 2 mice had any significant (p<0.001) levels of chlamydial LPS,
which were detectable on day 3 p.i. in the liver and continued to rise over the
following 3 days. On day 6 p.i., liver colonisation by chlamydiae was approximately
half that of the spleen in mice in Group 2.
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5.4. Discussion
The initial response ofmice to peritoneal injection with chlamydiae was a significant
influx of PMNLs into the peritoneal cavity. This did not depend on chlamydiae
being in a viable state, since H.I. inoculum induced an equivalent response to intact
chlamydiae. These results are in agreement with those of Barteneva et al. (1996) and
others (Brunham et al., 1984; Pal et al., 1993) who demonstrated that the
predominant cells recruited to the initial site of infection were PMNLs. It can be
speculated that the mediator of the inflammatory response was the heat-stable LPS
component on the chlamydial surface, since the early samplings (3h) would not have
allowed sufficient time for de novo synthesis of other possible stimulants. Ingalls et
al., (1995) also suggested a major role for LPS in the acute inflammatory reaction
demonstrating the induction of TNF-a in vitro in response to stimulation with
chlamydial LPS. They also showed that chlamydial LPS was approximately 100-fold
less potent than the LPS of either S. minnesota or N. gonorrhoeae and could only be
classed as a weak endotoxin. Thus, whilst PMNLs may help to control an initial
chlamydial infection, other immune responses probably supercede the inflammatory
response.
As the levels of PMNLs decreased with time, it was observed that higher levels
persisted in mice injected with viable chlamydiae in naive sheep serum (Group 2)
compared with immune serum or heat killed chlamydiae. This may represent a
continuing stimulation of the inflammatory response by endotoxin, which implies
that sufficient antigen was available only in Group 2 mice. Campbell et al., (1994)
demonstrated the secretion of LPS by developing chlamydiae on to the host cell
surface and it was perhaps this phenomenon which caused the continuing stimulation
of the PMNL response. When levels of macrophages and lymphocytes in the
peritoneal cavity were analysed, it was discovered that both cell populations were
present in lesser amounts in mice injected with viable chlamydiae in naive serum
compared to mice in other infected groups. A complex sequence of immune
responses is thought to occur against infectious chlamydiae, importantly the secretion
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of IFN-y which is a major cytokine involved in limiting chlamydial replication
(McCafferty et al., 1994). IFN-y has been shown to effectively suppress lymphocyte
proliferation in vitro (Richard et al., 1991) which could explain the apparent
immunosuppression observed in Group 2 mice from 48h onwards. Suppression of
the immune system was also observed by Lammert and Wyrick (1982) in a model of
peritoneal infection of mice with C. psittaci. In contrast to Group 2 mice, mice in
Group 1 responded with significant levels of both macrophages and lymphocytes at
48h, indicating a progressive immune response against chlamydiae, possibly
mediated by activated macrophages. This could also be responsible for the second
influx ofPMNLs observed at 5 days after infection in Group 1.
Interestingly, mast cell numbers only increased significantly in one instance; 5 days
after infection in group 1 mice. Again, the lack of response in Group 2 mice may
have been due to suppression of the immune system. In contrast to earlier
hypotheses, the role of mast cells in clearance of Gram-negative bacteria may be
considerable (Malaviya et al., 1996) and indeed mast cells may modulate neutrophil
influx at sites of infection through secretion of TNF-a. In the present study, mast cell
accumulation was accompanied by a simultaneous increase in PMNL levels, and
although cytokine levels were not determined here, other studies have demonstrated
the secretion of TNF-a in response to chlamydiae (Williams et al., 1989) and anti-
chlamydial effects of TNF-a both in vitro (Shemer-Avni et al., 1988) and in vivo
(Williams et al., 1990) have been observed.
Chlamydial antigen was rapidly detected by immunoperoxidase staining inside
PMNLs at 3h after infection of mice with heat-killed chlamydiae (Group 3). No
other groups were positive this early after inoculation and since staining did not occur
subsequently in Group 3, this pattern of staining could represent ingestion and rapid
degradation of non-viable chlamydiae.
In contrast, chlamydiae opsonised with immune serum were detected from 8h to 72b
inside peritoneal cells. Initially, the main positive cell type was PMNLs however this
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gradually changed to predominantly macrophages as the profile of cells in the
peritoneal cavity altered. The reason for the detection of antigen at different times
with heat-killed chlamydiae and organisms opsonised with immune serum, may be
due to different processing pathways by cells of the immune system. Opsonised
bacteria may invoke internalisation via FcyRIII receptors present on the surfaces of
PMNLs and macrophages. This may result in a different degradation pathway to
chlamydiae internalised by other means such as heat-killed chlamydiae.
Only chlamydiae pre-treated with naive serum were detected in a form which
resembled the inclusions typically visible by Giemsa staining of cell cultures. These
occurred after 48h and were restricted to the macrophage population. Larger areas of
staining appeared with time leading to the conclusion that these did indeed represent
developing chlamydiae.
Thus it would appear that neutralisation occurred in the peritoneal cavity of mice
injected intraperitoneally with chlamydiae pre-opsonised with sheep immune serum
and that organisms were internalised by both PMNLs and macrophages. Whereas
chlamydiae pre-opsonised with naive serum gradually developed large granular
inclusions inside macrophages, those incubated in the presence of immune serum
resulted in progressively smaller foci indicating the non-viability of these organisms.
The possibility that some chlamydiae persisted in a non-detectable form can not be
ignored, however two events would argue against this. Firstly, even at 5 days after
infection significant levels of immune cells were detected in the peritoneal cavity,
indicating considerable stimulation of the immune system. Rasmussen et al., (1996)
recently showed evidence that aberrant or persistent forms of chlamydiae in vitro
were not protected from cytotoxic attack. If this was also the case in vivo, then cells
infected with persistent forms of chlamydiae would probably be killed. In addition,
Beatty et al., (1994) demonstrated immunochemical staining of persistently infected
cells by MOMP-specific monoclonal antibodies, as long as fixative which caused
permeation of the cell membrane was used. In the present study, such a fixative was
employed as demonstrated by the internal staining of developing inclusions. Lack of
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positive antigen detection was therefore probably not due to inability of reagents to
permeate fixed cells, nor to a lack of specific antigen against which primary antibody
solution could react. The most likely explanation for disappearance of visible
chlamydial antigen was that chlamydiae pre-opsonised with immune serum (Group
1) were degraded in PMNLs and macrophages. In addition, only Group 2 mice were
shown to increase chlamydial LPS levels in either the peritoneal cavity, liver or
spleen throughout the experimental period.
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CHAPTER 6
SERUM NEUTRALISATION ASSAYS IN VITRO
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6.1. Introduction
Serum neutralisation assays (SNA) have been notoriously difficult to standardise for
Chlamydia spp. (Byrne et al., 1993), but their potential to identify protective
antibodies, exemplified by other organisms such as influenza virus (Couch and
Kasel, 1983) has maintained an interest in their development. Most chlamydial SNA
are described for C. trachomatis and have been standardised to a high degree of
consistency following an international workshop in 1993 (Byrne et al., 1993). No
such recognised methodology exists however, for C. psittaci. In vitro neutralisation
with certain strains of C. psittaci have been described (Anderson et al., 1988;
Buzoni-Gatel et al., 1990; Ando et al., 1993), but these assays are not ubiquitous.
This chapter describes a series of pilot experiments designed to develop an SNA for
C. psittaci, abortifacient strain S26/3. The data represent preliminary results only
and as such, no definitive conclusions could be drawn. During the development of
the assay, several technical difficulties were encountered which impeded the
development of the assay. The implications of these problems on future
developments for a reliable SNA are discussed.
Neutralisation has been shown to occur in vitro either by interfering with the
attachment phase of chlamydial particles (Ainsworth et al., 1979), or post-attachment
(Caldwell and Perry, 1982; Peeling et al., 1988). Complement may (Howard,1975;
Lucero and Kuo, 1985; Peterson et al., 1988) or may not (Caldwell and Perry, 1982;
Peeling et al., 1988) be required. Furthermore, cells expressing different receptors,
notably Fcylll, may affect the outcome of neutralisation (Su et al., 1991). Some
investigators have described differences in chlamydial binding to host cells by
centrifugation-assisted infection (Ainsworth et al., 1979; Caldwell and Perry, 1982).
In addition, the composition of medium in which the assay is carried out may inhibit
the neutralising action of antibodies (Peterson et al., 1988). Each of these factors
was investigated in this chapter using standard pools of immune and naive sheep
sera. Monoclonal antibodies against C. psittaci, abortifacient strain S26/3, were also
examined by SNA for protective capacity.
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6.2. Materials and Methods.
6.2.1. Cell lines.
A panel of 6 cell types was examined for infectivity by C. psittaci, abortifacient
strain, S26/3 (Table 6.1.). Inclusion bodies were counted on day 3 post-infection
using a light microscope to visualise Giemsa positive cells. Monolayers of cells were
produced on "Tracs" coverslips according to the methodologies detailed in Materials
and Methods, section .
Table 6.1. Cell types examinedfor infectivity with C. psittaci.
6.2.2. Infection of cells.
6.2.2.1. Materials and Methods.
C. psittaci inoculum was titrated in each cell line at 4 ten-fold dilutions (1 in 100 to
1 in 10,000). The cell lines was seeded at 2xl05 cells/ml on a glass coverslip in a
sterile bijou (Trac) and allowed to monolayer overnight. BHK-21 cells were treated
with IDU ( 80 pg/ml) 3 days prior to infection. All other cell types were treated with
1 pg/ml of cycloheximide at the time of infection. The infection procedure for each
cell line comprised the addition of 1ml of inoculum to each Trac, centrifugation at





Syrian hamster kidney cells
bovine embryonic tracheal cells (fibroblastic)
mouse connective tissue (fibroblastic)
sheep trophoblast cells (Morag Livingstone)





with Trac lids loosened. Coverslips were removed from Trac bottles and stained
with Giemsa (5% solution). Dark staining inclusion bodies were counted over the
whole coverslip area. Mean values were obtained from duplicate coverslips.
6.2.2.2. Results
Three cell types (EBTr, L929 and BHK-21) were prone to clumping which made
identification and enumeration of inclusion bodies difficult (Table 6.1.). STC cells
generally contained large inclusions, but the staining intensity of the inclusions was
indistinct. These 4 cell types yielded comparable levels of infection. In contrast,
McCoy cells were more susceptible to infection, with approximately 5-fold higher
infection titres. In addition, although the inclusions were relatively small, they were
easily recognisable and of uniform shape. ST6 cells which only became available
late in the study, were extremely susceptible to infection, with multiple inclusions
frequently present in a single cell. However, the inclusions were diffuse and
identification of individual infected cells was problematic. Thus, McCoy cells were
adopted as the standard cell type for further SNA studies.
6.2.3. Effect of centrifugation on infection.
6.2.3.1. Materials and Methods.
The standard procedure was followed for infecting Tracs, except that after addition of
inoculum to Tracs, halfwere centrifuged at 2000xg for 30 min., and half subjected to
stationary incubation for the same period of time. A second experiment investigated




Centrifugation increased the number of inclusion bodies compared to stationary
incubation (Table 6.3.a.) and this increase was related to the duration of
centrifugation (Table 6.3.b.) (correlation coefficient, 0.78; p>0.05). The plot was
sigmoid, with an initial sharp rate of increase in the number of inculsion bodies up to
30 inin. centrifugation, falling off to a plateau with centrifugation times of 30-120
min.
6.2.4. Effect of adding divalent cations (Mg2+) to infection medium.
6.2.4.1. Materials and Methods.
It has been stated (Peterson et al., 1988) that divalent cations in the infection medium
can have a detrimental effect on neutralisation in vitro and the extent of this effect is
related to the concentration of divalent cations present. Sera which exhibited
neutralising capacity under conditions of low divalent cation concentration, became
non-neutralising as the concentration of these particular components increased. The
effect of divalent cations on infection ofMcCoy cell monolayers was investigated by
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Table 6.3. a) Effect ofcentrifugation on infection ofcells.
Inoculum dilution inclusions per coverslip
centrifuged Stationary
1 x 10-1 > 500 >500
1 x 10 _2 > 500 204
1 x 10 "3 424 26
1 x 10-4 30 2
1 x 10 "5 0 0
b) Effect of increasing centrifugation time on infection.
Inoculum centrifugation time inclusions
(min.) (ifu/ml)
0 16




• Cells seeded at 2x105 cells/ml and allowed to monolayer on glass coverslips.
• Monolayers infected with 1ml of diluted inoculum, a) centrifuged at 2000xg for 30 min. or
left at room temperature for equivalent time, b) centrifuged as stated or incubated
immediately as below.
• After incubation of infected cells for 3d at 37°C/5% C02, cells were stained with 5% Giemsa
solution and inclusion bodies counted over the whole coverslip.
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6.2.4.2. Results.
Table 6.4. shows the effect of adding magnesium sulphate (800pM), on the infectivity of
C. psittaci. This addition increased the infectivity of the chlamydial inoculum. The
mechanism of the increase remained unclear, but since this effect might also potentially
abrogate neutralisation, as with C. trachomatis (Peterson et al., 1993), levels of Mg2+
cations were minimalised in future experiments by using RPMI as diluent for inoculum
mixtures and as culture medium as far as possible.
Table 6.4. Effect ofdivalent cations on infection ofcells.





• Refer to Table 6.3. for legend
• Magnesium sulphate was added at a concentration of 800pM where stated
• Monolayers were centrifuged for 30 min. at 2000xg.
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6.3. Neutralisation of infection.
6.3.1. Materials and Methods.
Immune sera from ewes which had aborted following experimental infection with C.
psittaci and a serum pool from ewes naive to abortifacient C. psittaci were tested at a
concentration of 25% in the infection medium used above. Inoculum mixtures were
prepared by diluting the chlamydial suspension to a working concentration of lxlO3
ifu/ml in RPMI. Heat-inactivated sheep sera were also diluted 1 to 1 in RPMI. Both
constituents were warmed to 37°C before being mixed in a 1:1 ratio which included,
where stated, complement in the form of guinea pig serum (Sigma Ltd) at 5% final
volume. The mixtures were vortexed and incubated at 37°C for 45 min. in a water bath,
with occasional mixing. After 45 min., inoculum mixtures were added in 1ml volumes
to cell monolayers in Tracs in duplicate. The Tracs were centrifuged at 2000xg for 60
min. followed by 2h stationary incubation at 37°C in 5% CO2. Tracs were then rinsed
with 3 changes of pre-warmed PBS (37°C) and 1ml of cell maintenance medium added
to each Trac (2% serum content). The cells were incubated for 3d at 37°C/5% CO2 then
stained with 5% Giemsa solution and inclusion bodies counted under a light microscope
(x200 magnification). The procedure was performed twice with pooled serum samples
(Experiments A and B, Table 6.5) and again using individual sera which had constituted
the pool of immune serum. The result was to generate a range of neutralising capacities
representative of a population of sheep experimentally infected with C. psittaci.
6.3.2. Results.
The mean number of inclusion bodies counted over 5 sample fields of view (x 200
magnification) in duplicate Tracs were calculated. Neutralisation was estimated as the
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percentage reduction in inclusion bodies with test serum samples compared with the
naive serum control
% Neutralisation = 100 - (immune serum/naive serum x 100)
The range of neutralisation in a sample of 8 immune sera are shown in Table 6.6. Two
modes of neutralisation were apparent, one dependent on the presence of intact
complement (GPS) and the other, not. These contributed approximately 15% and 75%
respectively to overall neutralisation (sem 0.7 and 3.3 respectively). The majority of
neutralisation therefore appeared to be due to a complement-independent mechanism in
this particular system.
Further experiments using immune and naive sera gave variable results and in some
cases, no neutralisation was evident with the standard immune serum. Several
experiments resulted in so few inclusion bodies that calculation of neutralisation was
impossible. The reason for these discrepancies was unclear, since all parameters
including inoculum batch were standardised.
One batch of inoculum produced consistently high neutralisation levels (86-100%) with
standard immune serum pool and only fell below this level when serum contents of the
inoculum mixture was reduced to 2.5% or less (Table 6.6). Serum dilutions of 1/2-1/10
(final volume) produced equivalent amounts of neutralisation (p>0.05). In these
conditions, the effect of exogenous complement was minimal, since all assays were
performed in the absence of complement.
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6.4. Neutralisation by Monoclonal antibodies.
6.4.1. Materials and Methods.
A range ofmonoclonal antibodies (MAbs) was assessed by SNA. These included MAb
4/11, a MOMP-specific MAb against variable segment 2 (IgG2b isotype), MAb 4/40
also against MOMP, but not VS2 (IgG2a isotype) and MAbs 13/4 and 13/5, against the
genus-specific LPS epitope of C. psittaci (IgG3 isotype). All MAbs were used as heat
inactivated, unpurified ascitic fluids at 1/100 dilution. Exogenous complement was not
included. Naive sheep serum was again used as the control.
6.4.2. Results.
The results in Table 6.7. show that 70-88% neutralisation was achieved with the genus-
specific MAb 13/4 and 13/5. In contrast MAbs 4/40 and 4/11 induced only 26% and
34% neutralisation, respectively.
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Table 6.6. Neutralisation in vitro by individual serum samples from immune sheep.
Immune Serum
(post-OEA)
Inclusions per 5 Fields of View
(x200 magnification)
% Neutralisation
+ GPS H.I. GPS + GPS H.I. GPS
1 40 86 82 63
2 22 16 90 93
3 36 80 83 66
4 22 50 90 78
5 8 56 96 76
6 22 50 90 78
7 4 48 98 79
8 16 72 93 69
mean±sem - - 90 ±0.7 75 ±3.3
H.I. - Heat inactivated.
Refer to Table 6.4. for legend, except that heat inactivated serum was incorporated at 1/4
final dilution.
• Neutralisation was calculated as 100 - [immune/naive x 100], where naive serum with and
without GPS resulted in 218 and 232 inclusions per 5 fields of view (x200 magnification),
respectively.
151
6.7. Neutralisation in vitro by monoclonal antibodies.
Antibody specificity isotype '% neutralisation
MAb 4/11 MOMP (VS2) IgG2b 34 ± 7.5
MAb 4/40 MOMP IgG2a 26 ± -
MAb 13/4 LPS - 70 ±3.5
MAb 13/5 LPS IgG3 88 ±0.5
2immune sera polyclonal IgGl/2 100 ± 0
1
mean of duplicate infected Tracs ± sem.
2 standard pool of sheep immune sera.




Initially it proved exceedingly difficult to demonstrate consistent in vitro neutralisation
of chlamydial infectivity. Infection was standardised by using confluent monolayers of
McCoy cells on 16mm diameter coverslips and infecting with lxl03 ifu of C. psittaci,
strain S26/3. Infection was assisted by centrifugation, otherwise an insufficient number
of inclusions were formed. This was possibly a reflection of the predilection of the
ovine C. psittaci for macrophages and trophoblast cells. Indeed, although the titre was
no higher in trophoblasts than in McCoy cells, inclusion bodies were considerably larger
in the former cell type. Caldwell and Perry (1982) observed that centrifugation may
result in an alternative mechanism of internalisation to stationary incubation, although it
is unknown which mode of uptake more commonly occurs in natural infections. Several
other groups have also postulated various mechanisms for chlamydial uptake including
pinocytosis (Reynolds and Pearce, 1991) and phagocytosis (Prain and Pearce, 1989),
each mode dependent on either static or centrifugal conditions respectively, at the time
of infection. Although chlamydial entry into host cells appears deeply complex, it is not,
as Reynolds and Pearce (1991) point out, an isolated occurrence. Other cases in which
multiple endocytic pathways are utilised have been documented for intracellular bacteria
such as Salmonella spp. (Elsinghorst et al., 1990; Finlay and Falkow, 1989) and for
Yersinia spp. (Isberg, 1989).
Interestingly, Prain and Pearce (1989) highlighted a difference in productive infection
between centrifuged and stationary infected cells, which appeared to result from post-
entry events associated with selection of the surrounding vacuole membrane such that
centrifuged chlamydiae utilised a phagocytic mechanism during internalisation,
subsequently adopting an alternative vacuole membrane to that with pinocytic entry and
consequently avoiding phagolysosomal-fusion. McClarty (1994) also alluded to a similar
occurrence, suggesting that chlamydiae may utilise a mechanism of internalisation
normally associated with uptake of nutrients into host cells whereupon not all ingested
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vacuoles are ultimately destined for degradation and may consequently avoid fusion with
lysosomal compartments. Again the question arises as to whether establishment of
chlamydial infection under manipulated conditions in vitro allows accurate assessment
of methods for preventing infection occurring.
In one instance, an elevated concentration of divalent cations in the infection medium
combined with centrifugation, resulted in increased levels of infection. The reason for
this is unclear, however it may simply have been a reflection of optimising magnesium
ion levels in the infection medium with regards their necessity for chlamydial ATPase
activity (Peeling et al., 1989). In addition, magnesium ions appear to cross-link the LPS
moiety of the outer membrane of chlamydiae (Vretou et al., 1992) and probably affect
exposure of epitopes situated on the MOMP. This may be beneficial to chlamydiae
under physiological conditions by hindering access of antibodies to neutralising epitopes.
Peterson et al. (1988) found this to be the case in vitro when neutralisation by
monoclonal antibodies was abrogated by high levels ofmagnesium ions.
In the series of experiments reported here, individual sera from immune sheep reduced
infection of McCoy cells with chlamydiae by between 82-98% when an exogenous
source of complement was added. If complement was omitted, neutralisation fell to
between 63-93%. Thus, although complement enhanced neutralisation of infection
under these conditions, the majority of infectious particles appeared to be neutralised by
a complement-independent mechanism. Since internalisation of chlamydiae is thought
to be directed by the bacterium rather than through activity of the host cell (Byrne and
Moulder, 1978), these results suggest that complement may enhance the association
between chlamydial and host cell membranes thereby aiding internalisation.
Furthermore, it has been shown (Hall et al., 1993) that MOMP was the primary binding
site for activated complement, and although activation was most effective by the
antibody-independent alternative pathway, this further implicates MOMP as an
important structure in the uptake of chlamydiae. Previous data (Eissenberg et al., 1983)
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had highlighted the absolute requirement of elementary body envelopes in ingestion of
chlamydiae.
The findings with monoclonal antibodies in the SNA were anomalous. The monoclonal
antibodies specific for MOMP (4/11 and 4/40), including one specific for VS2 (4/11),
yielded only low (34%) levels of neutralisation. This is in contrast to the in vivo findings
reported in subsequent chapters and documented for C. trachomatis. In contrast, anti-
LPS antibodies are generally considered not to be neutralising (Salinas et al., 1994).
However, the two anti-LPS MAbs evaluated (13/4 and 13/5) induced 70-80%
neutralisation in the present study. The lack of complement in the inoculation mixtures
may have caused the low neutralisation results found with MAbs 4/11 and 4/40,
although the immune sheep serum used induced 100% neutralisation. Furthermore, VS2
is thought to contain at least one protective B-cell epitope (Batteiger, 1996) and would
have been expected to have caused neutralisation in the present study. Therefore, it is
conceivable that conditions under which neutralisation assays were performed were not
favourable and possibly encouraged interaction of magnesium ions with chlamydial LPS
thereby abolishing neutralisation by monoclonal antibodies specific to MOMP.
Conversely, the presence of high levels of anti-LPS antibodies either in the form of
monoclonals or in immune sheep sera may have obstructed binding of magnesium ions
to chlamydiae by binding themselves to LPS epitopes. Overall, these results suggest
that the modes of neutralisation in vivo and in vitro are not entirely comparable at
present and can be significantly affected by modification of the infection process in vitro.
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CHAPTER 7




Immunisation of sheep with tissue-grown, inactivated chlamydial antigen
successfully protected sheep against chlamydial abortion (Jones et al., 1994).
However, the method of production was highly demanding technically and a more
commercially viable vaccine was sought. Previously, it had been possible to
demonstrate high levels of protection in sheep using a semi-purified chlamydial outer
membrane complex (COMC) preparation (Tan et al., 1990). It was therefore
envisaged that if the MOMP molecule was reproduced on a large scale by
recombinant protein technology, similar protection could be expected.
Neutralising antibodies against Chlamydia have been identified and shown to
correspond to epitopes in VS1, 2 and 4, ofMOMP. In particular, VS1 appears to be
highly immunogenic and with its charge and surface exposure, may induce a
protective response. Work by Villeneuve et al., (1994) indicated that
immunogenicity of MOMP may be determined by the surface availabilities of
MOMP VSs and not their primary sequences. Taking this into account, it was
important to generate recombinant MOMP molecules which more importantly than
having identical amino acid sequences to native MOMP, actually folded into a three-
dimensional structure which exposed the same antigenic regions as the original.
Experiments designed to elucidate the protective immune response against C.
psittaci, showed that both CMI and humoral immunity played a role in protection.
Transfer of primed T-cells and of immune sera in mice conferred resistance to
infection (Buzoni-Gatel, Rodolakis and Plommet, 1987). Likewise, immunity to
reinfection of guinea pigs with C. psittaci (GPIC) appeared to be dependent on an
intact humoral immune response (Rank and Barron, 1983). The immunogenicity
efficacies of recombinant antigens were examined in mice and compared to the
results in sheep.
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7.2. Design of MOMP Constructs
Recombinant MOMP constructs were kindly gifted by Dr Alan Herring (Department
of Biochemistry, Moredun Research Institute). A summary of the expression of
recombinant constructs ofMOMP in standard E. coli systems is given in Chapter 2.
The table below summarises the MOMP constructs included in the present study.
Acronym Name Site
fMOMP-pD fusion MOMP insoluble inclusions in cytoplasmic space
mMOMP membrane MOMP detergent extraction in outer membrane
mMOMP19 membrane MOMP probably in periplasmic space
tMOMP truncated MOMP insoluble inclusions in cytoplasmic space
7.3. Materials and Methods.
Recombinant antigens described above were analyzed for immunogenicity and
efficacy using the following techniques:-
a) immunoblotting and indirect ELISA
b) stimulation of peripheral blood leukocytes in vitro
c) in vitro serum neutralisation
d) protection in mice (i) active immunisation - Model 1, (ii) passive immunisation -
Model 2.
The results were compared to the performances of the recombinant antigens in
challenge experiments involving pregnant ewes, which were carried out by the
Department of Chlamydiology and involving myself as part of a larger team.
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7.3.1. Protective efficacies in pregnant sheep: The protective efficacies of
recombinant vaccines against C. psittaci were examined in pregnant sheep. No
universally accepted method of categorising sheep as protected or otherwise has been
agreed and so several criteria were assessed by Dr. G. E. Jones with respect to the
ewe and to pregnancy. These were:- a) number of dead lambs/abortions, b) mean
gestation period, c) % placental lesions, d) proportion of placental area grossly
affected and e) % of placentas positive for C. psittaci by modified Ziehl-Neelson
staining/culture/LPS-ELISA. A final combined score incorporating each of these
parameters was calculated for each group and expressed as a protective index (PI%)
(Table 7) (Jones et al., 1993).
7.3.2. Immunoblotting and indirect ELISA of sera: Sera from sheep vaccinated
with recombinant antigens were pooled from groups of between 3-4 animals and
tested by indirect ELISA (I. E. Anderson) and immunoblotting against native
chlamydial antigen. Pools of sera were used rather than individual samples, since it
would be impossible to test every sample in mice with sufficient group sizes to be
statistically significant. Therefore, it was deemed reasonable to assess ovine immune
responses to vaccination on a group basis for each assay performed.
Briefly, the indirect ELISA was performed by coating ELISA plates with soluble
chlamydial antigen overnight at 4°C (Anderson et al., 1994). The coating antigen
was prepared by I. E. Anderson by sarkosyl extraction from whole chlamydial
elementary bodies. Plates were treated with periodate, blocked with 10% horse serum
and fixed with glutaraldehyde solution. Sera were tested at 1/800 dilution and
chlamydia-specific antibodies detected using donkey anti-sheep IgG specific antibody
conjugated to HRP. The substrate used was OPD, stopped at an appropriate time
with 0.2M sulphuric acid. Immunoblots were also performed using heat-treated,
SDS-solubilised chlamydial antigen.
7.3.3. Stimulation of IFN-y in vitro: Two recombinant forms of MOMP available
at the start of the project (fMOMP and mMOMP) were used to vaccinate groups of 7
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sheep on 2 occasions, 3 weeks apart. Each vaccination contained approximately
50pg/ml protein and volumes of 1ml were administered subcutaneously on each
occasion. Venous blood was taken from each animal approximately 21 days after
second vaccination and collected into evacuated tubes containing lithium heparin (no
preservative) at a final concentration of 15 units/ml. Aliquots of 1.5ml blood were
mixed with 100 pi of appropriate antigen and the mixtures incubated overnight at
37°C.
The following day, mixtures were centrifuged and the upper layer comprising PBLs
collected. Reactivity of PBLs was tested in vitro using interferon-gamma (IFN-
y) production as a measure of the reactivity index of PBLs (Central Science
Laboratories, Bovine y- interferon kit). Two forms of native chlamydial antigen were
used to detect PBL sensitisation in vitro; semi-purified chlamydial elementary bodies
and a solubilised, purified MOMP preparation. Non-specific reactivity of PBLs was
measured by inclusion of an LPS control in the form of a B-cell mitogen (,Salmonella
minnesota Re mutant; Sigma Ltd) and a T-cell mitogen (concanavalin A).
7.3.4. Serum neutralisation assays: The serum neutralisation assay (SNA)
(Chapter 6) was applied to sera from sheep vaccinated with fMOMP and tMOMP.
Immune and naive controls were formed by the serum pools described previously
(Chapter 6) diluted 1/2, 1/4, 1/10, 1/20, 1/40 and 1/80. Test serum samples were also
diluted over this range.
7.3.5. Active immunisation-Model 1: The recombinant proteins were examined for
protective capacity using the model of active immunisation in mice (Chapter 4). In
the first experiment, mMOMP and tMOMP were tested and in the second
experiment, mMOMP 19 and tMOMP. Briefly, mice were immunised
subcutaneously with 5pg antigen on 2 occasions, 3 weeks apart. Three weeks after
the second vaccination, mice were challenged intraperitoneally with lxl06 ifu and
killed 6 days later. Liver and spleen tissues were analysed indirectly for chlamydial
infection using a sandwich ELISA to detect LPS.
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7.3.6. Passive immunisation - Model 2: Two phases were necessary to complete
passive immunisation in mice. Initially, sheep were immunised using the test
vaccines, followed by a second phase in which sera from the vaccinated sheep were
incubated with live chlamydiae and injected into mice.
Phase 1; Vaccination of lambs with recombinant proteins: Groups (n=7) of 6
month old lambs were immunised subcutaneously with 50pg of recombinant protein
per animal on 2 occasions, 3 weeks apart and blood samples taken 3 weeks after the
second vaccination (day 42). The recombinant MOMP forms used were mMOMP
and tMOMP, prepared as both soluble and insoluble forms. Pools were constituted
for each group using an equal volume of serum from each group member. MOMP-
specific antibody levels were quantified for individual animals using the indirect
ELISA described previously (section 7.3.2.).
Phase 2; Injection of mice: Equal volumes of pooled serum (25% final volume)
and chlamydial inoculum (l-2xl06 ifu/ml, final titre) were combined to form
inoculation mixtures. After incubation at 37°C for 45 mins, 1ml of mixture was
injected intraperitoneal^ into each mouse and the mice killed 6 days later. Liver and
spleen tissue were analysed for chlamydial infection by LPS ELISA.
7.4 Results.
7.4.1 Protective efficacies in pregnant sheep
Data in this section were collected by myself and members of the Chlamydiology
section over a 4 year period, in collaboration with Hoechst Animal Health Ltd. These
results are presented in order to determine any correlations between the in vitro
techniques and mouse models applied, compared with the efficacies observed with
the recombinant MOMP vaccines in their natural host and disease, namely pregnant
ewes and OEA.
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Table 7.1. Design ofexperiment 1: Assessment ofprotective efficacies ofrecombinant
proteins of C. psittaci MOMP.
Group n vaccine/serum source
1 10 mMOMP; lambs
2 10 soluble mMOMP; lambs
3 10 tMOMP; lambs
4 10 soluble tMOMP; lambs
5 10 native chlamydial antigen; lambs
6 20 immune serum; convalescent ewes
7 10 naive serum; adult ewes
7.4.1.1 Immunoblotting and indirect ELISA analysis of sheep sera: Pools of sera
from sheep vaccinated with recombinant antigens gave strong positive responses by
both indirect ELISA and immunoblotting in all cases (Table 7.3., Fig. 7.1.,
respectively).
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Legend for Table 7.2. Protection in pregnant ewes against challenge with C.
psittaci.
• ewes vaccinated with 2x50pg of recombinant antigen, followed by s.c. challenge
at 70-73 days gestation with 5x105 ifu C. psittaci (S26/3 + S95/3)
• abortion defined as premature delivery of dead lambs or of lambs dying within
48h due to no discernible cause other than chlamydial infection; mean number of
dead lambs and length of gestation calculated per group; placental material
analysed for chlamydial infection by culture/modified Ziehl-Neelson
staining/ELISA detection of LPS
• Combined protection score calculated from individual parameters:- Sum of [dead
lamb ratio x 0.5] + [% ewes aborting x 0.3] + [% ewes +ve for C. psittaci x 0.2]
PJ % = 100 x r1- [ Test value - Negative control value ]_ 7
L [Positive control value - Negative control value J J
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21 dpv 42 dpv
1 fMOMP 1, M/A 1.387 1.628
2 fMOMP 1, B/W 0.762 0.808
3 fMOMP 2, M/A 1.488 1.667
4 soluble mMOMP, M/A 0.936 1.379
5 EBs, M/A 1.708 1.790
6 EBs, B/W 0.587 1.114
7 purified native MOMP, M/A 1.620 1.812
8 placebo, M/A 0.301 0.344
9 placebo, B/W 0.273 0.296
Key: M/A, Marcol/Arlacel A + Alhydrogel; BAV, Beringwerke W19
• Groups of sheep (n=7) were vaccinated on 2 occasions, 3 weeks apart with
adjuvanted recombinant protein. A total antigen payload of lOOpg was injected
into each animal.
• Blood samples taken on days 21 and 42 post-primary vaccination were assayed for
antibodies in an indirect ELISA using soluble chlamydial antigen.
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Keyi 1, fMOMP 1, M/A
2, fMOMP 1, B/W
3, fMOMP 2, M/A
4, soluble mMOMP, M/A
5, EBs, M/A
6, EBs, B/W
7, purified native MOMP, M/A
8, placebo, M/A
9, placebo, B/W
10, +ve control (convalescent ewes)
11, -ve control (naive lambs).









vaccinated with recombinant antigens.
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7.4.1.2 Reactivation of PBLs in vitro: No significant production (p>0.05) of IFN-y
was observed when PBLs from placebo vaccinated sheep were incubated with C.
psittaci, strain S26/3 (Fig 7.2.). In contrast, incubation of PBLs from sheep
vaccinated with native chlamydial antigen resulted in significant release of IFN-
y(p<0.01), indicating recognition of chlamydial epitopes by sensitised PBLs.
Similarly, PBLs from ewes which had aborted due to C. psittaci, induced significant
production of IFN-y (p<0.05) on incubation with native chlamydial antigen. The
differences in IFN-y levels produced by antigen concentrations ranging between
5pg/ml-40pg/ml were not significant (p>0.05), therefore further assays using
recombinant antigen vaccines were only tested with 5pg/ml of chlamydial antigen in
vitro.
Results using PBLs from sheep vaccinated with recombinant antigens (Table 7.4a)
indicated that both forms of fMOMP were sufficiently similar to the native form of
MOMP in chlamydial EBs to stimulate significant IFN-y production in vitro
(p<0.05). The same was true with solubilised, purified native MOMP (p<0.01)
(Table 7.4b). In contrast, PBLs from sheep vaccinated with soluble mMOMP were
unable to produce significant levels of IFN-y (p>0.05), unless the antigen used in
vitro was solubilised, purified native MOMP (p<0.01).
Legendfor Fig 7.2 Stimulation ofPBLs in vitro.
• Lambs were vaccinated with 2x50pg ofantigen or placebo (n=7).
• Unclotted blood samples were collected in heparin tubes and buffy coats removed for
analysis.
• Samples were incubated with intact chlamydial elementary bodies and production of
interferon-gamma measured by ELISA. Increases in IFN-y levels were indicative of
recognition of the stimulatory antigen by PBLs.
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Antigen concentration (ug/ml)
—X—Placebo —O—Aborting Ewes —A—Native Cp.
Fig 7.2. Reactivation ofPBLs in vitro; IFN-y production by PBLs from placebo
vaccinated sheep when incubated in vitro with whole C. psittaci EBs.
Production ofIFN-ywas significantly different when antigen was present, compared to no
antigen using PBLsfrom sheep vaccinated with native C. psittaci (p<0.05) orfrom aborted
ewes (p<0.01).
Refer to section. 7.4.1.2 for legend.
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Tables 7.4. Reactivation ofPBLs in vitro.
a) IFN-y production by PBLs from sheep vaccinated with recombinant antigens when
incubated in vitro with whole C. psittaci EBs.
IFN-y release (OD450)
vaccine n mean sem
fMOMP 1 7 0.449* 0.15
fMOMP 2 7 0.439* 0.19
soluble mMOMP 7 0.515 0.27
whole EBs 7 0.893** 0.28
purified native MOMP 7 1.560** 0.17
placebo 4 0.070 0.04
b) IFN-y production by PBLs from sheep vaccinated with recombinant vaccines when
incubated in vitro with solubilised, purified MOMP.
IFN-y release (OD450)
vaccine n mean sem
fMOMP 1 7 1.056** 0.22
soluble mMOMP 7 1.214** 0.45
purified native MOMP 7 2.334** 0.34
placebo 4 0.046 0.03
Key: Significantly higher than placebo; * p<0.05, **p<0.01 (Student's t-test).
Refer to Fig 7.2 for legend, except that results in Table 7.4b represent samples
incubated with solubilised, purifiedMOMP.
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7.4.1.3 Serum neutralisation assays (SNA): In Chapter 6, validation of the SNA
was problematic, however considering these difficulties the following preliminary
results were obtained using sera from sheep vaccinated with recombinant antigens.
Immune serum resulted in a large reduction in the number of inclusion bodies (>
85%) compared with naive serum, indicating that substantial neutralisation of
chlamydial infection was occurring with this assay. Neutralisation by immune sheep
sera diluted to 1/2 and 1/40 was considerable, although because only duplicates were
used, no statistical significance could be attributed to the result. At the highest
dilution (1/40), approximately 89% neutralisation was obtained, with levels
decreasing only when immune sera was diluted beyond 1/80. A similar trend was
seen with sera from sheep vaccinated with tMOMP. Sera where divided into two
groups depending on antibody titre. As a result, the pool of low titre sera produced
considerably less neutralisation than the high titre pool at dilutions of 1/2 and 1/20.
The neutralising capacities of the two serum pools were indistinguishable at all other
dilutions. In contrast, sera from sheep vaccinated with fMOMP2 produced
considerably lower neutralisation than the immune serum at dilutions of 1/2 to 1/20.
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Table 7.5. In vitro neutralisation by recombinant antigens.
% neutralisation (duplicates, A/B)
serum fMOMP tMOMP tMOMP immune serum
dilution (low titre) (high titre)
A B A B A B A B
1/2 61 53 87 82 93 95 86 91
1/4 54 64 88 89 94 91 92 89
1/10 76 58 92 86 95 85 95 88
1/20 81 68 89 85 93 90 91 90
1/40 83 77 86 84 90 71 87 85
1/80 76 56 80 41 80 59 76 50
• sheep vaccinated with 2x50jug doses ofrecombinant antigen,
• serum samples pooled for each group and mixed with an equal volume of
chlamydial inoculum (1x103 ifu/ml): The SNA was performed as described in
Table 6.4.
• Duplicate "Tracs" were countedfor each dilution (A and B)
• % neutralisation =100- ( inclusion bodies with test sample xlOO)
(inclusion bodies with naive serum)
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7.4.2. Protective efficacies in mice.
7.4.2.1. Active immunisation - Model 1: Groups of 4 week old mice were
vaccinated subcutaneously with 0.1ml of recombinant or native chlamydial antigen
adjuvanted in Montanide ISA 50 with Alhydrogel. Recombinant antigens mMOMP,
tMOMP and mMOMP 19 were included in the vaccines at a concentration of 100
pg/ml, 100 pg/ml and 17 pg/ml, respectively. The vaccine prepared from VS1 and
VS3 contained a final protein concentration of 32 pg/ml, made up of equal
concentrations of each peptide. Native chlamydial vaccine comprised approximately
100 pgMOMP/ml (500 pg/ml of total chlamydial protein), whilst the placebo vaccine
contained PBS in place of the antigen portion. Booster vaccinations were
administered 3 weeks after the initial injection and mice were challenged with lxl06
ifu, C. psittaci, strain S26/3, 3 weeks later.
Only low levels of chlamydial LPS were detected in either the liver or spleen of the
infected control mice 6 days after challenge, at necropsy. The high variation in
values for this group made statistical analysis by the Student's t-test inappropriate
and therefore individual values were considered as either positive or negative and
analysed by Fisher's Exact test. The negative cut-off value used was mean value of
negative control group + 3SD. The proportion of positive mice in each group was
recorded. Of the infected control mice immunised with placebo vaccine, 90% were
positive for C. psittaci infection in the spleen. In comparison, only 30% of mice
infected after vaccination with native chlamydial EBs were positive on day 6 after
challenge.
In the groups vaccinated with tMOMP (either insoluble or solubilised), 50% and 67%
respectively were positive in the spleen. Both vaccines therefore appeared to
considerably reduce chlamydial LPS levels in the spleen. In contrast, 100% of mice
vaccinated with solubilised mMOMP and 89% vaccinated with the insoluble form
were positive for chlamydial LPS in the spleen. Likewise, 90% of mice vaccinated
with a combination of VS1 and VS3 were positive for splenic chlamydial LPS. No
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protection was therefore evident with the mMOMP construct or the VS1/VS3
combination in this model.
In a second experiment (Table 7.6b.) which used a more virulent inoculum batch,
higher levels of splenic infection were observed in control mice. The range of values
within this group was small and therefore analysis of data by the Student's t-test was
appropriate. Using this test, mice in Group 1 (vaccinated with mMOMP 19) and in
Groups 2 and 3 (vaccinated with insoluble and soluble forms of tMOMP,
respectively) had significantly less splenic chlamydial LPS on day 6 after infection
compared with the control mice of Group 4.
Legend for Table 7.6. Active immunisation ofmice with recombinant antigens -
Model 1.
EB - chlamydial elementary body
VS - variable segment, produced as recombinant antigen expressed by E. coli
• Groups of n mice injected subcutaneously antigen in adjuvant (Montanide ISA 50 +
Alhydrogel).
• Mice were challenged with lxl 06 ifu C. psittaci, 3 wcc/cs after second vaccination and
killed on day 6p.i.; spleens and livers assayedfor chlamydial infection by capture ELISA
ofLPS.
• % +ve ; percent ofmice greater than negative controls, (mean of Group 7 + 3
SD).
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7.4.2.2. Passive Immunisation - Model 2: Tables 7.7a and 7.7b show results of 2
experiments in which antibodies from sheep vaccinated with recombinant forms of
MOMP were used to treat chlamydial inoculum prior to intraperitoneal injection into
mice. Although immune serum reduced chlamydial LPS in mouse spleens
significantly (p<0.01), compared with control mice, serum from mice vaccinated
with placebo was also able to significantly reduce hepatic LPS levels (p<0.01). The
reason for this anomaly was unknown, however results which otherwise would have
been significant were considered with some caution. Nevertheless, reduced levels of
LPS were found in livers from sheep vaccinated with both forms of tMOMP, native
EBs and soluble mMOMP. In contrast, vaccination of sheep with the insoluble form
ofmMOMP resulted in similar LPS levels in mouse livers as negative control mice.
In the second experiment, serum from sheep vaccinated with placebo was not
protective and LPS levels were comparable to those in negative control mice. Pre-
treatment of inoculum with immune sheep serum resulted in lower levels of LPS in
both the liver and spleen ofmice, although the results were not significant. Likewise,
sera from sheep vaccinated with either tMOMP (insoluble or soluble) or to a lesser
extent mMOMP 19, resulted in reduced levels of LPS.
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Table 7.7. Passive immunisation ofmice - Model 2.




mean sem rank mean sem rank
1 tMOMP 420 115 2 196 44 4
2 soluble tMOMP 117 35 5 168 74 5
3 mMOMP 19 323 90 3 262 68 3
4 placebo 1120 566 1 473 187 1
5 immune serum 79 14 6 108 31 6
6 naive serum 290 118 4 429 201 2
refer to Table 7.7a. for legend. N.B. inoculum titre at injection was only lxlO6 ifu/ml.
No significant differences were apparent between the standard naive serum control
(Group 6) and any of the other groups including the immune serum control (p>0.05).
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7.5 Discussion
In this chapter, experiments demonstrated that sub-cutaneous immunisation of naive
sheep with chlamydial antigen presented as native or as recombinant MOMP
antigens, induced strong antibody responses. Western blot analysis of sera from
sheep immunised with native chlamydial antigen indicated that MOMP was
immunodominant compared to other chlamydial proteins. However, whereas
immunisation with all three recombinant constructs (fMOMP, mMOMP and
tMOMP) induced good seroconversion against MOMP, only tMOMP conferred
protection against OEA in pregnant sheep. Clearly, detection of seroconversion post-
vaccination was unable to distinguish protective from non-protective constructs. Only
some epitopes of the whole MOMP molecule therefore appear to be involved in
protection. Similarly, C. trachomatis infections in humans can induce
seroconversion without conferring protection. In fact, some of these antibody
responses are detrimental to the host, in particular those occurring against the heat
shock proteins, hsp 60 and hsp 70 (Watkins et al. , 1986; Taylor et al., 1990;
Brunham et al., 1992).
Considering each arm of the immune system separately, T-cell involvement in
protection was assessed using plasma from immunised animals. When PBLs were
stimulated in vitro with native chlamydial EBs, those which had originated from
convalescent ewes, or ewes immunised with either purified or MOMP-enriched
vaccines were able to produce IFN-y. This strongly indicated priming of T-cell
epitopes in vivo by various forms ofMOMP which could subsequently be recognised
in vitro by MOMP in its native configuration. Stimulation of PBLs also occurred,
although to a lesser extent, when the immunising antigen comprised fMOMP or
mMOMP (soluble), again indicating recognition of T-cell epitopes common to both
these recombinant constructs and chlamydial EBs. The IFN-y response was more
vigorous after substituting the native antigen (whole EBs) for a solubilised, purified
form of MOMP. This preparation had been shown to protect sheep against C.
psittaci infection (Tan et al., 1990) and was therefore considered to be an
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appropriate form against which to compare recombinant MOMP constructs. The
greater production of IFN-y in response to purified MOMP as opposed to whole EBs
may simply reflect a higher MOMP concentration in the purified preparation. IFN-
y production by PBLs from sheep vaccinated with recombinant MOMPs implies that
these antigens share common T-cell epitopes with purified, native MOMP.
However, IFN-y was released by ovine PBLs in vitro irrespective of whether the
immunising antigen protected sheep against OEA. Therefore, it was necessary to use
a more discerning assay to select protective recombinant antigens than in vitro
stimulation of T-cells.
Some correlation between protection against C. psittaci infection in vivo and in vitro
was evident using the SNA. The results were viewed with caution however, and the
unreliable nature of the in vitro assay taken into account. Chlamydial infection of
McCoy cells appeared to be reduced by over 80% in the SNA using sera from sheep
vaccinated with tMOMP. A similar degree of neutralisation occurred using sera
from convalescent, post-abortion sheep. In contrast, although some neutralisation
was evident with sera from fMOMP-vaccinated sheep, the effect was much less. A
vaccine preparation of fMOMP failed to protect sheep against experimental OEA.
Taken together, these results suggest that although overall seroconversion did not
represent vaccine efficacy, the SNA may be capable of differentiating between sera
which contain neutralising antibodies and sera which do not.
Due to the difficulties encountered with the SNA throughout vaccine efficacy trials,
it became apparent that mouse models would be the major tool by which to screen
recombinant MOMP constructs. Earlier work had demonstrated that CBA/ADRA
mice were receptive to vaccination with chlamydial EBs and strong MOMP-specific
antibody responses had been detected (G. E. Jones, personal communication). In
contrast, the current study found only limited antibody response after vaccination of
mice with recombinant proteins. An attempt during the current study to produce
hyperimmune serum against tMOMP (personal observation) required 3 vaccinations
to elicit a detectable antibody response in ADRA/CBA mice. Thus, there appeared to
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be a major difference between sheep and CBA/ADRA mice in ability to respond
immunologically to epitopes on the recombinant proteins. Interestingly, this did not
appear to be a total inability of the mice to produce MOMP-specific antibodies, since
native MOMP was stimulatory, as was recombinant VS1 combined with VS3 in a
vaccine formulation. The mice were assumed therefore, not to be deficient in
MOMP-specific B-cells. In addition, the antigen dose used in mice was one tenth
that used to immunise sheep and should have been sufficient to induce a good
antibody response. Since recombinants of VS1 and VS3 stimulated antibody
production, it appeared likely that T-helper epitopes may be located within one or
both of these regions. The apparent difference in induction of a humoral immune
response by peptides of MOMP in comparison to recombinant MOMP protein, may
be explained by elucidation of the processing and MHC class-II presentation of
chlamydial antigens. Indeed, presentation of vaccine as peptide rather than protein
may represent an important pre-processing of the recombinant construct. Leclerc et
al. (1989) reported a considerable increase in antibody response to a recombinant
peptide, after pre-processing of the bacterial preparation compared to immunisation
of mice with the live bacteria. This supports the presentation of a chlamydial vaccine
as an amalgamation of peptides which have been found to have both T-cell and B-
cell activity. With respect to the likely involvement of MHC class-II, T-helper cell
activity has also been reported for C. trachomatis (Su et al., 1990; Allen, Locksley
and Stephens, 1991; Stagg et al., 1993). Evidence suggests that T-helper cell
epitopes may be located in the VS3 region of MOMP, inducing B-cell clones to
produce neutralising antibodies specific to VS1 and VS4. An alternative explanation
for the apparent difference in induction of seroconversion between recombinant
MOMP proteins and peptides in mice can not be ignored. This may be manifest as a
loss of speculative T-cell suppressor epitopes in peptide preparations.
In general, some protection against chlamydial colonisation of mouse tissues was
evident after immunisation with either recombinant tMOMP or with mMOMP19.
Protection was apparent in both active immunisation of mice (Model 1) and passive
transfer of serum from vaccinated sheep to naive mice (Model 2). A major problem
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with the mouse models however, remained the variable infection levels of organs
(liver and spleen) obtained after intraperitoneal inoculation with live chlamydiae. In
some experiments low rates of infection made determination of protection difficult,
whilst in others, large variations in infection levels of mice resulted in statistically
invalid results. In other studies, although organ infections varied to some extent
between mice, the effect was insufficient to affect statistical analysis of the data
(Buzoni-Gatel and Rodolakis, 1983; Rodolakis et al., 1989; Buzoni-Gatel et al.,
1990). The reason for the discrepancy between the results presented here and those
of other workers is unknown, although in the case of the latter citation, Swiss White
out-bred mice were used rather than CBA. Accordingly, the extent of effect of
mouse strain on the outcome of vaccine efficacy trials may be significant. There is
evidence that both susceptibility and antibody response to chlamydial infection is
MHC-linked (Fuentes and Orfila, 1989; Tuffrey et al., 1992; Zhong and Brunham,
1992; Buzoni-Gatel et al., 1994; Qu et al., 1994). H-2k haplotypes such as the
CBA strain have been categorised as low-MOMP responders, although alternative
pilot studies indicated that CBA/ADRA in fact gave a higher response (G.E. Jones,
personal communication). In view of this, two factors, namely epitope recognition
and the resulting production of protective antibodies in mice are by-passed in the
passive immunisation model (Model 2). Furthermore, the mechanisms by which
chlamydiae are neutralised in the SNA and by Model 2 (passive immunisation of
mice) may be found to be similar, however the exact processes remain unclear.
Evidence in this chapter suggests that protective recombinant antigen preparations
can be selected on the basis of their performances in the mouse models developed
here, with tentative confirmation arising from the application of the SNA.
Presentation of the selected antigens as a vaccine preparation however, requires




IDENTIFICATION OF A PROTECTIVE, LINEAR, B-CELL EPITOPE ON
VARIABLE SEGMENT 2 OF MOMP
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8.1. Introduction
It has been shown that, in general, there is no relationship between antibody
titres and immunity to chlamydial diseases. In particular, individuals exposed to
the 57-60kDa heat-shock protein of C. trachomatis (Morrison et al., 1989; Yuan
et al., 1992) show signs of a hypersensitivity reaction which causes chronic long-
term damage to the host (Grayston et al., 1971; Taylor-Robinson and Ward,
1989). A similar occurrence has not, as yet, been demonstrated with C. psittaci
infection, except for guinea pig inclusion conjunctivitis (GPIC). This strain of
C. psittaci is often used as an experimental model for trachoma given the
similarities in associated immune responses between GPIC and biovars A, B and
C of C. trachomatis. Not only is it essential therefore, to differentiate protective
epitopes from harmful ones in order to reduce the occurrence of adverse
reactions to chlamydial vaccines, but elucidation of such epitopes will lead to a
greater understanding of the pathogenic mechanisms underlying chlamydial
infections.
This chapter describes ovine antibody profiles with respect to MOMP and
variable segments 1 and 2 (VS1 and VS2). In addition, pools of polyclonal
antibodies against recombinant VS1 and VS2 were prepared from post-abortion
sheep serum by affinity column purification and were subsequently investigated
for their neutralising and immunopathological properties using the passive
immunisation mouse model described in Chapter 4. Corroborative evidence for
the observed results was obtained using a VS2-specific monoclonal antibody.
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8.2. Antibody profiles in sheep vaccinated with recombinant antigens or
experimentally infected with C. psittaci.
8.2.1. Materials and Methods.
8.2.1.1. Serum sources
Serum samples were obtained from 4-6 year old, female, Blackface/Swaledale
sheep, from a flock certified free of abortifacient C. psittaci under the Premium
Sheep Health Scheme (Scotland). Groups of sheep were vaccinated with either:-
a) insoluble tMOMP (batch 1),
b) insoluble tMOMP (batch 2), or
c) mMOMP-19.
Six blood samples were collected from each animal over 12 months, during
which time the sheep had been successfully mated and subsequently challenged
with live, abortifacient C. psittaci. The diagram in Fig. 8.1. illustrates the serum
sample collection times in relation to other events during the experimental
period.
8.2.1.2. ELISA antigens
Each serum sample was tested by ELISA for immunoglobulin isotype using anti-













Fig. 8.1. Calendrical schedule of events in a typical sheep vaccination/lambing
experiment, (scale; 360°= 12 months)
In addition, tMOMP sera were assayed against 3 different antigens. These were:-
i) semi-purified chlamydial elementary bodies,
ii) 16 amino acid recombinant peptide (GST constuct)
representing variable segment one (VS1) ofMOMP, and
iii) 16 amino acid recombinant peptide (GST construct)
representing variable segment two (VS 2) ofMOMP.
Preparation methodologies for the ELISA antigens can be found in section 2.5.1.
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8.2.2. Results.
8.2.2.1. Determination of serum antibody isotypes and correlation with
subsequent protection against abortion.
Both IgGl and IgG2 contents were analysed by an indirect ELISA procedure. The
use of (rabbit)anti-sheep, IgG2-specific reagent (Serotec) allowed the determination
of IgG2 antibody levels in serum samples. IgGl antibody levels were calculated by
subtraction of IgG2 titres from total detected IgG. Although control sera from
uninfected ewes contained moderate levels of circulating IgG2 antibodies, levels of
chlamydia-specific IgG2 antibodies in the test sera or chlamydia-positive control sera
were below the level of detection in this particular assay. High titres of IgGl were
however detected in the majority of post-vaccination samples, in which levels varied
depending on the vaccine antigen used to immunise sheep. Sheep were categorised
as having aborted due to OEA based on several criteria:- a) lambs born either dead
or dying within 48h of birth with no other obvious cause, b) gross placental lesions
typical of OEA apparent c) shorter gestation period than uninfected control animals
and d) demonstration of chlamydiae at abortion in placental/vaginal samples.
i) Vaccination with tMOMP, batch 1.
Table 8.1. shows antibody titres post-vaccination with batch 1 tMOMP. Grouping
sheep into those which aborted and those which lambed, indicated that antibody titres
were lower post-vaccination (Days 21, 42 and 70) in animals which aborted,
compared to those which lambed. Statistical analysis revealed no significance using
the Student's t-test, although the trend appeared to be relatively strong.
ii) Vaccination with mMOMP-19.
mMOMP-19 which provided no significant protection against abortion, induced
varying antibody titres to MOMP (Table 8.2.). The predominant isotype was again
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IgGl. Again, antibody titres pre-challenge were lower in ewes which subsequently
aborted, compared to those which lambed, although the trend appeared to be much
weaker than with tMOMP. Antibody titres at parturition however, did not appear to
follow any trend either in ewes which aborted, or those which lambed. No statistical
significance could be attributed to this data.
iii) Lambing/abortion antibody titres.
As with the above data, only chlamydia-specific IgGl antibodies could be detected in
sera taken from ewes at the time of lambing or abortion (bleed 5). Furthermore,
unvaccinated, positive control animals responded to abortion by producing solely
IgGl antibodies in detectable quantities. IgGl antibodies to C. psittaci persisted up to
5 weeks post-abortion (bleed 6).
Immunoblots of sera from ewes at lambing/aborting (Fig. 8.2) illustrate the difference
in response to vaccination between recombinant tMOMP and mMOMP19. When
compared to Fig. 8.2, the top panel represents responses to tMOMP (regularly
immunogenic), while the lower panel represents mMOMP19 (irregularly
immunogenic). Both immunoblots used urografin purified chlamydial antigen
















Fig 8.2. Immunoblots of sera from ewes at lambing/aborting, blotted against
urografin purified chlamydial antigen (S26/3)
a) tMOMP vaccination, b) mMOMP19 vaccination
8.2.2.2. Specificity of antibodies to VS1 and VS2 peptides of MOMP.
i) Vaccination with tMOMP, batch 1.
Antibodies specific for VS1 (Table 8.3.) and VS2 (Table 8.4.) were measured
using an ELISA specifically developed for this purpose (Materials and Methods,
Section 2.6.1.). Comparing the specificities of antibodies produced, it was
apparent that VS1-specific antibodies were produced in higher concentrations
than VS2-specific antibodies (means of Tables 8.3. and 8.4.).
All animals seroconverted well to VS1 (Table 8.3). However, antibody titres
pre-challenge were lower in ewes which subsequently aborted, compared to
those which lambed. In contrast, antibody titres at parturition were not greatly
different in ewes which aborted, compared to those which lambed, all sheep
seroconverting well to VS1 after challenge (100 dpv),
Titres of VS2-specific antibodies pre-challenge (Table 8.4), were also
considerably lower in ewes which subsequently aborted, compared to those
which lambed . In this case, statistical significance was evident (p< 0.01).
Conversely, seroconversion to VS2 was undetectable at 100 dpv (post-challenge)
and antibody titres at parturition again appeared to be similar in ewes which
aborted and those which lambed.
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Table 8.1. Levels ofserum IgGl produced in response to vaccination ofsheep with
lOOpg/ml tMOMP, batch l'.
Sheep
Antibody Titre (OD492) Clinical
History21 dpv 42 dpv 70 dpv bleed 52 bleed 63
W2710 0.014 0.034 0.077 1.647 1.992 A
W2722 0.409 1.453 1.541 0.189 0.466 L
X2754 0.219 0.277 0.335 1.146 1.093 A
X2756 0.064 1.372 0.494 0.848 0.686 L
X2757 0.912 0.432 0.826 0.199 0.668 L
X2782 0.334 1.142 1.018 0.264 0.410 L
X2784 0.007 0.384 0.256 0.065 0.331 L
X2786 0.003 0.295 0.680 0.175 0.280 L
X2789 1.675 0.620 1.697 0.544 0.063 L
X2798 0.153 1.274 1.642 0.547 0.918 L
X2799 1.867 0.805 0.925 0.381 0.503 L
X2876 0.023 0.994 0.415 0.316 1.022 L
A, aborted ; L, lambed
' sheep vaccinated with 2x1ml doses; 1 ° vaccination at 14 weeks pre-challenge, 2 °
vaccination at 11 weeks pre-challenge, challenged at 10 weeks (70days) gestation.
2 sheep bled at time oflambing/aborting
3
sheep bled 5 weeks (approximately) after lambing/aborting
Student's t-test: Antibody titres pre-challenge were not significantly lower in ewes which
subsequently aborted, compared to those which lambed (p>0.05).
Antibody titres atparturition were not significantly higher in ewes which aborted,
compared to those which lambed (p>0.05).
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Table 8.2. Levels ofserum IgGl produced in response to vaccination ofsheep with
lOOpg/ml mMOMP-191.
Sheep
Antibody Titre (OD492) Clinical
History21 dpv 42 dpv 70 dpv bleed 5 bleed 6
W3057 0.010 0.673 1.059 0.729 0.646 A
X2768 0.720 0.842 0.550 0.532 0.508 L
X2772 1.127 1.393 1.544 1.035 1.116 L
X2774 0.084 0.340 0.668 0.704 0.626 A
X2775 0.156 0.596 0.416 0.273 0.696 A
X2781 0.692 1.042 1.054 0.644 0.000 A
X2787 0.040 0.638 0.978 0.081 0.215 L
X2788 0.400 0.669 0.799 0.398 0.000 L
X2797 0.256 0.676 0.568 0.238 0.298 L
X2837 0.008 0.118 0.685 0.899 0.740 A
X2852 0.356 1.082 0.621 0.292 0.232 L
X2854 0.217 0.613 0.346 0.554 1.017 L
X2873 0.106 0.482 0.140 0.562 0.740 A
X2885 0.702 1.240 0.876 0.590 0.490 L
X2923 0.062 0.090 0.108 - - A
refer to Table 8.1 for legend
Student's t-test: Antibody litrespre-challenge were not significantly lower in ewes which
subsequently aborted, compared to those which lambed (p>0.05).
Antibody titres atparturition were not significantly different in ewes which aborted,
compared to those which lambed (p>0.05).
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Table 8.3. Levels of VS1-specific antibodies in sera from sheep vaccinated with
lOOpg/ml tMOMP, batch 1.
Sheep
Antibody Concentration (OD492) Clinical
history21 dpv 42 dpv 70 dpv bleed 5 bleed 6
W2710 0.014 0.303 0.090 1.350 1.427 A
W2722 1.408 1.569 1.641 0.681 0.571 L
X2754 0.327 0.725 0.704 1.694 1.653 A
X2756 1.232 1.337 1.626 1.552 1.480 L
X2757 1.465 1.514 1.590 1.315 1.383 L
X2782 1.339 1.418 1.407 1.348 1.160 L
X2784 0.746 1.413 0.984 0.908 1.085 L
X2786 0.034 0.245 1.350 0.964 0.901 L
X2789 1.668 1.624 1.681 1.326 1.053 L
X2798 1.313 1.523 1.585 1.336 1.425 L
X2799 1.774 1.573 1.675 1.327 1.207 L
X2876 1.458 1.498 1.284 1.389 1.423 L
''4
see Table 8.1 for legend.
6
sheep bled approximately 6 weeks after bleed 5.
Student's t-test: Antibody litres pre-challenge were not significantly lower in ewes which
subsequently aborted, compared to those which lambed (p>0.05).
Antibody titres at parturition were not significantly different in ewes which aborted,
compared to those which lambed (p>0.05).
193
Table 8.4. Levels ofVS2-specific antibodies in sera from sheep vaccinated with
lOOpg/ml tMOMP, batch 1.
Antibody Concentration (OD492) Clinical
Sheep 21 dpv 42 dpv 70 dpv 5bleed 5 6bleed 6 History
W2710 0.012 0.049 0.019 -0.091 1.031 A
W2722 1.377 1.414 1.455 0.124 0.178 L
X2754 0.024 0.106 0.005 0.001 -0.197 A
X2756 0.497 1.008 0.121 -0.010 -0.008 L
X2757 0.120 1.083 0.628 0.036 0.058 L
X2782 0.972 1.511 1.368 0.621 0.329 L
X2784 0.035 0.567 0.132 0.014 0.019 L
X2786 0.022 0.020 0.072 0.014 0.112 L
X2789 1.326 0.641 1.218 -0.009 0.002 L
X2798 1.556 1.583 1.600 0.847 0.046 L
X2799 1.012 0.953 0.470 0.029 0.016 L
X2876 0.426 0.727 0.157 0.004 0.127 L
1'6
see table 8.3. for legend.
Student's t-test: Antibody litres pre-challenge were not significantly lower in ewes which
subsequently aborted, compared to those which lambed (p<0.001).
Antibody litres at parturition were not significantly different in ewes which aborted,
compared to those which lambed (p>0.05).
8.3. Neutralising abilities of VS1- and VS2-specific polyclonal antibodies in
vivo.
8.3.1. Materials and Methods.
8.3.1.1. Preparation of affinity purified polyclonal antibodies.
Affinity purified antibodies were prepared from a pool of post-abortion sheep
serum. Briefly, each variable segment was prepared as a recombinant peptide
(Section 2.7.2.) and individually coupled to cyanogen bromide-activated
sepharose beads at pH 7.0. Immune serum was passed slowly over each column
(lml/min) and adsorbed antibodies removed by reducing the pH to between pH2-
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5. A second antibody fraction was eluted from each column using elution buffer
+ 6M urea. The pH of each fraction was neutralised using 1M Tris. The
fractions eluted under mild conditions were termed "low affinity" antibodies,
whilst those eluted with 6M urea in the elution buffer, "high affinity antibodies".
All fractions were analysed for peptide specificity by immunoblotting and
quantified by indirect ELISA.
8.3.1.2. In vivo neutralisation.
Four pools of affinity purified antibodies were formed as follows:-
Pool 1 - VS1-specific "low affinity" antibodies
Pool 2 - VS1-specific "low affinity" + "high affinity" antibodies
Pool 3 - VS2-specific "low affinity" antibodies
Pool 4 - VS2-specific "low affinity" + "high affinity" antibodies
Concentrations of specific antibodies were adjusted to equivalent levels to those in
the original whole serum i.e. 0.67mg/ml VS1, 0.37mg/ml VS2. However, because the
ratio of "high" to "low" affinity antibodies in whole serum was unknown, each
fraction was adjusted to the total concentration determined for each peptide in whole
immune serum. This should have allowed for excess amounts of antibody except in
pool 2, where a low recovery rate of "high affinity" antibodies against VS1 meant
that this criterion could not be met in full.
Two experiments were performed using the passive immunisation mouse model
(Chapter 4). In the first experiment, Pools 1 and 3 were examined for their
abilities to reduce liver and spleen colonisation with live Chlamydia. Pools 2
and 4 were tested in the second experiment.
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8.3.1.2.1. Designs of experiments.
a) Experiment 1.
Table 8.5. Design ofexperiment 1.
Group n Inoculation Antibody Source
(C. psittaci)
1 5 + "low affinity" VS1-specific antibodies
2 5 + "low affinity" VS2-specific antibodies
->
J 11 + immune sheep serum
4 12 + naive sheep serum
5 6 - -
Inoculation mixtures contained 1 xlO6 ifu/ml C. psittaci..
b) Experiment 2.
Table 8.6. Design ofexperiment 2.
group n Inoculation (C. Antibody Source
psittaci)
1 9 + "high"+ "low" affinity VS1-specific antibodies
2 9 + "high"+ "low" affinity VS2-specific antibodies
3 10 + immune sheep serum
4 10 + naive sheep serum




The inoculum titre used was half the optimal, due to diminishing stocks of inoculum.
The effect of using a sub-optimal titre is shown by the lack of infection in Group 4
(C. psittaci + naive serum) (Table 8.8.). Nevertheless, a statistically significant
difference was apparent in liver infection levels control Groups 3 and 4 (p<0.01);
there was no difference between splenic infection levels (p>0.05). Both groups
treated with "low affinity" antibodies against VS1 or VS2 (Groups 1 and 2,
respectively), yielded enhanced infection levels in both liver and spleen (p<0.01).
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b) Experiment 2.
Infection levels in Group 4 (naive serum) were significantly higher than Group 3
(immune serum) in both liver and spleen (p<0.01) (Table 8.9.)- Unlike previous
experiments with this inoculum at the same titre (2xl06 ifu/ml), splenic infection
levels were considerably higher than hepatic (p<0.01). The reason for this anomaly
was unclear. The liver results indicated that although there was a trend towards lower
infection in Group 1 and 2, ("high and low affinity" antibodies against VS1 and VS2,
respectively), the data were not statistically significant. In contrast, infection levels
in the spleen were significantly reduced in both Groups 1 (pooled VS1 antibodies)
and 2 (pooled VS2 antibodies), (p<0.05 and p<0.001, respectively).
8.4. In vivo protection by chlamydia-specific monoclonal antibodies.
A panel of murine monoclonal antibodies against C. psittaci was tested in a passive
immunisation protocol. Passive transfer of inoculation mixtures containing C.
psittaci pre-treated with mouse monoclonal antibodies (Mabs) was carried out in a
standard passive immunisation experiment (See Chapter 4). Several modifications
were necessary due to the use of ascitic fluid rather than sheep serum; these are
described at the appropriate places.
8.4.1. Sources of monoclonal antibodies.
C. psittaci specific MAbs (Table 8.10) were used in the form of filtered, unpurified,
ascitic fluid collected from mice.
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Table 8.9. Properties of mouse monoclonal antibodies against abortifacient C.
psittaci (strain S26/3).
MAb Isotype Specificity Cone" (mg/L)
13/5 IgG3 LPS 493
4/11 IgG2b VS2 33
4/17 IgG3 VS2 >1000
4/35 9 MOMP (not VS2) 428
4/40 IgG2a MOMP (not VS2) >1000
8.4.2. Inoculation mixtures.
Heat inactivated ascitic fluids contributed 25% of the final inoculation mixture
volume. Guinea pig serum was included at 10% final volume and chlamydia
inoculum titres were 2xl06 ifu/ml. As before, each mouse received 1ml inoculation
mixture i.p. and was killed on day 6 p.i..
8.4.3. Results.
Only one MAb (4/11) significantly (p<0.01) reduced infection levels in liver and
spleen tissue (Fig. 8.3.). This MAb was VS2 specific and of IgG2b isotype. A
second anti-VS2 MAb (4/17), did not show any protective capacity. The isotype of
this MAb was IgG3. No other MAbs reduced chlamydial infection to a significant
degree. A repeat experiment restricted to MAb 4/11 confirmed the protective
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Fig. 8.3. Infection levels in the spleen and liver ofmice passively immunised with
monoclonal antibodies against C. psittaci.
Immune sera and Mab 4/11 - infection in liver and spleen significantly lower than control
(non-immune sera); p<0.01 (Student's t-test).
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8.5. In vitro competition between MAb 4/11 and affinity purified antibodies
against VS1 and VS2.
8.5.1. Materials and Methods.
The previously described pools of affinity purified polyclonal antibodies extracted
from sheep post-abortion serum, formed the test samples in this assay. An indirect
ELISA procedure (Anderson, unpublished) was used to assess the specificity of these
antibodies against VS2 and VS1 using the anti-VS2 MAb, 4/11. Briefly, sarkosyl-
treated chlamydial elementary bodies were used to detect chlamydia-specific
antibodies in the test sample. After incubation, horseradish peroxidase-conjugated
MAb 4/11 was added. Inhibition of binding of the conjugated MAb was indicated as
a reduction in optical density after addition of substrate. Pools were as follows:-
Pool 1 - VSl-specific "low affinity" antibodies
Pool 2 - VS1-specific "low affinity + high affinity" antibodies
Pool 3 - VS2-specific "low affinity" antibodies
Pool 4 - VS2-specific "low affinity + high affinity" antibodies
8.5.2. Results.
At the lowest antibody dilution tested (1/10), both pools 3 and 4 inhibited binding of
MAb 4/11 by 100% (Fig. 8.3) and significant inhibition (p<0.01) occurred even at a
dilution of 1/80. The difference between these groups at 1/80 antibody dilution was
not significant (p>0.05). Pool 2 ("high and low affinity" VS1-specific antibodies)
caused a small, but significant (p<0.01) degree of inhibition. The inhibition induced
was one third of that caused by pools 3 and 4 at a 1 in 80 dilution.
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0 0.02 0.04 0.06 0.08 0.1
antibody dilution
pool 1 - "low affinity" antibodies specific to VS1.
pool 2 - "low and high affinity" antibodies specific to VS1.
pool 3 - "low affinity" antibodies specific to VS2.
pool 4 - "low and high affinity" antibodies specific to VS2.
Fig. 8.4. Inhibition of binding of MAb 4/11 to native chlamydial antigen by
polyclonal sera specific for either VS1 or VS2.
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8.6. Summary of results.
Comparatively moderate levels of both IgGl and IgG2 antibodies were detected in
normal sheep serum. In contrast, the predominant anti-chlamydia antibody isotype
detected in sheep sera after clinical OEA was IgGl. Low levels of IgG2 antibodies
may have been present in the sera, however these were not detected by the assay.
Vaccination of sheep with a protective recombinant form of MOMP (tMOMP)
resulted in high levels of chlamydia-specific IgGl in at least one of the three pre-
challenge bleeds in each animal which lambed (n=10). In contrast, neither of the two
ewes which aborted showed comparable levels of seroconversion in pre-challenge
serum samples. This was also evident with the mMOMP19 vaccine, however
seroconversion post-challenge appeared to differ between the two recombinant
vaccines. Sheep that aborted and those that lambed did not produce vastly different
antibody responses post-challenge when vaccinated with mMOMP19. However,
they were considerably different when tMOMP was the immunising antigen. Unlike
tMOMP, seroconversion to mMOMP19 appeared to be less frequent and although
there was some correlation between seroconversion and lambing, both protective and
non-protective epitopes appeared to have been recognised in the recombinant
construct, as indicated by the random production of antibodies post-challenge. In
comparison, vaccination with tMOMP appeared to prime for antibodies which would
recognise native MOMP and which were mainly protective.
Vaccination of sheep with recombinant antigens of MOMP, also resulted in high
levels of seroconversion to VS1 and VS2. In a group of twelve ewes, two which
showed lower seroconversion in the three pre-challenge samples both aborted.
Lambing was accompanied by at least one high titred serum sample to both peptides,
pre-challenge (9 out of 10 cases), with one exception in which lambing occurred
despite only low levels of seroconversion to VS2. Notably, neither of the sheep
which aborted responded to the VS2 of tMOMP at time of abortion. In contrast, one
of these animals produced VS2-specific antibodies by 6 weeks post-abortion,
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indicating recognition of native VS2 following experimental infection with C.
psittaci. The second animal remained negative for VS2-specific antibodies in the
convalescent phase. Both animals seroconverted to VS1 at time of aborting, with
increased titres apparent in the convalescent phase. It was notable that no
seroconversion to recombinant VS2 occurred at lambing in sheep vaccinated with
tMOMP, indicating that native and recombinant MOMP may differ at the VS2 site.
Furthermore, while sheep W2710 appeared able to recognise native, but not
recombinant VS2, sheep X2754 failed to respond to either form ofVS2.
Haplotypes (MHC classes), have been shown to be important in inbred mouse strains
with respect to immune responses to MOMP. It may also be that the response of
sheep to infection with C. psittaci after vaccination with various forms ofMOMP is
similarly controlled by haplotype. The responsiveness to MOMP peptides, in
particular VS2, would be ofmajor interest following the initial results reported here.
A pattern of seroconversion following infection was identified in which sheep
responded by producing chlamydia-specific IgGl antibodies. The population of
antibodies generated, comprised high titres of antibodies specific to VS1 and a lesser
but still considerable response to VS2. This pattern was repeated when sheep were
vaccinated with tMOMP, which induced a measure of protection. Less efficacious
vaccines (mMOMPs) appeared to induce lower seroconversion. No distinction could
be made from this data as to whether the abortions which occurred were due to sub-
optimal levels of VS1- or VS2- specific antibodies.
Analysis of the protective capacities of VS1- and VS2-specific antibodies, was made
possible using passive transfer (Model 2). Antibodies against these regions were
first isolated by affinity chromatography. This technique generated two populations
of antibodies with different affinities for each peptide. Incorporation of both
populations into a single preparation, resulted in significant reduction in levels of
splenic infection by Model 2 for both peptide VS1 (p<0.05) and VS2 (p<0.001). The
concentration of anti-VSl antibodies was probably less than for VS2 in the
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inoculation mixtures, so levels of protection were not directly comparable, merely
indicative of protective potential. Both VS1 and VS2 were thus shown to confer a
significant degree of protection in Model 2. Interestingly, when antibodies of low
affinity were used in a similar experiment, no protection was evident; in fact
significant increases (p<0.01) in both liver and spleen infection were seen in both
cases. Whilst naive serum is known to opsonise chlamydia and increase its uptake
into host cells, the phenomenon described here implicates surface immunoglobulins
in attachment and internalisation of chlamydiae into cells.
A range of MAbs against C. psittaci was examined for protective capacities using
Model 2. Two MAbs against VS2 were included, one of isotype IgG2b (4/11) and
the other IgG3 (4/17). Only MAb 4/11 was protective (p<0.05). Furthermore, a
blocking ELISA involving MAb 4/11 and affinity purified polyclonal sheep
antibodies against VS2 showed clear competition between the two, indicating the




Chapters 4, 6 and 7 demonstrated that passively-transferred antibodies were able to
protect mice against hepatic and splenic infection with C. psittaci following i.p.
challenge. The ovine sera used were obtained from ewes convalescent after
experimentally induced OEA and therefore comprised a polyclonal population of C.
psittaci- specific antibodies. In general, seroconversion does not correlate with
protection when measured against the whole C. psittaci organism. It was the purpose
of experiments in the current chapter to identify antibodies which caused a reduction
in chlamydial infection in the passive mouse model and to identify antigenic regions
involved in this protection.
The predominant anti-chlamydial immunoglobulin isotype present in both post-
vaccination and convalescent sheep sera was shown to be IgG 1. This in agreement
with the results of Schmeer et al. (1992), who found species differences in the
predominant antibody isotype secreted following infection with C. psittaci. Bovine
animals produced mainly IgG2 chlamydia-specific antibodies, whilst sheep and goats
preferentially produced IgGl. In the present study involving sheep vaccinated with
recombinant proteins, no correlation was found between protection and high levels of
seroconversion. Conversely, animals which did not seroconvert well after the second
vaccination generally aborted, indicating a crucial role for humoral immunity in
protection against abortion. To determine if this lack of protection was due to failure
to recognise specific epitopes of MOMP, the sera were analysed for antibodies
specific to VS1 and VS2. Of the two animals which aborted after vaccination with
tMOMP, one animal did not seroconvert to VS1, and the other one did. However,
both animals produced VS1-specific antibodies after aborting, indicating that an
inherent lack of VS1-specific B-cells was probably not the reason for the lack of
responsiveness to vaccination. Interestingly, high levels of VS1-specific antibodies
were detected in the convalescent serum samples from animals which lambed as well
as those which aborted. In contrast, most sheep which produced live lambs also
produced VS2-specific antibodies after vaccination, but this was not followed by a
rise in VS2 antibody titres after challenge. This would imply that the recombinant
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vaccine tMOMP, contained an epitope of VS1 which was very similar to native
MOMP and that VS1-specific antibodies may be of paramount importance in
preventing abortion and possibly in maintaining protection against subsequent
infections.
In vivo neutralisation by polyclonal VS1- and VS2-specific antibodies derived from
ovine convalescent sera and MAbs raised against native antigen demonstrated that
both regions were involved in protection against chlamydial infection in mice.
Surprisingly, infection could be exacerbated by pre-opsonising chlamydiae with "low
affinity" polyclonal antibodies against both VS1 or VS2.
Chlamydia opsonic activity by non-protective antibodies has been reported
elsewhere, however in the present study the antibodies have been characterised and
were shown to be specific for Chlamydia spp. It may be that the increased infectivity
seen with chlamydiae pre-treated with naive sheep serum may only reflect the more
specific association of VS1- and VS2-specific antibodies with the chlamydial outer
membrane. Such a phenomenon may have important consequences in nature.
Zhong et al., (1994) reported on the pleiotropic nature of some chlamydial epitopes
and this appears to be supported by the findings in the present study. It would be
useful to quantify the ratio of "high" to "low" affinity VS1 and VS2-specific
antibodies, since it is possible that a balance exists under natural conditions between
"high" and "low" affinity antibodies which determines the infectivity of chlamydiae.
Indeed, the ratio found in ewes during primary infection may be considerably
different to levels in ewes experiencing a second challenge. "Low" affinity
antibodies may aid the internalisation process of chlamydiae in host cells, however
once inside the phagosome these particular antibodies may become dissociated, thus
permitting the organism to multiply unhindered. Indeed, VS2-specific polyclonal
antibodies competed with a MAb which mapped to a 12 amino acid residue on VS2
(Vretou et al., 1996). This MAb was an IgG2b isotype, which is known to gain
access to intracellular habitats via Fcylll receptors. Interestingly, a second VS2-
specific MAb did not show any protection against chlamydial infection; this MAb
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(MAb 4/17) was an IgG3 isotype. "Low affinity" antibodies competed less well than
the "high affinity" fraction, although inhibition of binding of MAb 4/11 still occurred
to a considerable degree with both fractions. Thus, the fractions were probably
specific to the same epitope on VS2, although the possibility that the effect was due
to steric hindrance between two closely sited epitopes should not be ignored.
The VS1-specific fraction was able to limit binding of MAb 4/11 to approximately
40% of its uncompeted capacity, indicating the close proximities of the VS1 and VS2
epitopes, assuming that the preparation was purely VS1 -specific antibodies. Such an
arrangement may have important consequences in the design of a recombinant
vaccine, as discussed by Ward et al. (1995). These workers highlighted the effect of
structural constraints on the formation of native conformational epitopes in







Several laboratory techniques were examined in order to develop a model which
would allow accurate analysis of vaccine efficacies, in particular, recombinant
vaccines against OEA. Initially, it was shown that good seroconversion to
vaccination in sheep with recombinant chlamydial protein constructs did not
necessarily result in protection against OEA (Chapter 8). Conversely, lack of
seroconversion generally culminated in abortion. Thus, whilst the latter case implied
at least a peripheral role for humoral immunity in protection, the former indicated
stimulation of a polyclonal population of antibodies ofwhich only a proportion were
protective.
Similarly, analysis of the production of IFN-y by ovine PBLs was unable to
distinguish between protected and unprotected animals. Presumably, the
lymphocytes which were stimulated were committed to both protective and non-
protective antigens. Whereas lymphocyte proliferation assays suffered from cross-
reaction possibly with enteric bacterial components (M. C. McCafferty, PhD thesis
1994), the stimulation of IFN-y by native EBs or semi-purified MOMP appeared to
be specific for Chlamydia spp., but was not dependent on the presence of protective
epitopes on the immunising antigen. Furthermore, although it was possible to
differentiate between sera from post-abortion ewes and from naive sheep using IFN-y
assays (this thesis, Chapter 7; M. C. McCafferty, PhD thesis 1994), the assay was not
effective in determining vaccine efficacy in sheep (Chapter 7).
Presumably, production of IFN-y occurred due to stimulation of Thl cells. Mossman
and Coffman (1987) categorised murine T-helper cells into two groups; those
secreting IFN-y and IL-2 (Thl cells) and those secreting IL-4 (Th2). The activation
of T-helper cells has been shown to occur in the early stages of infection in mice
(Buzoni-Gatel et al., 1987), as has the induction of IFN-y (M. C. McCafferty, 1994).
However, the continued effect of IFN-y on controlling infection is more ambiguous.
It may be that whilst IFN-y is able to aid the control of chlamydial infection during
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the early stages of infection, immunomodulation of the immune system during
pregnancy may abrogate its secretion and other factors may become more dominant
during this immunosuppressed period. Later control of infection may be transferred
to the Th2 cells, however neither the presence nor the activity of this group of cells
was examined in the current set of experiments. It would be interesting to perform a
similar assay to test for the secretion of IL-4 (Th2), as well as IFN-y and to compare
results with protection in pregnant ewes.
Immunisation of mice with recombinant antigens produced seroconversion in only
one instance, contrasting notably with the situation in sheep. The exception occurred
when mice were immunised with peptides of VS1 and VS3 in a combined adjuvanted
preparation. VS3 is not normally surface exposed in situ (Baehr et al.t 1988; Su et
al., 1990) and therefore few antibodies specific to this region are detectable in sera
from infected animals. Furthermore, production of antibodies against Chlamydia
spp. has been shown to be T-cell dependent implying that the presence of chlamydia-
specific antibodies may have been mediated by T-helper cell epitopes located in one
or both of these regions. Presentation of antigen as peptide rather than as intact
protein may result in an alternative mechanism of intracellular processing. This
could account for the lack of antibody response to whole recombinant protein in
mice, whilst individual peptides of MOMP were able to stimulate an antibody
response. A less likely explanation, but one that can not be ignored is that the
amount of antigen required to stimulate the murine humoral system may only have
been sufficient when concentrated into a peptide preparation. Even so, there would
appear to be fundamental species difference between sheep and mice in their abilities
to recognise T-helper cell epitopes, to stimulate B-cell proliferation or to recognise
T-helper cell epitopes on recombinant proteins. Whether this disparity relates to the
use of inbred strains of mice remains to be determined. However, there is evidence
that the MOMP-specific antibody response, like that against the heat-shock proteins,
hsp60 and hsp70, is linked to the H-2 haplotype in mice (Buzoni-Gatel, 1994; Zhong
and Brunham, 1992). Why the murine strain used here should respond to native and
not recombinant MOMP may be explained by elucidating specific areas in the
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recombinant antigen which may differ from the native form. Indeed, such an
experiment may indicate more precisely which regions or epitope within MOMP are
actually H-2 linked.
Passive transfer was able to overcome some of the problems associated with eliciting
antibody responses in inbred strains of mice. This technique, developed in mice,
provided a more accurate prediction of protective capacities of recombinant MOMP
vaccines in sheep. The most efficacious of the recombinant constructs was shown to
be tMOMP. Evidence suggests that this construct may be folded very similarly to
native MOMP, re-inforcing the hypothesis that protection is conferred by
conformational epitopes on MOMP.
An attempt to identify protective regions within MOMP, revealed protective
capacities of both VS1 and VS2. Antibodies purified from immune sheep sera and
specific to peptides representing VS1 and VS2 significantly reduced chlamydial
colonisation of mouse organs using the passive immunisation mouse model.
Furthermore, antibodies in the VS2 specific fraction, competed for an identical
epitope to that recognised by MAb 4/11. This MAb has been identified as being
specific for a 12 AA sequence in the VS2 region (I. E. Anderson, personal
communication) and was also shown to protect mice against chlamydial infection
using the passive immunisation mouse model (this thesis). In addition, examination
of the binding properties of VS1 and VS2, suggested that these epitopes were
probably in close proximity to each other, further enforcing the concept of protective
conformational epitopes.
The mechanism by which antibodies specific to VS1 and VS2 may inhibit infection
by Chlamydia is unclear. In Chapter 5, the physiological events surrounding passive
transfer of pre-opsonised Chlamydia psittaci into the peritoneal cavities of mice was
examined. Initial results indicated that chlamydiae could enter specific cells, such as
macrophages and polymorphonuclear leucocytes, even when pre-opsonised with
immune sheep serum. No colonisation of organs occurred under these
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circumstances. Furthermore, at approximately 48h p.i., development of inclusion
bodies ceased, contrasting with Chlamydia pre-opsonised with naive sheep serum,
where progressively larger inclusions were detected up to maturity at 72h p.i.
Thus, it would appear that in this case, neutralisation of infection occurred at some
point post-entry of chlamydiae into host cells. This pattern of growth and premature
cessation of development, could theoretically be caused by depletion of essential
nutrients required for completion of the chlamydial life-cycle and/or, accumulation of
toxic waste products within the chlamydiae. The question arises as to whether this is
the cause of restriction of development and if so, whether it is due to an inability of
MOMP to function as a porin and allow the exchange of materials. Gram-negative
bacteria are known to contain porins and electron microscope studies have shown
that they usually form trimers with sub-unit sizes of between 30,000-50,000 Mr. The
MOMP of C. psittaci has been shown to be composed of multimers (McCafferty et
al., 1995) and MOMP is within the molecular size range associated with porins.
Bavoil et al (1984) suggested that development of the chlamydial life cycle may be
related to opening and closing of porin channels. In this way, cross-linking of the di-
sulphide bonds could be integral in the process, such that following intemalisation of
EBs, reducing conditions would theoretically cause relaxation of the di-sulphide
bonds. This would result in opening of the pores and initiation of nutrient uptake.
When normal pore activity is prevented, the effects on development of the RB could
potentially be fatal.
It can not be ignored, however, that MOMP alone may not be sufficient to protect
against OEA. However, caution must be employed in order that detrimental
components of the chlamydial organism are excluded from a vaccine, the effects of
which have been demonstrated with early C. trachomatis vaccines.
Epitopes which are thought to stimulate protective humoral immune responses,
appear to include those present in VS1 and VS2. However, it has also been
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demonstrated that these epitopes may exhibit pleiotropic characteristics, a
phenomenon, which further complicates the search for vaccine components.
A feasible proposition may lie in a vaccine composed of MOMP or sub-regions of
MOMP, combined with other chlamydial components. The premise here would be to
provide greater structural and physiological support to encourage correct folding of
the MOMP construct and to elicit a cumulative immune response, stimulated by
MOMP and the additional vaccine components. LPS is known to be intrinsically
associated with the outer membrane and the effect of this association on the tertiary
structure of MOMP may be considerable. It must be noted, however, that such an
arrangement may have evolved in order to protect important epitopes, for instance by
exhibiting steric hindrance, in which case the benefits to correct folding may be
double edged.
The phenomenon of intermolecular T-cell help supports the inclusion of other
components of the chlamydial organism in addition to MOMP, in a vaccine. The
possibility exists that co-stimulation of the immune system by individual antigens
may be a pre-requisite for the development of a protective immune response.
216
APPENDICES
(N.B. Concentrations in parentheses refer to stock solutions)
Appendix I: RPMI Maintenance Medium
RPMI (+Glutamine/-Sodium bicarbonate; Flo Laboratories) 500ml
Gentamicin (lOmg/ml saline; filter sterilised through 0.2 pm) 2.5ml
Nystatin (10,000 units/ml) 1.25ml
lMHepes 5ml
8% Sodium bicarbonate 12ml
Newborn Calf serum (Heat inactivated) 25ml
Streptomycin (lOOmg/ml; adjust to pH 6.8 with sodium bicarbonate) 1ml
Appendix II: RPMI Infection Medium
RPMI (+Glutamine/-Sodium bicarbonate; Flo Laboratories) 500ml
Gentamicin (lOmg/ml saline; filter sterilised through 0.2 pm) 2.5ml
Nystatin (10,000 units/ml) 1.25ml
lMHepes 5ml
8% Sodium bicarbonate 12ml
Newborn Calf serum (Heat inactivated) 10ml
Streptomycin (lOOmg/ml; adjust to pH 6.8 with sodium bicarbonate) 1ml
Cycloheximide lpg/ml
217
Appendix III: Chlamydia Transport Medium (CTM)
Sucrose 149.2g
Potassium di-hydrogenase Orthophosphate (KH2PO4) 1.024g
D-Potassium hydrogen Orthophosphate (K2HP04) 2.474g
L-Glutamic Acid 1.442g
0.4% Phenol Red 8ml
Dissolve in reagent grade water 2000ml
Add:-
Foetal Bovine serum 200ml
Nystatin (10,000 units per ml) 30ml
Gentamicin (lOmg/ml saline; filter sterilised through 0.2 pm) 10ml
Streptomycin 0.2g
Final pH 7.2 (Adjustment should not be necessary). Filter sterilise through 0.2 pm.
Store at -20° C.
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